var title_f10_3_10288="Patient position and catheter";
var content_f10_3_10288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient position and the pulmonary artery catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 370px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFyAWsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKa7rGjO7BVUZJJwAKw7jxn4Xtrlbe58SaLDcNkCKS+iVjjrwWzQBvUVDaXVveRebaTxTx/wB+Jww/MVNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFec/EL4iTaXqyeF/B2n/ANt+MJ03C2BxDZoeks7fwjkHbkE8dMjIB0fjXxr4e8FWK3XiTU4bQPnyojlpZiOyIMs3UdBgZ5xXB/8ACQ/Enxz83hHSoPCOit93UNbj33co9Ug5C/8AAsg9jWx4A+GiaRqT+I/F15/wkHjCfmS+mXMdt/sQIRhFHrgH6A4r0egDyS3+CGmalMl14+13WvFt0pyFu7hordT/ALESH5fpuxXR2/wl8AW9s0EfhHRihGCZLZXb/vpst+tdxRQB5fd/AnwG8xn07TbrSLvtcadeywuv0G4r+lc14oh8VfB60h1y18V3viPw2t1FDc6bq6iW5CO4XMUwILMM8AgD2Ne615N+0aywaB4TvbpJDpVl4msbnUXVCyx2yl9zOB/Dkr+JFAHrNFRWtxDd20VxayxzW8yCSOSNgyupGQQRwQR3qWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimTyxwQyTTOqRRqXd2OAoAySaAOD+MnjG78MaBb2WgIJ/FGszCx0uDAP7xushB/hQHJJ4zjPGa0vhv4IsvBOitDE73eq3befqOoTHdLdzH7zMTzjJOB2HuSTxPwesJPGuv3vxO1sNI9y8lpodu64W0s1YrvAP8b4OT9ccNgex0AFFFFABRRRQAVFdW8N3bS291FHNbzIY5I5FDK6kYIIPBBHapaKAPGtCSb4UfEHTvDQuJJPBHiB5F01ZiWOnXfXyAx/gfPyg9z7MT7LXlX7TUDj4T3eqW4JvNHu7XULYgZ2usyrn8Fdq9QtbiK7tYbi2cSQTIJI3XoykZBH4UAS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXEfG+9Nh8IvFs4baTp0sQOcffGz/2au3ryz9qB2j+BficoSDi2Xj0NzED+hoA7P4e2K6Z4C8OWKqF+z6dbxkAdxGoP610FMijSGJI4xhEUKo9AKfQAUUUUAFFFFABRRRQBk+LtGTxH4V1jRZZBEuoWktr5hTd5ZdCobHcgnP4V5X4U+IT/DvS9N8LfE3TLnSBYQpZWusRRtNY3aRrtQ71yUYqBkEepO3pXtVVdVNkNNum1b7MNPSNnuDc7fKVAMsX3cBQBkk8cUAM0bVtO1vT477R762vrOT7s1vIHU+2R39qu14D8O9F0LVPjrea98PrIWPhfTrN7e7u7ElLa/vGOPLVc7WRVIbKADcoPIKk+/UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXl/wC05BJcfA3xOkKlmCQOQP7q3ETE/gATXqFYnjfSP7f8G65pOMm9sprdfZmQgH8CRQBrWs8d1aw3EDbopUEiN6qRkGpa4L4EawNb+EXhe53bpIrNbWTPUNFmM59/kz+Nd7QAUUUUAFFFFABRRRQAVyHxb8Par4r+HWtaHoF3DaajfRpEks0jImzzFMisVBOGQMvQ5ziuvooA8q+EniK607U/+Fd694dttF1bTLE3cJ05t1ncWwkCCRMkuCWPO7JJDEkHivVa8Q8W6ddeF/j54P1fStQ1HUtS8SNcWFza3bReVHZRhZGERCrsCcOByWIPOSd3t9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeRfDv/AIo74t+K/Bz5TT9U/wCJ9pYPQbztnQfRgCAOwJr12vLvjtpd3babpnjbQ4y+s+Fpjd7F4M9qRieI+xXn2AOOteh6HqtprmjWOqabKJbO8hWeJ/VWGRn0PPI7UAXqKKKACiiigAooooAKKK4v4i+Ol8JNpthp+mTa14i1SQx2GmQSCNpduC7M5BCIo5JP8gSADmP2glk0ODwx49gyT4X1APcIDgvbTlYpQvucoPxNet145L4K8b/EGSAfEm/sNO8OeYs8nh/TMs0205VJpu4BAJCkg44wcEex0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2REljaORVdGBVlYZBB6givFvCk8vwj8cR+ENRkdvButTM+hXUhyLScnLWrE9iT8v17ktj2usTxl4X0nxjoE+j69bC4s5cNwdrIw6OrdQw9fw6EigDborx+C2+Jfw9AgslTx54eTiNZphb6jAvYFz8sgH/fR9hVlPjhoVlhfFejeJPDL5wzajpr+Xn2dN2R74FAHq9FU9I1Ox1nToNQ0m7gvLKdd0c8Dh0YexHvx7GrlABRRRQAV5H4z26P+0N4I1e95tNS0+40mNm+7DODvUj0Z9233r1yuH+M3hO48X+Bbq10s7Nas5Ev9NkyFKXMZyuCeASMrk/3qAO4orkPhp44s/Gmi+YoNrrFpiHUtPlGyW1mHDAqeduQcHv8AUEDr6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmyIksbRyKrowKsrDIIPUEU6igDxbxT4a1j4XT3vir4esZdCMn2nVPDZXMZXjfLb/3GAGSo447gBa9W8Na5YeJdBstY0ecT2F5GJInHXHcEdiDkEdiCK0yMjB6V474Ghb4ffF3UvBkbAeHtdhfV9KjP/LvKDiaFfbqwHYAdyTQB7FRRRQAUUUUAee+PfhpBr2rw+IvD2oS+H/FtuAE1K3XcJlH8EydHXAxzz06gYrE/wCE38eeDht8d+FP7X09ODq3h0mTA9Xgb5h6kjA64r12igDlvBvj/wAL+Mo8+HtZtrqYDLW5OyZPXMbYYfXGK6muK8Z/C/wj4wkM+r6REt/nct9akw3Cnsd64J/4FmuXTwD8QPDWR4O8fvfWi/csfEUH2gADoPOX58dsACgD12ivMPC3xC1i08S23hr4laRbaLqt4P8AiX3lrKXtL5gcFFJ5R+mFJyc9iRn0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivPvH3xS0rw1crpGlRtr3iqZvLt9IsW3ybvWQjPlqOpzzjnGMmgDpPGnirSvBugT6vrtx5VtH8qoo3STOekaL/Ex7D8TgAmvO5dd+JPjqeGHw1pU/gfTEDSvqOrQxzTzHHyxiA/dBPUnt0PGDd8HfDzVNQ1638XfEy8TUdfi+ez0+L/jz0zPZF/iccfMe/qQGr1SgDgvg34xvfF3hy6XXY4IfEGlXkun6hDCCqiRG4YKSSARj8Qceg72vGPGovPAfxitfFek+H9b1XTNZ097bVINGtGuG86NlMcrKCADghQSRwGx3rovDPxn8D6/fRafFrH2HVH4ay1GF7aRHzjYSw2bvYMaAPRaKKKACiiigAooooAKKKKACiiigAooooAK8n+Oq/wBm6t8PfEsR2z6fr8Vq7ekFwCko/JVr1ivI/wBpafzfBem6PZI8+u6nqltHpsCYG6VZAxJJOFUAHnnGR9QAeuUUUUAFFFFABRRRQAUUUUAcZ8X/AAr/AMJf4C1KwgDLqUK/a7CVPvx3MfzRlT2JI259GNT/AAp8U/8ACZ/D/RtbfaLmeHbcqvG2ZCVkGO3zAkD0IrrK8k8Q+BtY8H6zceKPhdl5Z5Xm1Lw/PORbXu7kvHniOXPTt9BwwB63RXK/D3xvp3jbS5p7NJrS/tZDDfadcjbPaSjqrr+Bwe/1BA6qgAooooAKKKKACiiigAooooAKKKKACiiigAoorO8SarFoPh3VNXuEaSHT7WW7dF6ssaFiB74FAHn3xP8AEmq6j4jsfh/4Lufs+s38Zn1C/Ubjp1p0Lj/po3RfTI6ZBHWeBvA3h/wRpy2ugWEULlQJrlgGnnPdnfqcnnHQdgK5f4C6FLB4XfxVq5WbxB4pYandTDnbG4zDEp7KqEcdskdhXp1ABRRRQAVj+KPDOi+KtNaw8Q6bbX9qc4WZMlD6q3VT7gg1sUUAeJ+FfFcvwol/4RH4gyXSaRFKV0bXnVpIZYCTsilYD5HXpzxj0ABO7qvxx8G214LLR5r/AMR6gTgWuiWrXLn3B4U/ga9JvbS2v7SW1vreG5tpV2yQzIHRx6FTwRUOl6XYaTbC30qxtbK3HSK2hWNR+CgCgDyu5+NU1lPFear4E8T6T4ZEqw3WqalB5DW5bhWMXJK7iAWB4z3JAr2CvMv2hvDnibxX8ObzR/CkdlcPcNH9ot5vkkkVZFcGKQsEUgqMhgcgnBBAzzniP4nfELQ7zQ7rXfA1j4e8PzajBaX93c6il6UjkcAsvlFdmAG5YEZI/EA9wooooAKKKKACiiigAooooAK8g0Af8J78btT1qQh9F8HhtNsR1V71x+/k+qjC/wDfJr1HXb4aXomoX7Y22tvJOc/7Klv6Vwf7Oenf2f8AB/QHcE3N8j308jHLSPK7NuJ9dpUfgKAPSqKKKACiiigAooooAxP+Es0H/hJV8PjVbRtaP/Lmj7pF+UvhgPunaCcHHFQ6L418M63c3cGk65p93LaIZZljmB2IDgvnuoPBYcV49ovw78a6f461BbWW7s9NvNUv7u7vxfhre6t50xGpt92fNUk/MVGMcMeKsfDP4d6/DrOgxeJtHistN0fQ7jSJ2FykgvzLIT8oQ5CbTk7tpyenegD2jQdc0zX7NrrRr2G8gV/LZ4mztbAOD6cEH6EHoRWlWP4Z8O2Xh23nisnupWnkEks11O00jkIqLlm7BVUAe3qSTsUAeV/FTwnqdlq0Pj7wJH/xUtgmLyzXhdUth96NgOrgD5TyeAOoXHaeBPFumeNvDVrrWjS7oJRiSNvvwSD70bjsw/XgjgiugrxfxxpV98MfE9x498K20k+hXZB8Q6TD6f8AP1GOm4dW/EnqSAD2iiqWiarY65pNpqek3CXNjdRiWGVOjKf5H1B5B4q7QAUUUUAFFFFABVfULb7ZZzW/nzweYu3zYH2OvuD2NWKKAOV/4Q3/AKmPxJ/4Hf8A2NaF5oH2nTbWz/tbV4fI/wCW8Vztlk/32xzW1RQBzEXhDy5Uf/hIfET7WDbWvcg47EbelWtX8O/2lem4/tjWbTKhfKtbry0474x1rdooAwtI8O/2bei4/tjWbvClfKurrzE574x1rzX9oHS5dD+E3ijU4Nb1yRzEsRhku8xFZpVjYFcdMOeK9nryj9pTfe+A9O8Ox7VPiTWrLSfOb/ljuk8zfjvzEBj3oA7Dwx4RTQfCkWhxapqbxpbxwLKZ/mhCKFAjOPlHFM/4Q3/qY/En/gd/9jXVUUAYt5oH2nTbWz/tbV4fI/5bxXO2WT/fbHNUovCHlyo//CQ+In2sG2te5Bx2I29K6eigDC1fw7/aV6bj+2NZtMqF8q1uvLTjvjHWjSPDv9m3ouP7Y1m7wpXyrq68xOe+Mda3aKAOYl8IeZK7/wDCQ+Ik3MW2re4Az2A29Ku2egfZtNurP+1tXm8//lvLc7pY/wDcbHFbVFAHK/8ACG/9TH4k/wDA7/7GjxX4H07xV4XTQNau9Sm0/wCXzcXGHnwwYb2xzggH8K6qigD5nm+DviHwl8URL8JVhsrFdKQ3FzqtzL5TyNOxMYMY3E4jQkdAOvUV2Og6l4g1D4gT+F/iDdz6XrclqLyyl0G7dLK5hHDAK4LBwc5z1APAwC3s9eS/G6H7B4q+GOv2rbL6LxFDpmQPvQ3KssgP4J+poA73SPDv9m3ouP7Y1m7wpXyrq68xOe+Mdaqy+EPMld/+Eh8RJuYttW9wBnsBt6V09FAGLZ6B9m026s/7W1ebz/8AlvLc7pY/9xscVn/8Ib/1MfiT/wADv/sa6qigDFvNA+06ba2f9ravD5H/AC3iudssn++2OapReEPLlR/+Eh8RPtYNta9yDjsRt6V09FAHnvxl0P7V4D8W3/8AamqQ+Xo9032eG42wtthc4K45B7+tHwa0P7L4C8JX41PVJvM0e1b7NLcboV3QocBccAdq6L4iWhv/AIf+JrNc7rjTLqIY/wBqJh/Wsr4J3YvfhH4QlXGF0yCHj/YQJ/7LQBel8IeZK7/8JD4iTcxbat7gDPYDb0q7Z6B9m026s/7W1ebz/wDlvLc7pY/9xscVtUUAcr/whv8A1MfiT/wO/wDsa0LzQPtOm2tn/a2rw+R/y3iudssn++2Oa2qKAOYi8IeXKj/8JD4ifawba17kHHYjb0q1q/h3+0r03H9sazaZUL5VrdeWnHfGOtbtFAGFpHh3+zb0XH9sazd4Ur5V1deYnPfGOtZXhuS50nxtrGi6jf3d3HdxrqOnPcyBiIxhJYhwPuOVb6SqO1dlXJ/Ea3mh0y21+wieS/0Kb7asaD5pocFZ4h67oy2B/eVPSgDrKKis7mG8tILq1kWW3nRZI5FOQysMgj2INS0AFI6q6srqGVhggjIIpaKAPD/Lk+CnjGIwt/xbnXrrYyE8aTdN0I9Im/THbHze4A5GR0rL8UaFYeJvD99o2rwiaxvIjFIvcejD0IOCD2IFef8Awp1jVNC125+HPiuZbm/022W40zUOR9us87QSD/GnCnk5x3wSQD1SiiigAooooAKKKKACiiigAooooAK8o+Kqfb/i18J9KmP+iSXt7fsvrJbwB4z+BJr1evJfEn/Jyvg/7f8A8e39jXf9n/8AXzk+b/5CxQB61RRRQAUUUUAFFFFABRRRQAUUUUAFeP8AiWYeN/jro/hvzAumeFEXWrpC2GmujgQgDqQgYMSOPmIPavYK8y+LPh/VYdX0Xxx4StPtet6LvS4s1O1r6zYfPEPVh1UepOMnAoA9Norh/AvxQ8NeMruSwsLiez1eIZk02/iMFwvr8p4bHfaTjvXcUAFFeefED4l2mh3K6F4aSLXPGV03lW2mQvu8tu7zEfcRRyckHHoMkZEPw28W6632rxp8RNbt7gj5bXw5ILGGH23YJk+pANAHrVFeUn4UazY/vNB+J3jKG49dSuEv0/74YAVHP4a+Lul7bnTfH2la9IvJs9S0eO1jcf78RLZ/KgD1eWNJonjkGUdSrD1Bryv9nKeSy8HX3hO9P/Ew8M6hPYS8YLoXLo/0IY4/3aZB8UfEmk7rTxf8NvE/29ekmhW4v7eQeoYMNv8AunJriLXxzeaV8XtQ8T2PgDx6mkarpyRahA+ilZTPEfklUbsEBflOSMZoA+kaK8p/4Xv4StDt8R23iDw4/QJqulSoT/3wGq9pfxx+G+pz+VbeKrRG9bmKW3X/AL6kVR+tAHpFFVdN1Gy1S0S60y8try1f7s1vKsiN9GUkGrVABRRRQAUEZGD0oooA47wDnR7zVvCknCabIJ7DjGbKUsUUf9c2EkfsETPWuxrjPiAP7HudL8WxjaNKcxXxAPzWUpAlJx2QhJfYRt612YORkdKACiiigArx3466bZ3fjL4WztADqKeIYgkq53CJfnZfTGUQ888cYya9iryn4o/6R8XfhPZYJD3d9c4zgfuoAc/XmgD1aiiigAooooAKKKKACiiigAooooAK8n+OMN9o2p+E/H1lbm8g8Lzzte2yDLm2nQRySL7oBnHvk8A16xTZY0ljeOVFeNwVZWGQwPUEelAFbSNSs9Y0u11HTJ0uLK6jWWGVDwykZB/+tVuvFBFf/BLUZmtra71L4b3cjSmOBDLNo0h5JAHLQk/l9fv+p+F/E2i+KtNW/wDDupW2oWp6tC+Sh9GXqp9iAaANiiiigAooooAKKKKACiiigAooooA5bxt8P/C3jdYB4o0eC+aH/VybnjkUem9CGx7ZxXJ/8M+fDD/oWf8Ayfuv/jleq0UAc74O8E+G/Blq1v4Z0i2sFf77oC0j+zSMSzD2JroqKKACiiigArk/it4Ybxj8Pdc0OLAuLmAm3JOAJlIdMnsNygE+hNdZRQBxnwg8U/8ACX+AdNv59y6jCv2S/jf78dzH8sgYdiT82PRhXS6rpGm6vD5OrafZ30PTZcwLKv5MDXn3ig2HwmOs+LbOzu7my1nUrZtVjEoEVmp+RrhU25JJI3DPJI6Yr02N0ljWSNldGAZWU5BB6EGgDzC9+BXgeS6e60yzvtFumIJl0u9kg59lyVH4CqJ8MfEnwWS/hLxEvivTF5/s3X2xcAeiXAxk/wC9gD0r1+igDz3wd8U9L1vV10LWrO88OeJsf8g3Ul2mT3ik+7IPTGCeoGK9CrmvHngnRPHGkfYNetfM2HdBcRnZNbv/AHo36g9PY45BrjfBXirVfCniCDwP8Q7jzbmT5dH1thhNRQdI3P8ADMOBg9fckFgD1eiiigCO6giuraW3uI1kglQxyI3RlIwQfwrlfhzcywWF54dvpC99oMos97HLS25AaCU+pMZAJ/vI/pXXVxvis/2F4p0jxIp22k5XSdR5wNkjfuJD/uStt9hMx7UAdlRRRQAV5T8X/wDRviB8LNQx9zV5LXP/AF2i2/X+H/GvVq8p/aH/ANH0TwlqfA/s3xNYXRP+yGZSPp8woA9WooooAKKKKACiioby7trKEzXlxDbxA43yuEXP1NAE1FZaeIdFd1VNX05mY4AFyhJP51NeaxpllN5N5qNnbygZ2SzqjY+hNAF6iqNnrGmXs3k2eo2dxKRnZFOrtj6A1C/iHRUdlfV9OVlOCDcoCD+dAGpRVKHVtOntpbiG/tJLeL/WSpMpVPqQcCq//CR6H/0GdN/8Ck/xoA1a808WfCTTb7UjrnhK7l8K+Jhki909Qscp64li+64PfpnvnpXfTatp0FtFcTX9pHby/wCrleZQr/Qk4NQJ4h0V3VU1fTmZjgAXKEk/nQB5nZfE3WfB13Fpnxb0sWKu3lwa/YKZLKf03jrGx9/yAr1iwvbXUbOK70+5hurWUbo5oXDo49QRwapaxfaIY5rDWbrTTHKmJLa7kTDqezK3UH3ry5/hnokGoyXfwr8WP4a1V8yNbWVytxazEf34CSPTpwPSgD2aivDW+L2u+C5Db/ETSrK/tEO06v4fuFmX0zJASGTtk8D0Fd94X+KXgnxNCH0nxHp7ORkwzyeRKP8AgD4J+o4oA7SislvEuhKpZta0wKBkk3UYA/WvPvFXx78EaJKbTT72TXdSJ2x22mJ5oZuw8z7mPoT9KAPV6K8MsH8ZeNnN3r3jnT/CFnMcQ6RpM0MtwqnpvnJyH/3ePYHirl94R8QeGpCuhfFy7juEG/7L4haK6EnsWbDKD6gUAez0V4xoXxjm0nW7XQ/iRbabYz3JCW+raZdCeymbphud0X/AvxwOa9TbxFoqsVbWNODA4IN0mQfzoA1KKpQ6tp09tLcQ39pJbxf6yVJlKp9SDgVX/wCEj0P/AKDOm/8AgUn+NAGrRVKbVtOgtoria/tI7eX/AFcrzKFf6EnBqBPEOiu6qmr6czMcAC5Qkn86AH+IdQn0rR7i8tNPn1KePbttYHRGfLAfechQBnJJPABrz+y+MFneaDZ3cGh6g2p3erPo0Gn+ZHl50GWYS7thjH98EjNdd4yuo5dMn0+18Rafo2ovtIkuUjmAXPIaJ2GQwyOo69a8otfBOgaZa6RZRePtNTxH/bb6tYzCKIW/nMuGhS2VwAhGPlDAk9D2oA61/jBpX/CKWGtx2F1idrlZreWWKJ4Db/61SWYKz/3VBy3tg49LjcSRq6ggMARkYP5Vy3gLwTZ+FPC0GjySDUnS4e7luJ4lG+d3LFwvIXBPGOmOtdXQBR1zSrTXNHvdL1KIS2V5C0EydMqwwfofeuC+Cn9u6Lp+p+EfEkNw/wDYM4t7HUnQrHeWrDMWG6FlHykDp8o65r0uuT+Jvg2Pxt4aNgt3NYahbyrd2F5CxDW9wmdj8dRyQR78YODQB1lFedfCfxzda99s8O+KYVsfGekfJe2/RZl42zx+qtkdOhPoRXotABWF418K6V4y8Pz6RrkHm20nzI6nDwuPuyI38LD1/A5BIrdooA8p8EeKNX8L+IrfwL8QJjPdygjRtaIwmpRr/A/92ZRjOevuSC3q1ct8R/Bdl458ONpt3LJa3MUi3Fnew/6y1nX7sin27jjI7jqOP8G/EHUtD1uLwf8AFFYrLWTxY6qPltdTQdw3RJOmVOOT0GQCAes1R1zS7bW9GvdMvlLWt3C0MgHXDDGR6EdQexq9RQBzfgDU7rUNAEGqtnWNNlawvuMbpY8fvMejqUkHs4rpK43Uf+Kf+INnqA+XT9eRbC5wOFukBaBz/vL5kZPqIxXZUAFec/tD6ZLqnwd8RpbZ+0W0K3qEdvJdZCf++VavRqgv7WK+sri0uV3wTxtFIvqrDBH5GgCp4Z1WLXfDul6tBjyr61iuVA7B1DY/WtKvJPgNqFxo0WpfDrXDjV/DjHyHPAu7N2zHKv03BSO3yjrmvW6ACiiigAqG8tLa9hMN5bw3EROdkqB1z9DU1FAGWnh7RUdWTSNOVlOQRbICD+VTXmj6ZezedeadZ3EpGN8sCu2PqRV6igCjZ6PpllN51np1nbygY3xQKjY+oFQv4e0V3Zn0jTmZjkk2yEk/lWpRQBSh0nToLaW3hsLSO3l/1kSQqFf6gDBqv/wjmh/9AbTf/AVP8K1aKAKU2k6dPbRW81haSW8X+rieFSqfQEYFQJ4e0VHVk0jTlZTkEWyAg/lWpRQBRvNH0y9m86806zuJSMb5YFdsfUiiz0fTLKbzrPTrO3lAxvigVGx9QKvUUAZb+HtFd2Z9I05mY5JNshJP5Vj658OPBuuKRqnhnSZmxt8wWyo4HoHUBv1rrKKAPL7b4CfDO3nWaPwvEXU5Aku7iRfxVpCD+Irt7Lwr4esbJLOz0PS4LVTkQx2kaqD64x1962aKAMtPD2io6smkacrKcgi2QEH8qmvNH0y9m86806zuJSMb5YFdsfUir1FAGFqPg/w7qOnXNjd6Jpz21zGYpVFuqkqfcAEHuCOQQDXmfwV0e00/WfGXgrU7K0vl8OXcP2O4uII3kNtOheJGbHzFQOp9cdAAPaa8i0+VvDX7Ser205/0XxdpkNzCx/572qlCg/4Bub8RQB6hDpOnQW0tvDYWkdvL/rIkhUK/1AGDVf8A4RzQ/wDoDab/AOAqf4Vq0UAUptJ06e2it5rC0kt4v9XE8KlU+gIwKgTw9oqOrJpGnKynIItkBB/KtSigCjeaPpl7N515p1ncSkY3ywK7Y+pFVpvDGgzQSwy6JpjwyoY5ENqmHU9QRjkVr0UAcV/ZGu+Fvn8NTNq2kr10m9mPmxD/AKd525/4BJkejIOK2/DnibTdf86O0eSG+t8C5sblDFcW5P8AfQ849GGVPUEjmtqsXxH4Z03X/Jku0khvrfJtr62cxXFuT/ccc49VOVPQgjigDaoriv7X13wt8niWFtW0lemrWUJ82If9PEC8/wDA48j1VBzXWadf2mp2MN5pt1Bd2ky7o5oHDo49QRwaAMHxvoN7faZf3nhaSz07xWbYQ22oyW6OyqG3eWSQSFPI9s5xxWZ8K/Hi+MdOuLbUrY6b4n01vI1PTn4aKQfxKO6N1B/DJ6nuq888feDYj4hsvHGjzXdlrWlITdLZQea+pWyjJtymRuY4AU9vwGAD0Oiub8CeNNF8caMNR0G58xVO2aBxtlt3/uSL2P6HsTXSUAFZHifw3o3irS207xDp1vqFmxzsmXO0/wB5T1U+4INa9FAHkH/CE+NPAf7z4da1/a+jp/zANbk3bV/uwT9V9lbAHcmvVdJnubrS7S4v7T7Fdywo81t5gk8lyASm4YDYPGR1xVqigDH8XaKniHw7e6a0hhllUNBMOsMykNHIPdXVWH0pngzWm1/w5aX00YhvMNDdwD/ljcRkpKn4OrAeowe9bdcbb58P/EWa3J26d4iQzxZPCXsSgSKP9+IKw94XPegDsqKKKAPKfjRp91ouo6H8Q9Et5JrzQpDHqEMK5a4sH4kGO5TO4emSe1em6Xf2+qaba39jJ5lpdRLNE+0ruRgCDg8jg96skZGD0oAwMDpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct8QPBOm+NtNggv3ntb20kE9lf2rbJ7SQY+ZG/AZHfHqAR1NFAHnHwX8Sapqdrrvh/wATXAutf8O3zWc9xsCm4iOTFKQOm5Qf++c9Sa9HryDW/wDikP2htJ1Vv3emeLLI6bO5+6LuLmIk+rLtQfj+HrssiRRvJK6pGgLMzHAUDqSfSgB1FeU3nxal1nUJbD4Z+HbvxVLCxSa9EgtrGMjt5zDDn2HUdCaabD4xa43+kaz4Z8LW56fYrZr2cfXzPkP4UAesUV5V/wAIT8T/APorn/ltWv8A8VR/whPxP/6K5/5bVr/8VQB6rRXlR8F/FBPmT4spIw5CP4ctlVvYkNmmf8Xo0of8ydr8QH/Ta2mY/wDoAoA9Yrk9S8IeRfTan4UvP7F1OVt8yKm+1um7+dDkAk/31Kv7kcHkj8UfEuikjxj8NtdtIh1uNKkTUIwP7x242j611vgf4h+GPGwlXw/qaTXUP+ttZVMU8f1RgDj3GR70AGm+L/IvodM8V2f9i6nK2yF2ffa3TdvJmwASf7jBX9iOT1lVtRsLTU7Gaz1K1gu7SZdskM6B0cehB4Ncn/ZGu+Fvn8NTNq2kr10m9mPmxD/p3nbn/gEmR6Mg4oAyfG3wze51xvFPgXUP+Ef8WAfvJVXNvfDrtnTvnH3uvfBIGJ/EvxFuPBqadb+IvDev6hcNaRz3t9o1gZrKBySrDeWBGCucHnaQe+K6rw54m03X/OjtHkhvrfAubG5QxXFuT/fQ849GGVPUEjmtqgDzjw58bPh/4i1ey0vS9fV7+8bZFFLbTRZbGdpZkC57Dnk8DJIr0YEMAQQQeQRVW+0yxv1gW9s7e4EEouIvMjDeXIM4dc9GGTyOea8n1T4OyeHUGpfCvWL/AEXU7dvNjsJ7p5rG49UdGJIz65OP1AB7HRXMfDzxDqXiPQmn13QrvRNUt5mtrm2nHys6gZeJv4kOeD9RzjJ6egArnvHek3Gr+HpRppC6taOt7YMTjFxGdygn+63KN/su1dDRQBneHNXt9e0Kw1Wzz5F3Csqq33kyOVPoQcgjsQa0a43w4P7A8Z6roTArZaju1ew4wAxYC5jH0dlk/wC2x9K7KgAooooAKKKKACiiigAoorlfiR41sPAvh19SvUe4uZHEFnZRf6y6mb7qKP5nsPXgEAseNfGmgeCtOW88SajFZo+RFGctJMR2RBkt1HQYGRnFYfgb4teE/GWojS9Pu57XWgHLabfQNDOu08jkbScc4DE4+hxR+Hfga8bU28Y+PjFe+LbpR5cWN0OlxdRDCD0Yd265zg9S1/4s+AP+E9g8PxRXr6ZNp+pLdtfW/wAtzHEEcFYX/hYsYznoNuecAUAd7RXlJ+EeoWv73SfiX46iuR0a9v1u4/xRlANQY+MXhaTC/wBieOLHPGSun3eP/RY/U0Aena7q9hoOkXWqaxdR2lhbIZJZpDgKP6k9AByScCvOPCHxbn1rxTpWnat4Xu9D03W4pZdGvrq4Um8CYODGF/dkqdwyTnjGcg1FpXw817xZfWWsfFbU47pYHFxB4ds0C2UD448w8mUjPfjOeSDiuy+Ifgyy8a6GllcTTWV5bSrc2N9bnEtpOv3XXpn3Hf2OCACa68b+GrTxT/wjl3rVlBrPlCb7NJIFOD0GTxuPXbnOOcY5rVm1jTIdWh0qbUbOPU50MkVm86iaRRnLKmdxHB5A7GvNNK+Cml3I1258fXi+K9X1dojLfS2iWxiEcexPLCE7Dg8kHnC5HHNPQfgDoNr4bS11fUNRvNfDxSLrkMxiurfyhiNYWOdiqoAxznr2XaAey0V5LH8ItWklaK9+J/jeTTo8/Zo4LwQzpnr5k2CZfbIGKrWV3rvwx8b6Homsa3eeIfC2vzG1tLrUX3Xdlc9VR5MfvFfIAz+GMfMAex0UUUAFFFBOBk9KACivLta+MemnUZdL8EaVqHjDVIjiRdNX/R4j/tzkbR9RkVVa2+Lniv8Ad3dxo3grT2+/9l/028x6bj+7H1GCKAH/ALSz6T/wrW4F/q1tp2qW8qX2l+Y37yS4iIICL1YkMV4HG7JwK5rTINd+Md5BD40vP+Ed0Ewrcr4Zgl2Xd6gIBlmPDLEXyAMDPscMe68JfCPw3oGqDV7z7Zr2ucH+0dYl+0yKwOdyAjCnPQgZHr1o+J/gfUda1LSvEvhC8t9O8WaTuEMs6Ex3URBzBLj+Ek8HnGTjGcgA7jSNMstH02DT9KtYbSygXZFDCoVVHsBVuvP/AIe/EKTX9Sn8P+I9HutC8VWkXmz2kqlopEyF8yKQcMpJA698DOM16BQAUUUUAFFFFABXEePPhnoPjC4iv5ln03XYObfVtPfybmMjp8w+8PY574xmu3ooA8hTVPid4HJh1bSo/HOkqPkvtPK296g/6aQnhz/u/iav6Z8cvBc9wLTWLm98Pah0NprFo9u6/U4Kj/vqvT6q6lptjqduYNSs7a8gP/LO4iWRfyIIoA5+7tPDHjmGG6sr+2urm3GbfUdMul8+3z3SRCSB6qcqehBHFVG1nXPCgK+J4m1XSE6avZQ/vYl9biBf1ePI9VQDNZuq/A/4capcedc+FbRH9LaSW3X/AL5jZR+lUf8Ahnz4Yf8AQs/+T91/8coA7Cbx94PgjiefxXoESSqHjMmowrvU85GW5HIqL/hY/gf/AKHLw3/4NIP/AIquV1H4IeEYmiuvDukaZY30K7Ql3aLeW0wznbJHJk/8CUqw9SOC3TtH8EQ30OmeK/APhvRdTlbZC7adA9rdN/0xm2AEn+4wV/YjkgHY2nj7wdeXUNrZ+LPD89zO6xxRRajC7yOxwFVQ2SSSAAK6WuatPAPg6zuobqz8J+H4LmB1kili06FHjdTkMrBcgggEEV0tABRRRQBynxFs7j+yYNZ02Iy6pok326BFGWlQAiaIf78ZcD/a2ntXR6feQahYW17ZyCW1uYlmikXoyMAVI+oIqxXG+BiNE1XVvCb/ACx2b/bdPB72kzEhR/1zk3pjsvl+tAHZUUUUAFFFFABRRRQAV434Fgj+I3xM1XxveL5+iaLIdN0FG5RnX/XXIHQkk4VvT3UV0Px71u80X4aagukvs1PUZItNtTnBDzMEOPfaWI9CM11fhDw/Z+FfDGm6Hpq4tbGFYlOMFz/Ex92JLH3JoA2KKKKACiiigAooooAKKKKACvJvinEt/wDGL4S6dcktaNdX94Y+xlggV42/A5/OvWa4L4neD9V16+8P694Wv7az8SaDLK9n9sUtbSpKoSVJNoLDKjqORz65AB3tFeSN48+JGkQq2vfC+W6iiO2a60jU45vM/wBqODBfHsTmpG+Kuvag4i8N/C/xdPP3Gqxppyf99uWFAHqsjpFG0kjKiKCzMxwAB1JNeNazrN98XtVuPDvhG6ltPBlu/l6vrcXBuz3trc9wR95+mD6YDrd+HPHXxOuPs/jiBfCfhRGHm6TZ3i3FxfEdpJk4Eeew59uhHrWjaXY6Lplvp2k2sNpY267IoYl2qo/zznuaAIvD+iab4e0m30zRbOGzsYFCpFEuB9T6k9yeT3rRoooAKKKKAMjxV4d03xToV1pGtQtNZXKhZFSRo24YMCGUg8MAfwrzOfS/iB8NVE+g3s/jXwzEcvpt6f8AiYQJ/wBMpR/rMehHbAHevY6KAOV8O+PdA1zVjpEN01rrawRXEmm3aGKeMOgcDaeCQCMhScd66quT8d/D/wAP+N4Yf7atXW8tzm3vrZ/KuYD6o4598HIz2rG8NaT498KjUoLrV7fxXpcVo76eLlfJvmnGNkTyZ2FTzlzk59KAPRaK8r0/406Ra3cdh450vVPCGoucAajCTbyH/YmUbWHucCvTrO6gvbWG6s54ri2mUPHLEwZXU9CCOCKAJqKKKACiiigAooooAKrajYWmp2M1nqVrBd2ky7ZIZ0Do49CDwas0UAcV/ZGu+Fvn8NTNq2kr10m9mPmxD/p3nbn/AIBJkejIOK2/DnibTdf86O0eSG+t8C5sblDFcW5P99Dzj0YZU9QSOa2qxfEfhnTdf8mS7SSG+t8m2vrZzFcW5P8Accc49VOVPQgjigDaoriv7X13wt8niWFtW0lemrWUJ82If9PEC8/8DjyPVUHNdZp1/aanYw3mm3UF3aTLujmgcOjj1BHBoAs1x3xCVtLOm+K4Ad2jSN9rAP37KTAn+u3CS/8AbLHeuxpk0Uc8MkUyLJE6lXRhkMDwQR6UAORldVZGDKwyCDkEUtch8OZpLO0vvDN3I73OhSi3jd2y0lqw3W7k9/k+Qk9WjauvoAKKKKACiiigDyD493sTeIfhho8nyG48S2955rAlNsHVCACcsZAB245xXr9eTfHdV0/Vvhz4hjZormx8RwWjT5+WO2uAVm3exCqM16zQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5R8RfijqHhvXtYstJ0i2vbfRNPj1LUHnuGjZleTaEiAUjIHzZPHat2x8a3t744t9Kg0tv7MnVWSdlkEnltb+cJydvl+XuPlY3bt/bFAHdUUUUAV9QsbTUrOS01G1gurWQYeGeMOjD3B4NcJrfwzU6LpOn+DfEOreFV0vzfsy2cnmRN5jBmEqMcyDI4BbAya9DooA8lWf4w+GyBcWnh/xlaL/FBJ9gum9zn92PoAa1JPjJ4SsdfvdF8Q3NzoWo20rRhdRt3iSdQSBJG+MFDjIJxn0r0aq2oafZajCYdQtLe6iIIKTxK68+xFAGRp3jbwrqYuDp3iXRLoW0DXM/k30T+VEuN0j4b5VGRkngZqr/AMLH8D/9Dl4b/wDBpB/8VVrT/BXhXTftP9neGtEtftMLW0/kWESebE33o2wvzKcDKng4qr/wrjwP/wBCb4b/APBXB/8AE0AWj418KjSv7T/4SXRP7N8/7N9r+3xeV5u3d5e/djdt525zjmtTTtU0/U4/M02+tbyP+9bzLIPzBNZZ8E+FTpJ0s+GtE/swzfaPsgsYhF5u3b5mzbjft43dccVymofAr4bX83mz+FrdGyTiCeaFefZHAoA9LorzvxJ8P9VH9mzeBfFV/wCHpNNs47GCyYC4s2ij+6HjbktjjeSTim+EfFHjK31+Dw/458M4llDeTrWlHzLKQKpP7wMd0RODjPUngCgD0aiq2m6hZ6pZR3em3UF3aSZ2TQSB0bBIOCODyCKs0AFcnqXhDyL6bU/Cl5/YupytvmRU32t03fzocgEn++pV/cjg9ZRQByem+L/IvodM8V2f9i6nK2yF2ffa3TdvJmwASf7jBX9iOT1lVtRsLTU7Gaz1K1gu7SZdskM6B0cehB4Ncn/ZGu+Fvn8NTNq2kr10m9mPmxD/AKd525/4BJkejIOKAH+MP+JH4k0bxMgxBuGl6iQP+WErDypD7JKV+iyue1dlXM2uqaJ430nUtJkDh3haC+066QxXEIcEEOh5Hswyp6gnrSfD3Ubq70JrHVZPM1fSZm0+8cjHmOgG2X/tohST/gdAHT0UUUAFUtX1Sz0ezN3qM3k24YKW2s3J6cAE1dooA8v+KUulfEL4Y+JtL0a5NxeQ2hu4gsbqwkjO9cFgOSVx+NW/BPxU8Paz4R0jULvUPLu57ZGnTyZDtlxhxkLjhga9Frxz4LTJ4T8W+Lfh7dnyTb3j6lpKPx5lpLzhOxCHg47k+hwAek/8JTo/9jf2r9s/0Df5fm+U/wB70xjP6Vn/APCwfDH/AEE//JeX/wCJrqqKAMXVvFOj6R9n/tC88n7QnmR/unbcvrwDj8ar6f418P6hew2lnqHmXErbUTyZBk/UriuiooA53UPGvh/T72a0vNQ8u4iba6eTIcH6hcVY0nxTo+r/AGj+z7zzvs6eZJ+6ddq+vIGfwraooA5X/hYPhj/oJ/8AkvL/APE1of8ACU6P/Y39q/bP9A3+X5vlP970xjP6VtUUAcr/AMLB8Mf9BP8A8l5f/ia0NW8U6PpH2f8AtC88n7QnmR/unbcvrwDj8a2qKAOd0/xr4f1C9htLPUPMuJW2onkyDJ+pXFGoeNfD+n3s1peah5dxE2108mQ4P1C4roqKAMXSfFOj6v8AaP7PvPO+zp5kn7p12r68gZ/Cs/8A4WD4Y/6Cf/kvL/8AE11VFAGL/wAJTo/9jf2r9s/0Df5fm+U/3vTGM/pWf/wsHwx/0E//ACXl/wDia6qigDF1bxTo+kfZ/wC0LzyftCeZH+6dty+vAOPxqvp/jXw/qF7DaWeoeZcSttRPJkGT9SuK6KigDyH4iaJ4F13xFeS6zrOpWN3LbrY6hBZ7lS6iVw4ST923Q91IOOM4rsYfHnhWCGOKHUAkcahVVbeUAADAA+WutooA5X/hYPhj/oJ/+S8v/wATR/wsHwx/0E//ACXl/wDia6qigDlf+Fg+GP8AoJ/+S8v/AMTR/wALB8Mf9BP/AMl5f/ia6qigDlf+Fg+GP+gn/wCS8v8A8TR/wsHwx/0E/wDyXl/+JrqqKAOV/wCFg+GP+gn/AOS8v/xNH/CwfDH/AEE//JeX/wCJrqqKAOV/4WD4Y/6Cf/kvL/8AE0f8LB8Mf9BP/wAl5f8A4muqooA5X/hYPhj/AKCf/kvL/wDE0jfEDwuykHU+CMH9xL/8TXV0UAfMOpTwfCy9fW/hfrEl34eDGW+8NXAl2txgvFIyHaRwT3+XqRxXttj8SfC13ZW9ympFVmjWQA28uQCM/wB2uwIDAggEHgg0tAHK/wDCwfDH/QT/APJeX/4mj/hYPhj/AKCf/kvL/wDE11VFAHK/8LB8Mf8AQT/8l5f/AImj/hYPhj/oJ/8AkvL/APE11VFAHnXiPW/A2v8AkyXeoSQ31vk219bRzRXFuT/ccLnHqpyp6EEcVzHhrxLdWHxRtFa7j1qx1eAWUt7bW7xS+ZGS0LzRlQoIUyKXQ4OU+Vdoz7ZRQAUUUUAFFFFABXDfE/wKfFUNjqOkXf8AZnirSXM2m34Gdrd45B3jboR/PkHuaKAOF+Gnjz/hJvtWka3a/wBleLtM+W/05z+UsR/ijbggjOMjrkE91XFfEH4f2niyez1K1vrnRfEdhn7JqtnjzEBzlHH8aHJ+U+/Iyc8jbfEbXPAWoppXxchiFlIdtp4ksYW+zzHH3ZkAPlv9Bj2wN1AHsdFZfh7xDo/iSzN3oGp2eo24OGe2lV9p9Gx0Psa1KACiiigAoorj/HPxG8N+C9sWrX3majJgQ6dar51zMT0AjHIz2JwPegCb4j+NbHwNoAvruKS6vJ5Bb2NjDzLdTtwqKP5nsPU4B4aw+Fd/41K6p8YL+XUZpBui0O0neGzss9vkYF3Hds+2WGDV3wN4W1fxJ4mh8eeP4Ps99GjLo+jHldNib+J/WZh19PrgL6tQB5V/wz58MP8AoWf/ACfuv/jlR3H7PXw1kgkSDQZbaVlISeK/uN8Z7Mu5yMjryCPavWaKAPMvhLr+qwavrXgbxZdfa9b0TY9veMNrX1mwGyU+rDhWPqR1OTXpteYfGLw9qsdzpvjnwhH5niLQlYSWuP8Aj/tDzJCe+RyV9ycc4rs/BXifTfGPhqy1zRpfMtLpN2D96Nv4kYdmB4P+FAG5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyeKOeJop40kiYYZHUEEe4NPooA818RfCHSLrVF1fwpeXfhHWQpR7jR9sSTKcHEkWNrcjPbPfPGKS6N8YdJwmn+KfC+vION2rWElswH/bEnNer0UAeVf8Xv/wCqbf8Ak9Qbf413J8ua98A2SHrLbRXUjj8H4r1WigDyZ/hr4v1w48X/ABK1WS1PW10a3SwHuC65LA+4rq/BPw58LeC2eXQtLjS9kz5l5MxmnfPXMjZIz6DA9q66igAooooAKKKKACvJdZ+GOs6Lq+o658MfET6Pc3cxuptIuYxJYXEpHzcYzHuxyRk+mBjHrVFAHkMnxQ8WeHktbn4gfD+XR9F3rFdapa6lHdpCTwHMSAsEzjknjPc4B9Ysru3v7SK6sp4ri2mUPHLE4dHU9CCOCKW6t4bu2lt7qKOa3mQxyRyKGV1IwQQeCCO1eTXHwv1nwlezX/wm1tNMjlYyS6HqIaaxkb1X+KMn2/MAYoA9eoryKL4xP4ckFr8U/D194Zl6LfRI13ZTH/ZeMEgnrtwcdyK3NF+M3w71hmFp4s06Mr1+1lrX8vNC5oA9BormYPH/AIOuH22/i3w/Kw5wmpQsf0atuz1OwvTizvbW4zx+6lV/5GgC3RRTJpY4U3zSJGnTc7ACgB9FYt34s8OWWftmv6Rb4znzb2NOnXq3asO8+K3gG0J83xfojdv3V2kv/oJNAHbUV5fcfHz4ZwOFfxPGT/sWlw4/NYzUDfHfwpd5Xwza6/4kl6eXpelyuc++8LigD1es7Xtb0vw/p732t6hbWFonWW4kCDPoM9T7DmvMpfEHxV8VfutA8MWXhSzcY+36xOJpgPVYV6N7MCKvaF8GtHXUE1bxpe3fi/Wxz5+qHdDH7RwfcVfY59sUAVX+M8Oru0Xw/wDC2u+KHyQtxHAba0J95pBxz7UC1+MfiD5p9Q8OeErZ+iW8JvrlB/tFv3ZP0r1iNEijWONVRFAVVUYAA6ACnUAeTr8Hp9QJfxR4+8Xaq7fejivPssB/7ZoOPwNPH7P3w2b5rnQZrmU/elm1C5LN9cSCvVaKAPKJP2f/AIfxbJdJ0y70m/idZIb20v5/NhZWBBXe7DPGORXq4GABkn60UUAFFFFABRRRQAUUUUAFFFFABVLV7D+0rI2/2u7tMsD5trJ5b8ds46VdooA5X/hDf+pj8Sf+B3/2NH/CG/8AUx+JP/A7/wCxrqqKAOV/4Q3/AKmPxJ/4Hf8A2NH/AAhv/Ux+JP8AwO/+xrqqKAOV/wCEN/6mPxJ/4Hf/AGNH/CG/9TH4k/8AA7/7GuqooA5X/hDf+pj8Sf8Agd/9jR/whv8A1MfiT/wO/wDsa6qigDlf+EN/6mPxJ/4Hf/Y0f8Ib/wBTH4k/8Dv/ALGuqooA5X/hDf8AqY/En/gd/wDY0f8ACG/9TH4k/wDA7/7GuqooA5X/AIQ3/qY/En/gd/8AY0f8Ib/1MfiT/wADv/sa6qigDlf+EN/6mPxJ/wCB3/2NH/CG/wDUx+JP/A7/AOxrqqKAOV/4Q3/qY/En/gd/9jR/whv/AFMfiT/wO/8Asa6qigDlf+EN/wCpj8Sf+B3/ANjWRrXwo0LXWVtbudR1Fl6G7kjmx/30hr0GigDyS5/Z+8CXK7ZLKUDkfuxFGfzVBVD/AIZo+Hn/AD7al/4GH/CvaqKAPFf+GaPh5/z7al/4GH/Cj/hmj4ef8+2pf+Bh/wAK9qooA8bt/wBnD4f27Fo7S9JP/PScOP8Ax5TWzZ/BfwrZYNmlxb45/dCJP5R16XRQBx9t4Dt7VNttrmvwrwMR3YUcdOi1N/whv/Ux+JP/AAO/+xrqqKAOV/4Q3/qY/En/AIHf/Y0f8Ib/ANTH4k/8Dv8A7GuqooA5X/hDf+pj8Sf+B3/2NH/CG/8AUx+JP/A7/wCxrqqKAOV/4Q3/AKmPxJ/4Hf8A2NH/AAhv/Ux+JP8AwO/+xrqqKAOV/wCEN/6mPxJ/4Hf/AGNH/CG/9TH4k/8AA7/7GuqooA5X/hDf+pj8Sf8Agd/9jR/whv8A1MfiT/wO/wDsa6qigDlf+EN/6mPxJ/4Hf/Y0f8Ib/wBTH4k/8Dv/ALGuqooA5X/hDf8AqY/En/gd/wDY0+Lwh5cqP/wkPiJ9rBtrXuQcdiNvSunooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic illustration of the phlebostatic level. As the patient moves from the flat to the upright position, the phlebostatic level rotates on the axis and remains horizontal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Bridges, EJ, Woods, SL, Heart Lung 1993; 22:99.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10288=[""].join("\n");
var outline_f10_3_10288=null;
var title_f10_3_10289="Peripheral IV placement 4";
var content_f10_3_10289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Using your nondominant hand, stabilize the vein and area around the venipuncture site. Insert the needle at a shallow angle (approximately 10 to 30 degrees from the skin surface) to enter the vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10289=[""].join("\n");
var outline_f10_3_10289=null;
var title_f10_3_10290="Patient information: Ischemic bowel disease (The Basics)";
var content_f10_3_10290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83034\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/48/8962\">",
"         Patient information: Acute abdomen (belly pain) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/24/5506\">",
"         Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ischemic bowel disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ischemic-bowel-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11643978\">",
"      <span class=\"h1\">",
"       What is ischemic bowel disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ischemic bowel disease is a condition in which there is not enough blood flow to the intestines. It can happen in the large intestine or the small intestine (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). It can cause belly pain, nausea, diarrhea, and other symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11643993\">",
"      <span class=\"h1\">",
"       What are the symptoms of ischemic bowel disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain &ndash; This can be mild or severe. It can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Start suddenly, or happen over several days or years.",
"       </li>",
"       <li>",
"        Start about 1 hour after eating, and last about 2 hours. Eating a big meal can make this pain even worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Nausea, vomiting, or both",
"       </li>",
"       <li>",
"        Blood in bowel movements &ndash; This can be bloody diarrhea",
"       </li>",
"       <li>",
"        Weight loss, when not trying to lose weight",
"       </li>",
"       <li>",
"        Eating problems, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Food fear -- Not wanting to eat because pain starts after eating",
"       </li>",
"       <li>",
"        Feeling full too quickly when eating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11644008\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about the symptoms and do an exam. He or she will also order 1 or more tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        X-ray, CT scan, or ultrasound of the belly &ndash; These imaging tests create pictures of the inside of the body. They can help show the cause of symptoms.",
"       </li>",
"       <li>",
"        Blood tests &ndash; These can show signs of bad nutrition. Or they might show that a different condition is causing symptoms.",
"       </li>",
"       <li>",
"        Tests called &ldquo;endoscopy,&rdquo; &ldquo;upper endoscopy,&rdquo; &ldquo;sigmoidoscopy,&rdquo; or &ldquo;colonoscopy&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ) - For these tests, the doctor puts a thin tube down your throat and into your stomach, or up your rectum and into your colon. The tube has a camera attached so the doctor can look inside your body. The tube also has tools attached to it, which the doctor can use to take samples of tissue. These samples can go to the lab to be checked for problems.",
"       </li>",
"       <li>",
"        A test called an &ldquo;arteriogram&rdquo; - For this test, the doctor injects a dye into the arteries that carry blood to the bowel. This dye can be seen with an imaging test such as a CT, MRI, or fluoroscopy (a moving X-ray). The test can show if arteries around the bowel are blocked. If they are, this could be keeping part of the bowel from getting enough blood.",
"       </li>",
"       <li>",
"        Laparoscopy&nbsp;&ndash; This is a procedure that the doctor does in the operating room. The doctor makes a small cut near the belly button. Then he or she puts a small device called a &ldquo;laparoscope&rdquo; inside. The doctor looks through the laparoscope to see if he or she can find the cause of symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11644025\">",
"      <span class=\"h1\">",
"       How is ischemic bowel disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for ischemic bowel disease depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What is blocking the arteries around the bowel",
"       </li>",
"       <li>",
"        Whether the symptoms started suddenly or came on over a long time",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people with ischemic bowel disease need treatment in the hospital. In the hospital, the doctor can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give you fluids and nutrition through an &ldquo;IV&rdquo; (a small tube that goes into your vein)",
"       </li>",
"       <li>",
"        Put a thin tube called a &ldquo;nasogastric tube&rdquo; in your nose, down your esophagus, and into your stomach. If there is extra fluid and air in your stomach or intestines, the tube can suck it up. This will make you feel better and help keep you from vomiting.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Antibiotics to prevent or stop infection",
"       </li>",
"       <li>",
"        A procedure to open a blocked artery",
"       </li>",
"       <li>",
"        Surgery to take out part of the bowel that is not healthy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These treatments can help the bowel work correctly again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11644040\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=see_link\">",
"       Patient information: Acute abdomen (belly pain) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"       Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/3/10290?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83034 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10290=[""].join("\n");
var outline_f10_3_10290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11643978\">",
"      What is ischemic bowel disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11643993\">",
"      What are the symptoms of ischemic bowel disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11644008\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11644025\">",
"      How is ischemic bowel disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11644040\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=related_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_3_10291="Calculator: Post-test probability from likelihood ratios and multiple test results";
var content_f10_3_10291=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PostTestProbMulti_form\" name=\"PostTestProbMulti_form\" onkeydown=\"clrResults();\" onkeyup=\"PostTestProbMulti_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Post-test probability from likelihood ratios and multiple test results",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Input:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Pre Test Prob",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Pre_Test_Prob_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Pre_Test_Prob_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" colspan=\"3\">",
"         <span class=\"medCalcFontCCTabBold\">",
"          &nbsp;",
"          <br/>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 1",
"         </span>",
"        </td>",
"        <td colspan=\"2\" nowrap=\"nowrap\">",
"         <span class=\"medCalcFontOne\">",
"          <input checked=\"checked\" name=\"Test_1_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Not Done|0\"/>",
"          Not Done &nbsp;",
"          <input name=\"Test_1_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Pos|1\"/>",
"          Pos &nbsp;",
"          <input name=\"Test_1_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Neg|-1\"/>",
"          Neg &nbsp;",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 1 LR Pos",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_1_LR_Pos_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_1_LR_Pos_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 1 LR Neg",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_1_LR_Neg_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_1_LR_Neg_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" colspan=\"3\">",
"         <span class=\"medCalcFontCCTabBold\">",
"          &nbsp;",
"          <br/>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 2",
"         </span>",
"        </td>",
"        <td colspan=\"2\" nowrap=\"nowrap\">",
"         <span class=\"medCalcFontOne\">",
"          <input checked=\"checked\" name=\"Test_2_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Not Done|0\"/>",
"          Not Done &nbsp;",
"          <input name=\"Test_2_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Pos|1\"/>",
"          Pos &nbsp;",
"          <input name=\"Test_2_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Neg|-1\"/>",
"          Neg &nbsp;",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 2 LR Pos",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_2_LR_Pos_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_2_LR_Pos_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 2 LR Neg",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_2_LR_Neg_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_2_LR_Neg_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" colspan=\"3\">",
"         <span class=\"medCalcFontCCTabBold\">",
"          &nbsp;",
"          <br/>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 3",
"         </span>",
"        </td>",
"        <td colspan=\"2\" nowrap=\"nowrap\">",
"         <span class=\"medCalcFontOne\">",
"          <input checked=\"checked\" name=\"Test_3_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Not Done|0\"/>",
"          Not Done &nbsp;",
"          <input name=\"Test_3_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Pos|1\"/>",
"          Pos &nbsp;",
"          <input name=\"Test_3_radio\" onclick=\"PostTestProbMulti_fx();\" type=\"radio\" value=\"Neg|-1\"/>",
"          Neg &nbsp;",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 3 LR Pos",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_3_LR_Pos_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_3_LR_Pos_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Test 3 LR Neg",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Test_3_LR_Neg_param\" onblur=\"PostTestProbMulti_fx(); minMaxCheck();\" onchange=\"PostTestProbMulti_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Test_3_LR_Neg_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"          <option value=\"0.01|0|%\">",
"           %",
"          </option>",
"          <option value=\"1|0|fraction\">",
"           fraction",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|ratio\">",
"           ratio",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Results:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Pre Test Odds",
"         </span>",
"        </td>",
"        <td nowrap=\"nowrap\" valign=\"top\">",
"         &nbsp;",
"         <input name=\"Pre_Test_Odds_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"        </td>",
"        <td valign=\"top\">",
"         <span class=\"medCalcFontOne\">",
"          <select class=\"medCalcFontSelect\" name=\"Pre_Test_Odds_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"           <option value=\"0.01|0|%\">",
"            %",
"           </option>",
"           <option value=\"1|0|fraction\">",
"            fraction",
"           </option>",
"           <option selected=\"selected\" value=\"1|0|ratio\">",
"            ratio",
"           </option>",
"          </select>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Post Test Odds",
"         </span>",
"        </td>",
"        <td nowrap=\"nowrap\" valign=\"top\">",
"         &nbsp;",
"         <input name=\"Post_Test_Odds_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"        </td>",
"        <td valign=\"top\">",
"         <span class=\"medCalcFontOne\">",
"          <select class=\"medCalcFontSelect\" name=\"Post_Test_Odds_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"           <option value=\"0.01|0|%\">",
"            %",
"           </option>",
"           <option value=\"1|0|fraction\">",
"            fraction",
"           </option>",
"           <option selected=\"selected\" value=\"1|0|ratio\">",
"            ratio",
"           </option>",
"          </select>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Post Test Prob",
"         </span>",
"        </td>",
"        <td nowrap=\"nowrap\" valign=\"top\">",
"         &nbsp;",
"         <input name=\"Post_Test_Prob_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"        </td>",
"        <td valign=\"top\">",
"         <span class=\"medCalcFontOne\">",
"          <select class=\"medCalcFontSelect\" name=\"Post_Test_Prob_unit\" onchange=\"PostTestProbMulti_fx();\" style=\"width:105px;\">",
"           <option value=\"0.01|0|%\">",
"            %",
"           </option>",
"           <option selected=\"selected\" value=\"1|0|fraction\">",
"            fraction",
"           </option>",
"           <option value=\"1|0|ratio\">",
"            ratio",
"           </option>",
"          </select>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td colspan=\"3\">",
"         &nbsp;",
"         <br/>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\" colspan=\"3\">",
"         <span class=\"medCalcFontOneBold\">",
"          Decimal Precision:",
"         </span>",
"         <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"PostTestProbMulti_fx();\">",
"          <option>",
"           0",
"          </option>",
"          <option>",
"           1",
"          </option>",
"          <option selected=\"selected\">",
"           2",
"          </option>",
"          <option>",
"           3",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontOne\">",
"       <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"      </span>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Use this calculator to evaluate the contribution of different test results to an overall post test probability (",
"       <b>",
"        Post Test Prob",
"       </b>",
"       )",
"of a disease or condition based on the",
"       <b>",
"        Pre Test Prob",
"       </b>",
"       (prevalence) and the likelihood ratios of the various tests employed.",
"      </li>",
"      <li>",
"       Input one or more test results and the associated",
"       <b>",
"        LR Pos",
"       </b>",
"       and",
"       <b>",
"        LR Neg",
"       </b>",
"       values associated with that test.",
"      </li>",
"      <li>",
"       When a test result is positive, only the",
"       <b>",
"        LR Pos",
"       </b>",
"       input is required.  If a test result is negative,  only the",
"       <b>",
"        LR Neg",
"       </b>",
"       input is required.",
"      </li>",
"      <li>",
"       This calculator then mutiplies the appropriate likelihood ratios by the",
"       <b>",
"        Pre Test Odds",
"       </b>",
"       to produce the",
"       <b>",
"        Post Test Odds",
"       </b>",
"       .",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        Post Test Odds",
"       </b>",
"       are then converted to an overall",
"       <b>",
"        Post Test Prob",
"       </b>",
"       .",
"      </li>",
"     </ul>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10291=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function PostTestProbMulti_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PostTestProbMulti_form){",
"",
"",
"doCalc = true;",
"if (Pre_Test_Prob_param.value.indexOf(',') >= 0){ Pre_Test_Prob_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Pre_Test_Prob_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Pre_Test_Prob_unit.options[Pre_Test_Prob_unit.selectedIndex].value.split('|');",
"Pre_Test_Prob = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_1_radio[0].checked){ Test_1 = 0; }",
"if (Test_1_radio[1].checked){ Test_1 = 1; }",
"if (Test_1_radio[2].checked){ Test_1 = -1; }",
"if (Test_1_LR_Pos_param.value.indexOf(',') >= 0){ Test_1_LR_Pos_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_1_LR_Pos_param.value);",
"unit_parts = Test_1_LR_Pos_unit.options[Test_1_LR_Pos_unit.selectedIndex].value.split('|');",
"Test_1_LR_Pos = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_1_LR_Neg_param.value.indexOf(',') >= 0){ Test_1_LR_Neg_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_1_LR_Neg_param.value);",
"unit_parts = Test_1_LR_Neg_unit.options[Test_1_LR_Neg_unit.selectedIndex].value.split('|');",
"Test_1_LR_Neg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_2_radio[0].checked){ Test_2 = 0; }",
"if (Test_2_radio[1].checked){ Test_2 = 1; }",
"if (Test_2_radio[2].checked){ Test_2 = -1; }",
"if (Test_2_LR_Pos_param.value.indexOf(',') >= 0){ Test_2_LR_Pos_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_2_LR_Pos_param.value);",
"unit_parts = Test_2_LR_Pos_unit.options[Test_2_LR_Pos_unit.selectedIndex].value.split('|');",
"Test_2_LR_Pos = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_2_LR_Neg_param.value.indexOf(',') >= 0){ Test_2_LR_Neg_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_2_LR_Neg_param.value);",
"unit_parts = Test_2_LR_Neg_unit.options[Test_2_LR_Neg_unit.selectedIndex].value.split('|');",
"Test_2_LR_Neg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_3_radio[0].checked){ Test_3 = 0; }",
"if (Test_3_radio[1].checked){ Test_3 = 1; }",
"if (Test_3_radio[2].checked){ Test_3 = -1; }",
"if (Test_3_LR_Pos_param.value.indexOf(',') >= 0){ Test_3_LR_Pos_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_3_LR_Pos_param.value);",
"unit_parts = Test_3_LR_Pos_unit.options[Test_3_LR_Pos_unit.selectedIndex].value.split('|');",
"Test_3_LR_Pos = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Test_3_LR_Neg_param.value.indexOf(',') >= 0){ Test_3_LR_Neg_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Test_3_LR_Neg_param.value);",
"unit_parts = Test_3_LR_Neg_unit.options[Test_3_LR_Neg_unit.selectedIndex].value.split('|');",
"Test_3_LR_Neg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Pre_Test_Odds =  Pre_Test_Prob / (1 - Pre_Test_Prob);",
"",
"unit_parts = Pre_Test_Odds_unit.options[Pre_Test_Odds_unit.selectedIndex].value.split('|');",
"if (doCalc) Pre_Test_Odds_param.value = fixDP((Pre_Test_Odds - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"var Overall_Odds = Pre_Test_Odds;",
"if ((Test_1 == 1) && Test_1_LR_Pos) Overall_Odds = Overall_Odds * Test_1_LR_Pos;",
"if ((Test_1 == -1) && Test_1_LR_Neg) Overall_Odds = Overall_Odds * Test_1_LR_Neg;",
"if ((Test_2 == 1) && Test_2_LR_Pos) Overall_Odds = Overall_Odds * Test_2_LR_Pos;",
"if ((Test_2 == -1) && Test_2_LR_Neg) Overall_Odds = Overall_Odds * Test_2_LR_Neg;",
"if ((Test_3 == 1) && Test_3_LR_Pos) Overall_Odds = Overall_Odds * Test_3_LR_Pos;",
"if ((Test_3 == -1) && Test_3_LR_Neg) Overall_Odds = Overall_Odds * Test_3_LR_Neg;",
"Post_Test_Odds =  Overall_Odds;",
"",
"unit_parts = Post_Test_Odds_unit.options[Post_Test_Odds_unit.selectedIndex].value.split('|');",
"if (doCalc) Post_Test_Odds_param.value = fixDP((Post_Test_Odds - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"Post_Test_Prob =  Post_Test_Odds / (1 + Post_Test_Odds);",
"",
"unit_parts = Post_Test_Prob_unit.options[Post_Test_Prob_unit.selectedIndex].value.split('|');",
"if (doCalc) Post_Test_Prob_param.value = fixDP((Post_Test_Prob - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PostTestProbMulti_form){",
"",
"if (Pre_Test_Prob_param.value && Pre_Test_Prob < 0) {",
"Pre_Test_Prob = 0;",
"Pre_Test_Prob_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Pre Test Prob is 0 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Pre_Test_Prob_param.value && Pre_Test_Prob > 1) {",
"Pre_Test_Prob_param.value = \"\";",
"clrResults();",
"Pre_Test_Prob = 0;",
"doCalc = false;",
"alert(\"The maximum value for Pre Test Prob is 1 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PostTestProbMulti_form){",
"",
"Pre_Test_Odds_param.value = '';",
"Post_Test_Odds_param.value = '';",
"Post_Test_Prob_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f10_3_10291=null;
var title_f10_3_10292="Insertion-removal of contraceptive vaginal ring";
var content_f10_3_10292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F85546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F85546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Insertion and removal of the contraceptive vaginal ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A and B illustrate insertion of the contraceptive vaginal ring. C shows removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10292=[""].join("\n");
var outline_f10_3_10292=null;
var title_f10_3_10293="Multiple pulmonary nodules in primary amyloid";
var content_f10_3_10293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Primary amyloid of the lung: Multiple, confluent calcified and ossified pulmonary nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple, confluent calcified and ossified pulmonary nodules in a patient with primary amyloidosis of the lungs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10293=[""].join("\n");
var outline_f10_3_10293=null;
var title_f10_3_10294="Pneumonia anatomy PI";
var content_f10_3_10294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 533px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIVAioDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAprnaR6U6myDKmgaHDkUUyI5Xmn0CCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKCcDJ6V5p4y+KNrp00lloQju7pTteZuY0PoMfeP6UAel0V826j428R6i5Mup3MSH+GDEY/TmsttTv3O46nfFj3M7f40AfUVxPFbQvNcSJFEgyzuwUAe5NcPqvxQ0S0laOzjudQYfxQqAn/fRIz+ArxK7v8AUL2FYJr27uYlOQkjllz64NMSK4KjdHMw9uKAPWZfi7GEbbotwHx8uZlIz78VVg+LkzuFbTI8+m8r+vNeaxRqT+8jlT6k1Y+xJIMxOc+/NAHtOjfEjRr6RYbwS6fM3H77BTP+8P64rtVYOoZCGUjIIOQRXy8zmFdt0FZem6us8D+NZtAuIrW6mM2kscFWOWh919vagD3aimxSJLGkkbBo3AZWHQg9DTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAAMUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVTU9TstLtzPqN1DbRf3pXC5+nrXA+NfiJoknhnUoNJ1LffSRGOPZG46nBIOPQmgDG+J3jGS8kuNN024MemwnZcTxNzO3dFI7DofWvOIGjUAJEsWfxNUWu41tbeJRlYxux/tGoI5izZYk57DvQBtZiPcs1OWKAsPMVmI5CqM1Qt5JMjyoG/Ktewv4oSFuoZIif4sUATwzSIo8qxkC+pAFWItQZSBNbsv1FbFolrdRhomZgfem3OmblzA+G9G4oAbBLbTjBGCf4TUF3pUD5e2IV/7p4BrNuFubKYmeJimfvL2rY0+6guFALgnHBB60AQW0EciYNshdeGG0ZFSjTbCfiaBEPsKsahBJBsuYDk9DjoarrqAmX9/BnHV060AQ3WgzR/Ppl1KCOi+Y2P58VHp3ibxBo1wIkv7hHH/ACxuD5qN9N3P5EVp2zZI8p9wPSm6jax6nAYrgbZkOFk7g0Adt4W+ItpqEiWusRrYXTHaJM5ic/X+H8fzrva+aWjy729wNsyHa2e/vXpfwu8SymQaHqUhdlGbWRjyQOqZ78cj8qAPS6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhfiN45Xw6osdOCS6rKMgNysIPQkdz6D/J6XxRrUHh/RLjULnBEYwif33P3V/E181PdzX1/c6hdsZJ5XLFj3Y/0HSgCfUZ7zVb0zahdSXd2x+9IchPoOgqEaWHznJwep71Pbrsh3/wATVrQpuRG9Rg0ActPphSXymyrEZRuxqWy0yaZGMIHmp1jPU/SuqvrPztPZgP3kRDqfakgiEbwXSfcfAYCgDmQro/GUdeqmtay1ITL9nu1V16YcfyNdHrukpPbC4iAE0YzkDqPWubkskkEdyigDdtlXsPegDRslitrlAHZIHOAw/hPvXSw3DRMsd0odD91x3rnJLGSAjrsI5VuRV+0vVWIQ3GdvTmgDdltoZUww3Ien/wBauY1LTf7Pm8yFd8Dnkf571u2MuC0O/cpGVNLfFXVUYcSj8jQBRsDmI25y0Z5GTnFQQKbfU2s5QCHG6Nj0I9KT54TG/IOcEUk6y3d8hhUsbcFmYdlpXVrjs9jWNiikGMbd3I9jSTQ4+ZsZI2t7+lEt35KDJ54Iz0J7809ruGbzVBGQoyPSmI53U4PNngmdSJM+U5HcjoabLHPaSJcwMVmgdXjccEEcirl2GHG/Kbg2TyVq5DGZ4AkhWQYxuXt+FAHsWkXi6jpdpeJjE8SyYHbI6Vbrj/AOqQR6dBpMx8u4hyI89JFyTx7+1dhQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHcTR21vLPMwSKNS7sewAyTQB4t8cNZe41i30mJv3dugdgO8jev0X+dcDDFysa9AMVPrmo/214kvtTYY+0OWVf7q9F/QCprVAsTOevWgBrsFjUDp0roLKAm2iJHvXOWytcyW8YGSW7egrvEhEUQX+6oFAEMMQeN0I4YbaztPiL6dLH/zzcgfnWzbjDk44xVXTVHl3Ix1dj+tAGvGN9lHn+JdprjimwX0XZSTXZWv/AB6qnpXNGMPJcsP+WkmxffJoA1SvnafEzffCDNZDJ5cuxhlD0rd+WGbyf4QNtZ10qvFIF+9Gc0AOsXEEoRvuE4Vj/AT/AENaF5EzbVCEkHgjtWZPHm3ik/vqYz9cZFbWnSma2gkbqyAn8q5MTUlSacdmdWHpxqppmfrduUiiVAWkbBwoyeAc/qRW1oelLZoZJOZ5ECuPzJH6/pVuFRkHA3YxnvVyIVwyrylHlOpUYxlzGTPpiIGVkEkDdj1H+fWs+LTbYSsqgq+PlbcCV/xFdVIMCqc0SF9+1d2MZxzWn1qXJyv7yPq8ebmRyeoW+xWWQY24B9s9x7H9Kxre8nsZG3p5kCNtz0Irs9Tt/OtZFxltpArmbSB5Yr1mUqjqFGR1bHNdEcV+753ujJ4b95ydGattcpexrLauVlQ5U9GUj1r1PQL/APtPSbe5Iw7DDj0YcGvKG0h49c046cfLjvreOWME/LkjDKfbP8xXovgZGj0iZHUqy3MgKnsQQCPzrsTurnI1Z2OiooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4n4xX5sfAt2qNh7p0txj0Jyf0Brtq81+O3PhuwXt9sBP/fDUAeL2CgzOPQYq7cSkR+UnUmoLFArufbrWxpNqstzuUFhnJJ70AaXhuwNnGby5XDsNsansK35sqqK3+sk5xTEVYsTXLA7eEjFT2W2ac3M7JxwEByaV1sOztcnkiEMOe+2s7TwA85HIyQMVPrV20UWAMTScIvp703SYgIiW+6q8n1NMRKjt5DqnDtxn0FVxBHGwJ+6gJX3PrVor5cJJHzEfzqm7bpnA6KpFAETz7iG7nBqKZgl3cD+/EDVcNvUY7YH61Jexl7l2X7oATP6n+dJuwJXLMrZ0yLYDnI2j1ODW3YweRbxRnqihT9aoaPCblYpXQrCg/dhurH1roI4s815uLqKclFdD0cLBwi5PqOgTIFXVXApsCYFWNvFctjZshk+7VRzg4q5NwtUpeTSY0VZDhjVC8wUNXp+Mms+fkVDNonT+DLFb3TdIu5SCtmk0QXuW8wYP4Ba7JUVM7FC5OTgYyfWuZ+Hg/4p1f8ArvL/AOhGunr3aLvBeh41ZWqS9QooorQyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK8V1X4v6jo3xtvvDGqWdmvhiGS3tRfKjCSKeeEPH5jFtu0sHX7oxwc8cgHtVFeQ+BfjANT8D+E77WrFrrxH4gluI7bTdJjAL+VI6lh5sgCqFUEln9ce126+NvhqHStJvYrLWrp9Ru5bBbS2tQ9xDcRgFonTd975lxt3ZzQB6jRXl138Z9JtZNRim8P+JEn07T49Tu4Xt4o3hhfH3laUHcu4ZXr6ZrV0T4oaPrOuDSbOy1MXc2lrrFn5kcaLeW7dDGS/yk9MSbPyoA7yivKLj4waVqcHiPStLFxY+ILLSbm+h3y2twoaNG/ihllQMpGSjYPtiup+EesX3iD4a+HtV1ef7Rf3dqsk0uxU3tk84UAD8BQB11FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwnxntTceD/NAz5E6OfYHK/1Fd3VLW9PTVdIu7GX7lxGyZ9CRwfwNAHy8pZmWKLl3/ya6zSI8SRW8K5c4GfeufsrOSyvrxbpdssMhhI64KnB/Wuy8GRq0k10/CoMCsq9T2cHI1ow55qJtzz2Wjxp54Ek7DuNx/AVJa3tjqyldgDL3A2sprO0mIXrTXtxyZCSuew7CqBkFtrsDRcB8qQO9eK5Nu7PYUFaxdvtPdZnkcl26Ak9aSxlxGVfCqOgralO5c1g/ZS+obT9wEtivQwmIc3yyPPxVBQXNEsXMhkZmXPlpzn1NZ9puf7S3XapP6Vp3a4tmA78Cq1gqu1wi9ZH28f3R1P6V3NqKuzjSbdkUYrYiaGGPmQqGYenfmt+3t4okC7Qxzkk9zUixKrEqoBPU+tPC815NfEOrotEepRw6p6vVliBcmr0QFVYB0q2gC8kgAdzWBrIsRipjjFYtzrNvBwoeVj0CDr9PX6is+41bVU/eR2O6McsrEAge2CTWiizJtHQ3BGKoStg1gReMImKCeIHd1EZPHr16/QVYsNZt9SnaKP5ZOSoJ6j8qJU5xV2hwnFuyZemOTiqtwmFNLHOHuJUHPlkAn8KkR0ukzGQRWTOhaHV/D0Y8Or/ANd5f/QjXS1zXgJlGjzRA8x3Dgj0zg/1rpa9qj/Dj6HjVv4kvUKKKK1MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvNtX+FNlrOs+OrvU73zrfxPb20PkCDBtGhTasgbd8x3AMOBjGOa9JqvfXtrp9u09/cwW0C9ZJpAij6k8UAeT6F8GG0LSPBq6Zr6rrnhiS5MF7LZFoZknZi6PCJAejYBDjv68O034KwafL4ani1p3utM1iXWruV7Yf6ZNJt3AAN+7GEAH3q6e8+K/ge2nMK+IrS6mH/LOxD3bflEGqIfE/S5ebPRPFd2p6NFoVyAfxZBQBm+JfhV/bfiHxhqn9s+R/wAJDpS6Z5X2Xd9nwF+fO8bvu9MD61nSfBWOa5s3m16URQeFh4ZZYrbYzgAjzg284zn7mD9a6U/Em3UZfwv4xUev9izH+QpjfFnwtB/yEn1bTP8Ar+0m6hA/4EY8frQBymlfBO5tbm1luvEVtItr4fl8PxJb6X5I2OHAlb982Wy5J6bj6V6T4B8O/wDCJeDdJ0H7V9r+wQCHz/L8vzMd9uTj8zTdD8beF9eKro3iDSryRukcV0hf/vnOf0roaACikBOeRS0AFFFFABRRRQAUUUUAFeDfHXUvEWheNbCDRL/VEi8U2H9j26QzuI7W78+P98oB+RvLZuRg8fWvea5bVfFotPG9h4bt7RZpHs5NRvbmSfyktLdW2huh3EtkY44BOaAPnzSPF3imfwt4z1fVbu/aTwppUGjPbSXlxEk92twd8zGN0fftVQW3BvmwTjOe21X4r+JNP1XWBFb6Q+m6Xq9hpzRPFL50sdwgJbzPMwGB9VOc+3Pe+FPir4Q8R6KdTi1izsYhO1uY766hikDAtjjeeGClhzyBmtyHxh4Zn1KLToPEWjSahNtMdsl9EZX3KGXCBsnKkEYHIOaAPn/VvHGo+JPiJ4Tub5tMtp9M1nUIY9LSNvtFuI4SFacl+d2OMIvQ8ntbsvjNrut+Grt5E0i88zw7c6nOumieB9PmjJCpK6TFhuxkYKMMjnufU/iN8SNA8O+GNemhvNM1fUNPi/f6VFqCJMQXVGDAbmXG/n5a0fCGp+DtH8HpDoOqaVb6HpaiOTbfrIloSc7XkZjg5J+8c0AeSar8Zdf0qe8tLRdFklsrTSpLXT5Y5pLrUWuUQyJGxlzuXdnJVzjrk8nesfir4hufidJoEmmaXa2Ueqtp7QXVxDDdGEcLOm+cNJk87VhII6OTxXaw6t4B0nU7rxQuu6HbXGtqsb3r6mnl3IhG0Bcvs+UMM7fUZq3qnjCPTvFnh7TJbaOTTddjcWmpRzhlMyrvEZXGMMmSrBjkjGO9AHV1X1G4+yafdXP/ADxiaT8gTVis/wARRmXw/qSL95raQD/vk0AfNl3csIgScyzMWJ9STk12nhkGPw1O3coxzXAMxkuAeyLwK7vwjJ9o0CWDPJDLXHjf4a9Trwf8T5FyO5FtpcSrxkVSggMt7HM5xtOfpUUsh+xWjNwFbY3scVNdz7LGVozhgua8s9U6UMGiBBzVJ8JO7D72zAHqSaSwdTZoU+6QCKdn584GfWqo1PZTUmRVp+0g4oNUzHEqQr5kxIUAdjipdPtFtYFyMykfMaSCICVXDHAzweck96uV04jE+0XLHY5aGH9m7y3G4pQOaULmp4o/WuU6rj4BipJkWRNrjcM9D0pypgUxwfXFFyHqLHsyfu7uhNNlWIqc4/OqN5b29xkXEWSf40JVh+I5rmNU07WIUd9P1aOVFHEV1AHJ/wCBDn9aaV+o9uhF4tt7aFfMg4dmyIwuct6gjBB96xtMN9DqNvcQxEGNSNpPcg/pzWhp9rqMsw/tMQM+PvRk8e2D0/OulsrJEOcVr7WUVy3J9lBvmsM0q0lh0uZpmLTOGZm9zXJ6Jc3sqbbS4/0gHAUE8KPXsB9etejwpm3dfauW8N2NzdX1zpdkFVxIdztwFQnhj69aVGTTdldsKkVJXbskdx8LpJp9Mv5bhcSG52njjIRc12tU9I06DS7CK0thhEHJPVmPVj7k1cr2IR5YpHkTlzSbCiiiqJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiua8Z+M9M8KxwR3PnXeqXZK2em2i+ZcXTeir6erHAHc0AdIxCqWYgADJJ7Vwt58SbG6u7iw8G2F34p1GE7ZBYFVtom9JLhsRj6AsfaqR8Ia7402TfEK7W20s/MPDunSHyj6C4mGGlP8AsjamR3rv9NsLTTLKKz021gtLSIbY4YECIg9ABwKAODGgeOvEfz+IfEcfh+zf/lw0FA0oHo1zICc/7ir9a0NK+F3hDT5/tL6PHqF71N1qbteSk+u6Utg/TFdrRQBHb28NugS3ijiQfwooUfkKkoooAKKKKAMfWvDGg63GU1jRtOvgeP8ASLZHI+hIyPwrzXXPB0Hh7UUTwLrer6BKo3PDHcG5tcnoDDKWX8sV65e3CWlrLcSnCRqWNebo8l1cvNLzJKxY0AN03xj4u0cBfEmiRa1Zgc32ifLKo9XtnOT/AMAZvpXaeFvFeieKraSbQtQiuTEdssXKSwt6SRthkPsQKoWEIKqCKy/F3hDS9WuI9SXzdO1yFcQarYt5VwnsxHEi/wCy4INAHf0V5Tp3xDv/AA1dRWXj8W7WLkRxa/aqUiLHgC4i58on+8CUJ/u16nFIksavG6sjgMrKcgg9CDQA+iiigAooooAK4e90TUrT4v2fiKytPtWm3ulnTLwrIqtbMkhkjkwxG5TuZSFyRwcV27MFUsxAUDJJ4AFV9N1Cy1WxivdMu7e9s5QTHPbyLJG4BwcMpIPII/CgDye2+CqCw0jS7/V7W+0bTdYfVY7abTdxlVy5aGQmQqw+YfNtHQ8HPFjXPhHear4rsNTbxRKmnadqdtqFlp/2d9lqkP8AywjVZViCn+95e4dMkZz6zRQB5FJ8Ir5fh9q/gq28RWyaDeu8kTSaaXuomaZZfnkEwEnQjlAeRzxik8QfBWHWLvxHc/23LbyapdafeQCKAoLeS1jZBu2yAuG3E8FCDjByM169RQB43P8ABq/bR20608UfYLW4nuZ763tYrsRXjTIqF5C120hYYJ5kKHIynXdeh8C6pbXnw50JMz6J4YU3VxqR2J50qRmOKNY9xYfeLHtgYzmvVq5Tw3rV7b6zN4c8Suh1RVaazulTYl/bg/eA6CRMgOo9Qw4PAB1dI6h0ZWGVYYIpaKAPlrULR9N8QahYSj57eUx/UZ4P5YrY8GXy2t/JbSH5ZOV+tWPilam0+IN5Jt4nVJfrxj+lczCH+1rJCcPGN/FZ1Ye0g4l05+zkpHol3bRwTSeaoazuPvD+63rWbqGjTRxk6fKZEbgxu3b2NXtB1WHUbQRzgcjaynsa1YrEx/6uTdH2B7V4kk4Oz3PbjJSV0UtEtZbbToopjl1GDirZX5qsFSnFIFz1rNloYgIFTI1OWPinLHzVITsTQjNWVWo4VwKp67rljoduJLyT94w/dwpy7/QenuatJvRGdnJ2Rq8BSSQABkk9BXOan4rsICY7M/a5QcHYcIP+Bd/writV17UfEDlJCbeyzxBGeD/vHv8AypbS02gBRXXTwy3kdcMKlrM6FdWvr05BSFT2Rf6mtazgJTdK7OT6msnT4cbRW+o2xqKivaKskKpZaJEQjUPkAZqxGuRwKpX04t49zHqcVLa3Ssoxkg965DFo07cY49af4KggXxFqSSwRNLtSaN2QFl5IOD27UyE9DTLWf+z/ABVp9weI5ibd/wDgXT/x4Ct8PLlqJnNWjzQaPQqKKK9o8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK47x94nutOa10Pw2kVz4q1MEWkMn3IIx9+4l9ET/AMeOFHsAM8beK7y0v4fDvhO2j1DxRdJvCyH9xZRdPPnI5C+i9WIwK5l7vSfhrrtkmpWereJfGGtW808+pRJCJJEgUM4HmSIsaAHhF447nr3Hgjwpa+FNMeGKWS71C5fz76/n5lu5j1dj6dgvQDgVz/xH+HP/AAmPiPQdX+06WP7Kjnj+yanpn26CbzQoyyeYnK7cjrzj0oA2NF+IHhnVdK0q+Gr2dl/acKz21vezpBMys2wfITk/N8vGQT0JrRg8U+H7i5vLeDXdKluLJGe6iS8jZoFX7zOAcqB3JxivP/DPwXsNK1rQ77VdQXW49K057JIr20DnzGnMolRix2bdxVQASB/FVSx+CQt4LG1l8QeZZaXZahZ6cqWWyRRdhgzTv5hEu3ecABPegD0mw8W+HNQW5aw8QaRdLbRiacwXsbiJCMh2w3yr7niuY1z4raBp+s+HLezv9Kv9M1Wa4hn1KLUY/JszFEJDuIypyGHBZcZBrmbr4E213ax28+uyBF8OwaETFahSzRTrMJj85BBKAFCDx/FXU33gXU9Y1zwtqmvazYTS6FNcOsdpprQpMksQj2kNM+CCCcjg5AwMZIB0EPizSp9Ugtba6tpoJ7Jr9LyO7gaIxK20kDzN5H+0FKf7WeKw/FXxL0fS/DseraFc6fr8RvrexkFnfIyxmVguSy7uRnOO9cdp3wFgg0O00u78QSzQwaLc6QzxWvlM3m3JnEg+c4wSF2859RnFWbv4Lzag91dal4iibUJ3sBvttP8AKhEdqRtXyzKxLNjlt3HYY4oA9Oi8R6JNrTaPFrOmvqy53WS3SGcYGTmPO7ge1ateTaD8HYdG8XDV49SS6tk1KXU4obpLlpIZJPvbGW5WLP8AtNESRwc8Y77xHoen6mBc6jcapAsCHmz1S5tFx1JIhkUE+5yaAMzxzelmg06I/fPmS49OwrJsoAHGBXJJ4Z069vJblrjXsSN8u7XL0kL2BJlz0rovD/hyx0y9W5gn1R5ApGLjVLmdOf8AYkkZfxxQB2VjHhQcVS1u4CIQD2rRSRY7fOa5PX7ndvIPSgDjfE1yssckEirJG4KujDIYHsR3qPwPd654J02S+0+3n1LwZC+LmwUmSaxHUy24PLRjq0fbqvcVl3pe4vlRQWLMAB617z4X0tdI0W2tcDeq5f3Y8n/CgC5pWoWmrabbX+m3EdzZXKCSKaM5V1PQirVeY6vbXPw11q417So3l8HXshl1axQZNhIet3Ev9w9ZEH+8O4r0uCaO4gjmgkSWGRQ6OhyrKRkEEdQRQA+iiigCG9RpbO4jQZdo2UD1JFeD6ToPjyz+AKeD9M0TVtK8S2kQaO8jv7aNHIuRIUSSOcuCUJHIUdQT6+/UUAeEX2h/EjUr7VZ0XW7K1u/EVjcwwHVkV4bAK3nqNkpCjJGVU89gaw9cj8W+FI7b/hKtZ1GHw7FrepFYn8QJBd3FoY1+ykTNOruqtuJTdv8AY8CvpOigDg/gTNqlx8JfDk+vS3k2oywNJJJeOzyuDIxUsW5PylcZ7YrvK5zxF4gm8P6vYyajDGPD9ziB7wE5tZy2E8zt5bZC7v4Wxnhsjo6ACsXxX4fh8Q6csLTPa3kEgns7yIfvLaYZ2uvr1IKnhgSDwa2qKAOb8H+IJtUW507WIo7XxDp+1L23TOxs52zRZ5MT4JB7EFTyprpK5rxjoFxqBttV0OSO28RaeGNrLJnZMhwWglx1jfA91IDDkc3fC2v2/iLS/tUEckE8bmC6tZhiS2mX70bj1GevQggjIINAHBfHDSSYLPV40z5Z8mUjsDyp/PI/GvL9Jw13Kh/558V9N6pYwanp1xZXab4J0KMPr3r501fRbnw/4he1lUsUO0H++p6H8aAJLWBkmd7c7Tj8zW7pmtTDEUqOGHB4yKqWkBVAT1PWp7PC3J9TXiYiqqlRtbHt4ek4U0nudJDKZU3HvUyVUib5eKsxHmuc2tZFtBxUypxUcXIrN8Ua3HoWlPPw1w+UgQ/xN7+w6mtYxvojNJydkU/F/iZNDgEFsEl1GUfKh5EY/vN/Qd689jjudSu2ur6R5536u/8Ange1RWME97dvcXTtJNI25nbqTXUWsKQgDFejSpKCPTp040VpuJZ2KxoCwq4iqrAAU5plxikWRNw5rclts0rIfMK1WPFZVrKpI2mr00m2Mt7V5mI+I5ZrUytYkWS7toT93cWP4CtzTzbhBuK5+tYJsGvizklTn5D6VVvvDN9dTRsmoywQqOVi4LH1zWOhErbHcqF6oQRWf4iQy2LFDtdPnU+hHSsGyj1LR4pPMuHuIxjbv6j1yalXVL3Vv9GsrGWaR/l+QcfiegoSb2M7W1Z6zo939v0q0uu80SufqRz+tXKoaDZNp2jWdo5BeGIKxHTPf9av170b2Vzw5Wu7BRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBj+L/ENn4W8OXusaiWMFsmRGnLSuThY1HdmYgD3NYfw58M3enC917xGyTeKNYKyXbDlbZB9y2j9EQcf7TZJrKaJvG/xPkEw3+HfCki7UPKXOpFQ24+ohVhx/ef2r0mgAooooAKKKKACiiqGpara6ev798yHpGnLH8O340DjFydkX6K5G68WSqcxQQxL2M0nX+X86ig8XzM4Gyzm/2Y5cH+tTzI3+q1Ox2dch8RL65SxjsbKPzJJfmkG7B2A8D8T/ACNadl4lspztuA9s+P8Alp90/Qj+uK8z+IfiOTT9Gv8AVNxW8uD5Vsp6qTwv/fK5P1ovfRGuHwzc7TRx1/8AES1sZHhM1x5sbFWSCIcEcEZJpunfFK2aYB7u8tz6zRBl/HGa8wtrB5juIJz3NWn0k7fu1pyRPdWGpWtyr7j6G0zxmt7bIZTFJE3AngbK/iKh1q5DQkqwORkEd68H0Se+0S8E1qzbCR5kR+7IPQj+tespcLdWEckRPlugdM9ge1Q/ddjzcbgYxjz0zZ+HOljUvEqzyLmG1Hmn/e/hH58/hXs1cx8PdIGl6BG8i4uLn96+eoH8I/L+ddPTPHGyxpNE8UqK8bqVZWGQwPUEdxXm3hETeAfFUfg+4Z5PD2o+ZNoc7nP2dh8z2ZJ64GWT/ZBH8Nel1znxA8NDxT4ansYpja38bLc2N0v3re5TmOQfQ9fUEjvQB88/EHxRq9j8Q/G32fxBdwvp2o6e1paR6zMs7RlF8yK3sv8AVzbs5OcbevOa7W6+J/jZLfx1qtppOi3Oj+Hr2axjiVZhdFg0YV3AJUoqszNjBOOAME16d8OfEreKfC0F5dRC31OFmtNQtu8FzGdsi/nyPYiumoA8Hn+LviBY7iKyGh6iia9Y6VDrFtBJ9jukuFYuUXzSd8ZABw5HPaiz+LfiB3istSOg6YU12/0i61u4hk+xQi3VChKGUFWkLEDdIBx36D3iigD5k1rxjq3hTxr8Q/FOj3Oj6mILTRXuG8lzFdpIoTdCVkOwHfuBJfj1611F18YdWg8Wf2G8WkrdDxfHohgZHEv2Jx8s23fncezY2+1e3Xnnm0nFmYlutjeUZQSgfHy7gMEjOM4rG8I+IBrtnMlxB9i1ezfyb+xZtzQSYzwf4kYfMrdGB9cgAHnXw9+IF3448Uap4c8QR6PPavbTObfT40vYGh37F33KXDrkjOUeJCc/get8O3dx4W1iHwvrM0s1lPn+xr+ZsmRQMm2kb/nog5Un76g91bPbVm+ItFs/EGkzafqCsYZMFXRtrxODlZEb+F1IBB7EUAaVFcp4Q1m9F3N4e8SMp12zTzFnChUv4M4E6DsckB1/hY+jKT1dABXH+KtLvNM1Q+KfDkLTXqRhNRsYx/yEIFzjA6ecmSUPflDwQR2FFAFLRdUs9a0q21LTJ1ns7lA8ci9x6EdQQcgg8ggg1w3xOmsri8tLVYw99D8zSD+BT0U+uevt+NU/G2p/8K41S41XS9smnakTJfWABP2eX/n7UDop/wCWi98bhzuzhwFrpzdSyec8x8xpM53Z5zXFi6/IuSO7O7B4fnlzy2Q5Iv3fFVNuy4FaxX5cCqk8eG3Y6V5J6ty/b8qKuRjFULNuBWilAMtwZxXlfjC/bVfE8qA5gtT5KD3H3j+J/lXqHmiGCSVukalz+AzXjOlFrid55OWkYuT7k5rtwyu7m2Ej7zkdDYosUYNPur1IRycVDLJ5UJY9hWr4K0OLUlbVNRQSxbisETfdOOrEd+eAK7KlRU1dnTOSguaRmWsep36hrKymkjPR8YX8zV2PRdcyC0EKj/amH9K9Ac4GB0HAHpVdzXFLFS6HJ9Zk9kcza2WoW5BliQ+uxwa1SrSqAwIA61eC5609YweMVhOo57mcqjluQwJtA4q4gIFV7u7tLBf37gueiLyahgj1rVj/AMS+ykigP/LST5B+Z/oKIwlLRGTfV6IlQpfa3Y2LqGhklw4/vYBJH6V6TDFHDGEhRUQdFUYArlfDfhJtPvY77ULjzriPJjjTO1CRgnJ6nBNdTLPFDjzZUjz03MBmvVwtJ04+9ueXiqinK0XdElFMimilz5UiPjrtYGn10nKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3xA8RDwr4P1LVgnmzwx7beEdZZ3IWNB9XZRXQ15942ibXviN4P0I4azszLrl2vqYsJAD7eZIW/4BQBh+INWl+DfwYsj5lrc6/JIke+7bEc95M5eV3II+XJkbORwBSeEfi1/bugeC7yZoIrzVr6TT7yK3tvOQTRqSQreauwEAMDiThhx3rtfHcHhi2TTvEPiwBV0afzbWUtIdkr4UYjT/AFjHgAbWPpUUHw+8Lf2qNXj0tlvXvTqe8zTL/pDLtMmwtgEg8jH1GaAIfhp8QrH4hWM17pOla3Z2aKrJcahaiKOfLOpEbBmD7Sh3Y6ZH4Zej/F/Q9Z/tY6faXbppokMplubOBjscIf3ck6ugyesioOOucA9B8Oh4atNCn0bwZ8mm6NeTafJD+9Pkzq26RN0nLcvnOSOeDVC++FnhDUTdHVNOudRkuYBbPJfajc3LiMOHCo8khZPmAPykUAY+m/Grw3qVmHsbbUbi9bUBpkVjD5Ekk0xUsNjrKYiuATu3496u6x8VNN0fXbDRdS0rUrXVbuET/Z7iezh8tS+wAu86o7E87Y2c49+Kvj4Y+ExDcRnTp3ee6S9ed7+4afz0XasgmMm9WA4yGFYcFh8O/FlvBE+o3mqxxvIsdjd6teyGZoGJc/Z5JMylT32t29qAPQ9WvBYWEs55YDCj1Y9K+efiV49l0y4m07SX36oxzcXLAERE84Hq38v5etah4h07xHo+mX2jXIutPuHdg4VkJKHaQVYAgg5BBANfK+qM19rF7dScvNO8h/FiaIpN6ntZbRTjzMzpzeajM017cS3ErHJaVyx/WhLKaJg0RZWHIKnBFbllaZxxWxbaeHxkVbnY9tRRZ8KePdS0lkg1oyX1h0LHmWP3B/iHsfzFXPHmqQeIdTtU0+TzrK3jyrgEB2bBJwfQYH4GqF9pCm2JAp3h20CQ4borEVk5LcydGKfOi1pumqsQyorXtdKjmcDaDUAvLWOTyzPEGHGCwzXQ6QyA7iazbbYpSsjmfEOkx2uNq8nsK7rwt4XCnSrUvIJBtM6E5U/xMPbuKyYIhqfia3jI3Rw/vWXrnHQfnitK88f6N4evX3alGbtQUZYY/OK889OAePWq1ehyVnOUeSO9j2oDAwOlFeM6f8Y9NuZlQ6mYie9za7V/Neld/pHiqG5WNrkw+TJ9y4hbdGfx7Vd+54tTB1aerR09FAORkdKKZynnm4eGPi/s27NO8V2+QewvoF5+m+HH1Mdeh1wvxosJrjwNPqdgu7UtClTWLX3eA7mX/gSb1/4FXYaVfQapplnf2jbre6hSeNvVWUMD+RoAtUUUUAFcp4v0W9F7B4i8Nqv9u2ieW8BYImoQZyYHPQHOSjH7rZ7M2erooAzfD2s2ev6RBqOns5hlBBSRdrxODho3X+F1IIIPQg1pVxHiG1m8KavN4n0mF5NOnIOtWUSFmYAYF1GB/wAtFAAYD7yD+8oz2NndQXtpBdWcyT206LJFLG2VdSMgg9wRQBj+L/D412zhe1n+x6xZP59hehdxgkxjkfxIw+Vl6EH1wQnhDxAdbtJ4r2D7FrNi4hv7MnPlSYyGU/xRsPmVu49CCBv1yPjfSZopYvEuivDBrWnxlSJW2R3lvnLW8h7ZPKt/C2OxYEA66ua8UeKIdKVre12zX5/g/hj92/w61y0nxGXxBpyv4eSSGJwUkkmG2WNxwybf4WByDn8OxrFhtsEsxJYnJJ5JNcGIxnL7sNz0MPg7+/U2GSCW7nknu3M0spy7Pzn/AOt7Vz1gp8J6hFYyZ/sC7kCWshHFnKx4hY/3GP3D2J29CtdhHF7U+70621CyntL2FJraZDHJG4yGU9RXmqXfqehLy6DliwKimiyDxWRoN1caTqK+HtXkaXKltOvH63EYGTG5/wCeqD/vpRu67sdK8eaUlyijO5mwqVbFX4zxUZi5zSrlaRd7lXxHOYfD2pODyIHH5jH9a840RAsS5rufG0mzwxeD+/tT82FcXoVoL/UodPM5t90TMGAySQOBXdhmowcmdmHtGDZLqrYtjivSvDsaw6Bp0adBAh/MZP8AOvJ9Tlks3ms75dk8Zx/ve49Qa9S8O+ZH4f05JgVkWBAwPUcUYqSaTROK1ijUY1A3JpxOTTlWuI4thgGBVPVbqW3tWW2/4+HBCH+77/hWhIMCs254l3nsKENanC6ONVg1MTzh3nD747mNwQvocdq948Jas+saMlxMoWZWMcmOhYdx9a86tvDuq3I83TbWZIpRuBkwqkHuMnOPwr0jwvpP9i6RHas/mS5LyMOhY9ce1enhIzTu1oceOlScEk7sv390llZXF1L/AKuFGkbHoBmvO7az/tFmvtSAmuZvmO7kIOyj0A6V2fi//kWdRHrER+fFc7Y4W2jHtSxsndRMcIrJyOd1ny9HkW4sybadeVkj4I/xHsa3k8X6xNGkkVhaqNoyrszEnHPI4H61zvirE+oWsOM5cZ/n/SuptLdY7ZAB2rlp1ZwVos6qlOErOSLFj42gEix6vbNZE8eaG3x/icAj8sVJJ4v8w5sNOmnh7SO4jB+gIJ/lXGa+ouNSitxjDtyPYc/4V01vAIrVUHYVr9bqWsZPC01qX7fxnZ5C39vcWhJxuI3qPxHP6V0dvcwXMCzQTRyRN911YEGvJdbnCzMiDc3QD1NTaZoqm2Z7j5i5yR2B9hVxxskveVxTwUXrF2PWqK8qF9eaHMpsLqTYOsMhLIfbB6fhXo+jalDq2nxXVucBuGU9UYdQa6qOIjV0W5y1sPKlrui9RRRXQc4UUUUAFFFFABRRRQAUUUUAFcF4NkbU/ib451FsNFaNaaTA3p5cZlkH/fU/6V3tcD8Fx53hvVdS76lreoXWfUfaHjX/AMdjFAFT44f6Np/hbVbgE6Xpev2l5fHGRHCN6+Y3srMpP59q5n4iab8RNS8afa/Cltdw6dFPaSwXVrqrGO6i480PG1ysagDsIW3ddw7+31X1G6+w6fdXZhmn8iJpfKhUNJJtBO1QSMscYAz1oA8KufCHxA0az1vVfC0UyauPFl9qEFj9tRYb6znVVDON+wkEBgH5GDxmo/EXgr4lQvpNpZ67rl1Yw6VHG9xZ3e+dL3fukdhJdQBwckDcXULxs717F4N8YaJ4w01bzQb1Z12K7xMCksQYZXeh5GRyD0I5BIrfoA8OTQPiS3itJ5bnU2m/tmG4F99vVLEacEAeBrVZf9ZnOSEOT0fuT4c+FvF/hvXdFk1COay0OG51e41BftqCLbIwaB3UPhuMkcHb3xXuNZuo61Z2D+XIzPN/zzjGSPr6UFRi5O0UeSfDu3Nz4c1zXbdGXS9Q8RXl3YjGAbdyqhwOwZ0Zh/ve9eQ+JtKk0fxDdWrj5Q+5G/vIeVP5GvpfVvF1p5EtveRQQpIpX99cqjfXBry/x3BpWsWCTx31qb63GF2uD5i/3eO4PI/GkpWdz28vc6a5ZI4vRrUygYFdfp2jkgErXPaETauC4yPauyt9Yhjh+UEt9KmTTPUm5pWRQ1m0W3s2yO1cHr2oPY2sdpbnbNKC7sOqj0rur66a9YmT7g5ArzfXYy+uyFvb8qIWbCN7WZmW+mS3GX+Yk85Ndv4SuLqBXtZ3ZlC5Qt1HqKfplun2ZdoHSrKReVc7wOitn8qUpuRrKK5Tk/E/iK+huru0sbl4Y5gEmKcFh/dz1A9cda5eG2eTGBUtxma9kJ5LMTXSaNYb4wcV0aQiZxWuhiR6c5HSuj8H67f+G74AFpLF2/fW56MPUeje/wCdbVppe49KnvdIRbZmK8gVi6l9C5Ri1ZnvPgrV1uoUt/M8yFoxLbv6p6fhkf5FdVXk/wAL2k+x6Hk8jen/AAEbxXrFEdj5XG01TqtIZNEk0MkUqh43UqynoQeCK4z4N5g8A2emSMTLpE0+ltn/AKYSvGv/AI6qn8a7auC+GubbxL8QNOJ/1WtC5X/dmt4X/nuqjkO9ooooAKKKKACuCA/4V9q393wdqE/HPy6Xcu36QSMfojt2Vvl6XWfEWn6UxjmkMlxj/UxDLfj2H41wXiDWrvxBBPaXCrFp8ylHt15EikYIc9wR24Fc9XEwpaPc6KOFqVdUrI7PXfFVnpoaKAi6u+nloflX/ebt9OtcHqV9fazKHv5iyg5WJRhF+g/qea5LRGk0DUotD1B2e0lz/Zt05yWA5MDn++o6H+JfcGuxSPivNr4idR26HpUKEKSutzk9VsZdCv313TImlhfA1K0QEmVAMCVB/wA9FHUfxLx1C11NjNBe2kN1aSpNbzIJI5EOQykZBFWUSuWkA8G6g06jHhq8lzMM8WEzH749InY8/wB1jnoTjFe8rdTRvld+h1saY7VOi0IAenNSgVANmfrujW2t6a9pdbl+YSRSxnDwyKcrIh7MDz+nQkVm+G9VuJpptI1oImtWahnKjalzFnCzxj0PQj+Fsj0J6UEVh+KNGOqQwXFnKttq9mxks7kjIRiMFWHdGHDD8eoBFxenKyGne6NRlGKjKA1n+G9ZXWLWQSxG11G2fyby0Y5aGT691I5VuhBB9q1DUtWdmUnfY5D4iSeVo9vD3muFH4AE/wCFcTFO8Gs2UkL7ZNwUMOxNdX8QElvtZ0XTrf8A1sm4j2LEDP4AGs3VNH0zStfYLcuRCVCefIAN+ATz+Nehh4/uz0KE4pKD3d2dhpWoRalH+/ijFzD95SoOPdc9q1RKTXHaJ5v9swmJSylG8wryNuOv54rqvM29RmuWvT9nKy2MKsVGVkXI2zVmMZrNW4XscVMlyo71ijFouOuazL5cKx7irRulx94Vn3s6uCFOSaphFMtaR4+/sfbp2o2byQRcJNG3zbewKnrjp17V2+j+J9I1cD7Hex+Yf+WUh2OPwP8ASvDdTYXF/KF5AwufpTLXS7iaPdEhZAfvnAH4E1208VOKV9TkqYSEm2tD3fxh/wAi5e49F/8AQhXOwDEKD2rgo9b1uwsms7mWZ7F8Bll+cKAQeG7dPpWzLr0giURxADH3iayxNRVWmh0aLppxZDqLb/EcC9cEn9DXZBwIQO+K4CGUvq9vKWDFmP8AKu4z8mfasL2NprY5uD9/4kO7kICR+ddRcyBISfQVy+kNu1+4OOAoH6mtjV5fLtHJPGKL2CSu0c5YD7brg3chMt+fA/rXXXDLDCAOABXKeGZoI7i6eWRVYkAZPbFW9a1OMxMkT5GCWb0FJvoU43ZWvZxcTMRjb0yelanw/wBRe11sWxP7i6BUjsHAyD+QI/KuOsZFvG812mK9I4UToPUn1NbNnIbO+tJwNnlSoxHoAwz+lXSlyTTHVgpwcT2eiiivdPACiiigAooooAKKKKACiiigArhPgYuPhVoJPV1lkP1aZ2P867uuD+Bh/wCLW6Mh+9EZ4T7FJ5FI/SgDvKKKKAPL7fwtpkPii60C4EtncASajoeoWreVPBE75ngR+6pIwbY2VKyoNp21t/27rPhb5PFsP2/TF6a1Ywn5B63EIyU93TK9SQgq58Q9OurjSoNV0mIyaxo0v261ReswAIkh/wC2kZZfqVPat7R9RtdY0qz1LT5BLaXcSzxOP4lYZH86AMzV9cgOkwT6XcxTi8XME0Th1K93BHB9vrXzX8Q/iFcz3U2meHZ2igRis14h+eVu4U9h79TXWfF6yj0a21jVPDVw2lTTy/Z2ghA8ictwzFP4W4Y71wT3zXh+kfvLlbe5haG4PIB5V/8Adbv9OD7U4JfEz3cBRUY+8txI7WeVzI7Ozk5LEkk/jXQ6DPPFdxw3DkwsduW/hrX07S94A21YvNJMWGC4xSnUueyorZm7HEIB79KoatrVnpwxcyEydo05NRa3qotNPjkXmZ0GPrjk1wQikvLhpJiXdjkk1EYJ6szUW9zqU8Zwl8C1kCeu4VYxZ66wltZNlwg+43BIrn49J3LwtRiCewnWSMsjA5BHaqsvslOFjutMguIBsaM8VpNbnypC332Uj6VHo939qsIJz95l+Ye/ercsqqCSaxbdzNyb0PIpbd4NQdHGMNiu88MRJIgHeo9Q0GTVbkvp8TSS91QZP5VLp/hvxBZyArZXAGfSuhzUlqHMl1Oxs7RE5I4qprLiUpbWyF5XO0BepJ7VYsNK1mZQJ1W3XuZHH8hk103h/wAPlZz9iQ3N0eGnYYWP/D+dYmM60afvN3NbwJpzW9xZ24AK2cWXYdNxyP1JP5V6DVHSNPj020ESYaQ8yPjG4/4VerRKyPnMRV9rNyCuE8IjZ8VfH47OunSfiYXX/wBlFd3XB+Dj5nxS+ITjlUOnw/iICxH/AI+KZgd5RVa/vrbT4DNeTpDGO7Hr7Adz9K4fWfGN1dExaUptoenmuMyN9B0X8cn6VjVrwpL3mbUqE6r91HY6trFlpUe68mCueVjXl2+g/r0rh9X8VX+oK0dsPscB/uHMjD3bt+H51hbXllaWRmeRzlnY5LH3NWIofavMrYydTSOiPTo4OFPWWrK0cAz06nJ96txw1YjhqxHHjpXIdTkZWr6Nbaxpstleq3lPghkO142Byrq3ZgcEHsRVDw1qFyLqXRdbI/ta2TesoAVbyHOBKo7HoGX+E+xGeqVKyPE+hf2tbRPbSfZtStW82zuguTE+McjupHDL3B9cEXF9GYy7ouNhajlMU8MkMyJJFIpR0YZDAjBBHcVl6BqraxbTRXUP2XVLRvKvLXOfLfGQVPdGHKt3HvkCxNFIhyCaTTTsNNSRjaPdSeGdRi0S9kZ9LnbbplzI2Sh6/ZnJ7gA7Ceo46jnrPOFc1q1rHqenzWV9GXglGDg4IIOQwPZgQCCOhANZnh7WruC6fRtafdqEK74bggAXkI43gdnHAZfXBHBFU/eV+pKXK7dDufOo82scXfPWp4rgN3qC7Gd4i065F3HrmhKp1a3XZJCTtW8h6mJj2PdW7H2JrX0bVbbWdNivbFmMUmQVcbXjYHDIw7MCCCOxFTxkEcVzOswzeHdRm17TYnks5edTs41yXAGBOg/vqByP4l9wM2veVupm/ddy0kKSeOrrUJ/9Rplipz/tNuP/AKDn865pLkzJNcTbf3zNI6sMjk5wQa6nQL/TNSuNRDS28sF5JuBc/JNFsUKQ3cdeh71MfDGi290kge58sMGEYuFaP9RnHtmvXowapxQ6eNp0qkufyS+X/BGeG9Ki0zSy0cCQXF4BJIqLt2r2XA6e9Wp42PSrk0vzsTgkmqU02AWZgqjuTXmYipzz02Q6fM7zlu/6/AqyCVTxz7GovNlQEvENo778VDNqSFiIFMjf3jwtVZWluMCZiw/ujgVmkbXHS6qckRwMwHfd1qE3t1MCqokQPcHJqzHb8dKkFsR2p3QtTJNttRto5IOPriu00SO3vbCEpjZtAwO3tXPvbnBwKZpVzPYajGsbARSth0bpn1Hof51XxIhm5q2nfZ1Z05U9QehFYFuEivo4JlzAVzFu6A+n+Fd1dbbi1K9ciufn08BDvQMCMYIqNhp3Wpja6yackV0m1HV1IXpu554+ma3F16QwgeSOR97Nc3eaJDLMVO/959xyxJU+nPapdHibP2W93eZCuACcbh6+9VpYVr7li1v5LK7eaNQxYc5+p/xqa/1me+jCeWqqT2NV7yGGC9tVkLLBMSnXof8ACnX1nHasJY2IjXlgx6Y70h2KckDxRLMwXYzdR1FNZHu9tqhIM/DH0Qdf8KnjXUbuxhT7GoBAO5nwD6ZFbGj6YLQF5WElw4+ZsYAHoPak9Bp6ElvbzQxBA0e0DAwuDVe7QmOTPUg1uugEdY9z1NQNO561p0v2jT7Wb/npEr/mAasVm+GST4d0wnr9nj/9BFaVfRRd0mfPSVm0FFFFMQUUUUAFFFFABRRRQAVwHweP2fT/ABLpZ4Ona/fRBfRZJPOX9JRXf1wfh6MaX8XPFdoSQmrWlrqkS9tyBoJf/QYj/wACoA7yiiigArjPDbf8I94tv/DbjZY3gfU9LPYAsPtEI/3XYOB/dlx0WuzrmPiBpV3e6TDf6PGH1vSZhfWS5x5rKCHhJ9JELp/wIHtQB4v8ZNx8P2J5wbti31Kn/wCvXD+HrMT4wK9W8X2UPibwjN/ZmZUmRb20JGGZfvAY7HaSuPUYrzHwpcJbTBZTjnvQn7tj6rCzThdHZaZpjKRxxVvWbMRWLM3WtOzvLVbcOXHSsrVLwag/lIfl7+wrJ6GqnKUr9DzLxOzGaCM9AnFS6LZ78EirviyxP2uKQD5duPyrZ8K2ccsa561pf3dDTmtqLBZDgAVJqmjh4N23oK7K20yFAGaqOvyRLD5MQyx9KzV0T7bmdkcrpTrZ6c/mHbGhJJ9q5HV/EF3fysluWigzwB1P1Nbnipzb6WkCnmRvmrnLG3DAcVcV1Lik3cqRtdq4cSyBhyGDHIrrtB8c6zprolzMb23HBjuDk49m6j9arw2AdRxSto+/7opOSZpKEZK0lc9e8LeI9N1kia3jExj5ltJuGA9R2P1/PFesaZPbXFlHJZBRARwqrt2+ox2NfJlgl5omoQ3ds5SSM5B7EdwfUGvfPAuuJILeVRttr3GVz/q5On8xj8qE7Hh5jg7Lmieg0UUVZ4YV5B4X8Qmx1bx1cQQ+beXWuyxqzcIqRRRRAnueUbgfnXq2p3sOm6bd310223toXmkb0VQST+Qrwr4fRSy+E9Pu7pSLm+D38wPXfM7Sn/0OuXF1ZU4e7uzqwlKNSfvbI3J3uL65NxeSvNMf4m7ewHQD6VNFbE9RVuC39quRwgdq8d3k7s9fmSVkU47fHarCxYqyI8Uu2ixHMQhMU9Vp+KUCgLjlUVIEGKjHFPD4qk0Zu5zninRLl7iHW9DVBrNou3y2bat3D1aFz29Vb+FvYsDc0W8tNd0yK9si2xyVaNxteJwcMjr2ZSCCPatcSVxfih28L6m/iHTUaWGfA1OxTrKoGBOg/wCeigAH+8ox1C1cVz+71J1Tujo5bBSCcCuV8VaZYahZiMXJgvYG822uYl3NBKOh9COxXoQSDS3mvHVIIpoJ1e1lUPH5JyrA9DnvWU865OfvDse1dNPC21kzshR5l7xJoGvxX8clvfW3kanakJcwhuMno6+qN1B+oPINdNp621022JismM7W6/hXnur6dJcXNvf2Eqw6lb8K5HyyRk/NG+Oqn9DyPfoLGZ4bhZEY7kwy1c8LBr3dCvY6WO1WDZSmPNT7hIiOvRgD+dNkYJGxJAGK8+MbyUTllLlTZyPhK102x1HUI5PIj0eTMkdpcRlXtpSfm8th/wAs2yTt7HoOeJYbfQZtWkayjV3j+dcAlQc9c9K625khttFEt5Ztcrg5ZYfMK/Xviue0zZqFpJJZRlUWQggps7ele1XlyUm0eVQjz1FcszSKoz1NZFzEZpDJMcqOgPQVsx6dIfv1ia3KIrgwpyE4P1ryKVN1JWPbhHmdkQ5gQ81btpLV2AL7T7isITHp+ZoMpUZ44rteGgzodFWO1itUKgrgg9xUwth/drmdO1KW2IaIho+6npXV2N7FeRbo+HA+ZT2/+tXLVoSp69DnnBxK01sAOlYuoWYYE4/KuqdQRVG4twe1YJ2ITM3QdXYSi1u/9YPut/fH+NdFdBJYfl71yOp6e4IlhJV0OVI7GrGma2QRDdARy/o30qnrqga6mlFZFpMsOAaddaNHcFS4IZTlWU4Zfoat210jjjFXlcEdaSZLbMB/D8Em4zq0zMMbpGLED29KjOhxgqJZZ5I1ORG7krXSFhVecjaafMwTM/eiDb0xSRyAtms2/mKzqo7mprdvl5qWaW0NKeQeX1rHnPU1Zll4xWfeviCQjqRgfjQNKx654fTy9C05fS3j/wDQRV+snwnL5/hrTXJyRAqH6qMH+Va1fQQ+FHz89JMKKKKokKKKKACiiigAooooAK88+JznQvEfhHxYCVtrO7bTr9s4At7nC7m9llWI/nXodZfinRLXxJ4c1LRr8Ztb6B4H9V3DG4e4OCPcUAalFcf8K9Xu9S8KR2msMDrmkyNpuoDPWWPjf9HXa4Po1dhQAUUUUAebJpY0/wAXX2hBhFDfB9T0pz91WLD7TB9N7CUf9dGxwtcb4u8Ai4v5JrYiwvj80kbj93If7wI6Z9uPpXpnxPtJpPD0d/puBrOmTpd2BP8AFKMgxn/ZdGdD7NntXjfjH4gb9Ptzok7Pd3sazS3DD5ogw+7js/qP4enXpL30PVy51W7RZj3lle6FKsOqTQIDwNk6sT+Gcj8RWpYzwlMxMGHcg5ry6WCe6naaV2kkc5Z3JJJ9zViC3u7ciSB3Rh3U4pygme8oya1Z6VeRRXSFXUEH9Kp2ltLZvmF8rWFoviGTzFg1HqThZAMfnW9quoR2dk8zfwjgeprOzWhNnHQ0m1K4EfzyBR6lqhjuEkJIlWR+5DA4ry25vLvUJy8js2TwM8ClRZ7dg6MysO4OKt0/Mrludh4vi8y3jZRnaaydGAdgpHNdn4BntvEGlX2kaiP3rKJUbHII43D8xkVhzaLcaJrBgu1AI5DD7rjsQfSnHazIU7SceqNy1sCYwQtaVnpjZyVrT0GOKaJcMpx2rdaNIl5IArPlIniGtEcbqmmr5JLDmtnwYGTRJUBPyTNs9jgH+dVtbuUK7E5J9K6rwjo7r9kspF+bPmze3IJH8hSsZ16lqXvHpy5IGetLRRWx8sebfHa9d/Ctt4ctXK3niK6TTwFPzLB96dvoI1YH/eFNtrRIo0SNAsaAKqjsBwBWULiPxZ8TNU1iPL2GhI2j2bfwvOSGuHH0wkef9lq6lYwB0ry8ZPmny9j0sLHkhfuV0ix2qULUwSlCVyWOjmIdtG2p9lIVosK5XxRipitN21Nh3IqKeVrO1fUEsIuMGZh8q+nuacYuTsikruyG6rqKWSFVw0xHC+nua46+uXlmzK5JPJJPWlubgyOWLFnJySazpH8yQ5OSK9KlSVNeZ3UqVjnJ2/4RvUGkUldCuXywHS0kJ6+0bE8/3W56E46OHGcD5iecd6aYEuI5Ip41kikBVlYZDA9QRWb4ejk0fVYtJu2drCbK6fcvk9BnyGP94AHaT94D1HO+4SkqPp+RtRrtD7hg55HtUdtKrXDov8L7P0rRnhKz7gMrtx9awNPbF5dqT8wnOP0osXBqSuj1HTPn062b/YA/pTdUtEu7JreUsEkIB29fWnaJzpVvn0P8zUOvW0F1HawXFw0AMu5WVgGyB2/OvNpRvXS8zysS7RkR6jpVxZ6Wq2mr3SIF4UjP8yataBBJBpkSzSmWQ5YuQATn6Vn65pdwtkqPq9xJHgADkE/jmtrToBbafbQgkhIwuT3rsxztBLzOLCL3myWVhHG7t0UFj+FeXXczSSuW+8SSfxr0XXJPK0i7YddhA/HivMZmJkG3qVrDCLRs9vCrdlm3AKjPTFRyQsUySQKtWvCoHGBjmnyQiWUgMdoHauw3ctSpC208nGeD71pWd08Lo8ZKsOhFZU8bI7KOgp8EpXpyCORQ1fRg1c9B0+7S8g3rw44ZfQ1Oy5Fcjpl49tOki8qRg+49K62ORZY1kQ5VhkGvMr0vZvTY45x5WQvEDkEcVjanpUc68KM1vNUDjIrC9iUcgJ7zTHwd0kPoeo+hrasNZjmUbH57qeCKsXMCyAhhmue1LSSv723JVhzxVXTKOoW/z1NRXF7lcZrkrS/ufNEMjKWPALDrV5hO4+dc+wOBSeg1FE5fzp/M/hHA96siXAx3qmkcnVsA9gOgp/lHGWPHtSLdidpVAyzAD3qpM7TMCARGvIz/ABH1+lTRwAtlULH1IqWaArGxbljQS2d98NLnz/DflE5ME7x/QE7h/wChV1dec/Cm423mp2hP3lSZR9Mg/wDstejV7mHlzU0eHiY8tVoKKKK2MAooooAKKKKACiiigAooooA808Wk+BfHEHi6IEaHq5isNbHaFx8sF1+BIjY+hU9q9Lqtqdha6pp1zYahAlxZ3MbRSxOMq6kYINcH8P8AVLzw/qzeBvE08k11AhfSL+U/8hC1H8JPeWMYDDqRhvU0Aei0UUUAc74yObezQn5Wmyf++T/jXyRNbvJ4i1aQbfJuLp51QD7jMxLD6Z5/E19eeMIy2nRSqP8AVShj9DkfzIr5l8Q6edI8W3UbriJ5DJGT0KMcg/0/Cktz3sr5eXzG2OlFkBI4rSt9MXpjNdLo1vFPbrgDkVqR6bHG3IFRK7PT9skeYa5ovl5kQYxWNrVxNPa20LMSAMn3r1LxPbRra4UDca4rxdox006VlSHmthJID2YsePyxVQY+dSsZGl2IKLxzWodJL8YrV0ix/cK23ORW5bWJJzt4+lTKTbNeZJHHaOZdD1y2uU48twSPVTwR+Wa9i1SwtNTtjBdoXjHzK68FM9CD2z+tcFrOmjO8jmvXPB426jBEwDK9rscMM5wF6/lRuzz8ZPlSqLdHAx+Gr2ykJsLuOWPsHOxh/Spzp2ryELI0QHqZQf5V67caBp03P2cRn1iJX9BxUcXhvTkOWSR/96Q/0p8rOFZmrar8DzjR9DEV5G/N3edY0A+VT64749TwK9L0HS/7OgZpSGuZeXYdvYVetrS3tQRbwxxZ67Vxmp6ajY4cTi5VtAri/ip4ivNF0OGy0Pa3iHV5fsVgrfwMRl5iP7sa5Y+4A7102t6rZaHpN3qeqXCW9laxmWWVzgAD+ZPQDuSBXl/hO1v9c1m48Y+IoJLe9u08nT7GXrYWmcgEdpH4Z/wHaorVFTjfqYUqfPKxs+FtBtfDug2WlWO5obZNu9/vSMTlnb3ZiSfrWuEqRVpxryrX1Z6N+iIwlOC0macDQIYwxUTVI5qI1EikNoooqSyvfXCWls80nReg9T2FcLfXb3E7zTHLHt2HsK0vE1+bi58iJv3cZxnsW7n+lc9OcnAPA/Wu/D0+Vcz3Z20KdldjZ23HHr1p2nRxvdASr8nQVASS4A61ZjjfIHY8kiuhHRP4bI0rvTTG++2jLKRzg8CpL/TrS70WXT9QhYrKoOVOCrDkMpHIYEAg9iBU2l3hibyXyyn7vPNS37OJlZk4I2j1HNaK26PIm5yapVDkdJ1G5im/sbWmzqcI3xzYwt1DniQejDgMvY89CKq2xC6rfD/psP1Arf8AF2kDU7ONo5Db3tsfNtrhR80UmOvupGQR3BIrj/D9+13q9/HeQi3voiouIAchWx1U91PUH0PqDUno0Hb3H8j2TQxjSrf3BP6ms7xSf3lkG0w6hFliyAkFenTFbNgnlWFumMERrx+FZmtpqr3ds2kNHlAS6vjB/PH868/D617+p5mLfuMoavdxpbILPQ5oXVQclQPwzya6e0YvaQMw2lo1JHpxXN69N4kmhRZLaBVUAmQgnH/j1b2kyNLpts0jpJJsAdkOQWHBroxy91M5cI/eZS8VMU0WbHdlH615ffXG1/k+82FH1JxXpPjN9ujY7mQD9DXmUYNzrFtH1SM+c/4dP1qcIvcPfwukLnU2sWXPHGABSsgEhxwPar1qmISWGMjNUbkjLLtPtiuglSuyO4tXZA6oSO5xWQ+Yzkdjiu004q2nkMS/BHWuUu4Mz7YhlskbR602rEUK/PKUZaWFtJDt6k88j0rqPD92cNbyH1Kn+dc2bCS2Qu5w/XB6Vas52R0Zfvg7s1nVp88XFltxqL3TsmNQuadG4kjV16MM0yQcV47Rzkbc1BImRTy2DSnkUActrtlsPmxAgg54q5pTLd2qyEfN0bBI5rRvYhLEymsPQ3+zalLbMcK43L9R/wDW/lT3RRuxW6A52iraQj0oQCrcKjFIlshEOKq3afIa1tvFUrxflNMSZl+Frz+zPFlnIxxHKxgf6NwP1xXs1eC6rGQcqSD2I7GvZ/DWo/2roVlefxyRjf7MOG/UGvTwM7pxODHQ1UzTooorvPPCiiigAooooAKKKKACiiigArnvHHhiHxTowtjPJZ38EguLG+iA8y1nX7rr/IjuCR3roaKAON8EeKrq8vZvD3imCOy8U2UYeREP7m8j6CeAnkoT1HVTwe2eyrnPGnhGx8VW9sZpZ7LUrJ/OsdRtTtntZPVT3B6FTkMOtYWgeNLvS9Xi8N+P0istXkbZZ6ii7LTUx22E/cl9Yyev3cgigDu7qBLq3kglGY5FKmvI/HHhEX2y3umEV3Fk29xjKuvcH2/kfrXsNQXlpBeQmK5jWRDzg9j6g9jSa6o6MPiHRlfofOVuL/QZxb30LKB91xyrD1DdDW7HqylM45r0u/8ADEyg/YZlkjPWKf8Axxg/iKzoPDV+smVs7aIn+IFR/IVLuz2I42lJXZxNrZyalMs1ypS1Q5JYY3+w/wAaTxzpDapp8dxCpM1sSxXHJQ9ePbH869P07w0FkWTUZFlKkERp938Sev0pviHRJXma8sQWZjukjHXPqv8AhSs1qZfX4uordDx3w/c26QrFMMMK3luLVFJ3Cpr/AECwuJmZke2mPUR/Lz/un/61RQ+HLWM5e5uHHpwv60rnc6lOWt2Z3lNq2opDEP3QO527Be5r03whAZNQnucYRF2D6kg/yH61haNpjz7bbTYNsefnk/hHuzdz7V6Fp1nFYWiQQ52jkk9WPcmnFX1PNx2JTXIizRRRWh5AVBf3ltp9lPeX08dvawIZJZZWCqijkkk9BWf4p8R6V4V0iTU9cu0trVCFGeWkY9ERRyzHsBzXl80Op/ES5ivfFVrLp/h6KQS2ehOfmmI5WS7x1PcRdB3yazqVY01eRcKcpuyHmW5+JOr2mr3yPB4Ps3E2m2Tghr+QH5bmVeyDqiHr949hXcIO561HGoAHAA6ACpVrzJ1HUlzM74wUFZEg4prGkJpOtRcoTFFFIxpDGOaZQxpM1m2WkFUtYuxZ2Ejg/O3yp9TV2uP8UXhnvxAp/dxfL9T3/wAK0ow55GtOPNIw5XJJwcAdTVGR9wJHQGrqPGHCyEYNSx2cE4Yo+Mtjg16iVztlVVP4inGoXDdWNatlcR7ViljKkn7/AFwKkfRzCoaJi+OxqL7HI8oVMggZyRTSaMJ1qVWNmy39iVZUkhl3qemP8Ks3xYuhCswC8j+tUbeC4hvFJYZA4962XbM4YDcNuDjtVI4KjaktblG/RpLMFDg46HvXn+r6TeXHibTr/RUDahsKCNjtWcL8xic9gRnB7Hn1B9MeB2t3OCR6elYNs7WWoxTxgbkJJHr6/oaiV0tDupSVSLsdZoesWut6Wl7abkXJSSKQbXgdeGjcdmU8Ef0rNgFlq+rSyRXl3Z38Y2xnoGA9j1HfH6Vk+K7a90+8m17wtH5pljU6lZqhb7QgxiRFH/LVRkYHLLxyQtaN7qVl4g8Nq9s5juolDxuh+ZGxkYPdSORWOFo8vv8Ac8jEVL+52Jr+Sa/lk0+90ZL69iXMbo2EdT/F7Crvhzz4LdrO8Nss0ZyscHAVfT8+9ZD+Ir5NJsvLhKahdYT5lwBj7zY/l9anvIbHQYo9RWR5ryQ4ZmbLTMeoA9K3rU/aQaMqUnCaIPiNeJb2NtGcl2csFHU8Y/rXNeHNPdFeSVMzzHL/AOyOwq/qRbV9ZW7lUrgbYkP8C/41tW0KW0BPesaMOSCTPoVLkpqKIJCIrd1J56VnF26kcetTXcwkzg/e4qJlLJtJwfatGOKsaujrmPdGOhOfem2dki3FxPONockr7VJohYwOem3OfrVidomtFjmI+bkjNarZHk1ZNTkl1Zx+r3j3Vw5B+ReOO/vS2MhB5OQBxW1e3GnIGVAoGMcCsVpozMTDwnQVDPToS5o2UbI6vRZt9uU7ryPoavSMMVz+iSlJ1U9/lNbUrcGvJxEOWb8yZqzKT3CiQrnkGp43yK5PWb17bVlj/hcZH1Fbem3Hmxg5rJxsiS+9c3qwNtfR3C/wMG/DvXSnkVla1AHgJxzilF2YzYhYMoIPBFXYDWLosvm6fCx+8F2n6jiteA80iWXKq3S5Bq0OlRTrkUyEczqMWVNdX8KdR+W80uQ8ofPi/wB08MPzwfxrAvo+tZ2lX7aLr1rfDOyNsSD1Q8N+nP4Vvh6nJNMVaHtKbie5UUikMoZTkEZBpa9s8MKKKKACiiigAooooAKKKKACiiigAqjrej6drumy6frNlb3tlKMPDOgZT789COxHI7VeooA8z+weLfATF9HkufFnhpTk2FxJnULVf+mUjHEyj+6+G6AE11PhfxroXiWR4NOvNmoRD99p9yhguoT6PE+GH1xj0NdHXPeLPBmgeK0i/tvTo5p4eYLlCY54T6pIpDL+BoA6GivPIvD3jnw6wXw94kttc08Hi08QIfOUeguYxk/8DRvrU0vjzVdLKjxH4I163X+KfTgmoQj3/dnzMfVBQB3tFcPZ/FjwPcyeVJ4itLKbvFqAa0cfhKFrobTxPoF4oa01zS51PQxXcbA/kaANKa3hnAE8McgH99Qf51D/AGZYZz9itv8Av0v+FMk1nTIl3SajZIvq06j+tY2o/EHwfpoP27xTokJH8LXse78gc0DUmtmdMiqihUUKo6ADAFLXn5+K+g3Xy+HrPXPED9B/Zmmyun/fxwqY991Pm1Px/rKbdI0HTfD8Tf8ALfV7n7RKB6iGHK5+slAjuLq4htLeS4upo4IIxueSRgqqPUk8AV5lrvxWW8kax+H9gdcujlTqL5TT4D6mX/lrj+7HnPqKlv8A4fWn2ObVvHeqXniu7tlMkcN2BHZo/bbbJ8nXA+bcazbCBYYIokVVVFChVGAPoB0rkxWIdGyjuzrw2HVW7lsinovhyR9UXWfEmoTa5royUuJxiK2z1WCL7sY9x8x7mu0gWqFsvStKEcCvN55Td5M7nFQVok6ipAKYtSdqtGTGHrSUrdaYzYpMaFJqNmprPUbSCobLSFY0gNQmUZp6tmouXYZe3ItbSWY9VHA9T2rz28kZ5c7sscljXTeLLk7YrdTjPzn+Q/rXKTMO38NehhoWjzdzroQsrlNmLTZH3RxW1p1pbwwrJcMMtk5rEUkYHcmr0Lbl2SHO3tXSnY1rwc48qdjXbUpEbCcxdiRUX26VpS6DjpVaDJjye/alV2DFWUkDoRT5mc6w9NdC1FeyGZmYAkYAB7VYh1JUmw64U9cetZjKTKrcgng/SnOo2EDgnofejmYSw9N9Dq9Ou42jkkc/J2HesuawKsZpvlZ2JCnsKi0i5niZPLhLuDyOxFaOqvDqFq4YFXXnB6qfWr3R50k6VRxTMGDUJ9C1uKOIM9nfHYyddknZh9e9dJYaUkV7NfTjN1MBuHYf/X96xNBdJtUthcIHeMkKW52tjg/WuxxXHiasl7iNJUEp87W5FLCk6bZVDD37fSuLFsF1m4lnl88K2yI9kX2H866rW7r7Hp7spw7/ACr7eprjLWUmdT2Jxj1pYW6T7G8KHOnPqbcFi7KbidghbiOJeTVW4mZYgHyCOta0FyllatcSDc7fIg9PaqN5avcICigSPyRnha7Gr7GFGs4StPYyHCuuV656ilVTnDPuP0q2bKUOq4IBPXFTw2aQzDzAW4zU8rOyWJppXWpb0uMQxFMHkZJ96ydWkD3O0HlegxW5jKjycE5zyeKpX1m10fMjADx5B561bWhw0KijU55HL3C7mc9BVaI/hWhdxEOxYY4xg1mM/wAynofSsz2otNXRt2UpR1PfO4GukkIZcjoRXI2TfdB9eK6a3bfaIfQY/KuLGR0UjCojkfGqbBBOP4HGT7GrOhXO4gZpfG8edHnb+6N361jaFNiROeormWsTHqd/G2VqC+XdAwpbZsoKllG5CPashozfDb5imjP8Mh/Xn/GughrmNBOzUbqPsQD+prpoutN7ksvp0okGVpIugp78rQR1Mm8TINYN/CGB4ro7kdayLpM5FCLTO9+HGqnUNBW3mfdcWZ8psnkr/Cfy4/CurrxvwZqP9k+JoGdtsFx+4k9Ofun8Dj8zXsle1hqnPDXdHkYqn7OppswoooroOYKKKKACiiigAooooAKKKKACiiigAoorM1/XtJ8O2JvNd1G00+1Bx5lzKEBPoM9T7CgDTorz6Tx/qWrME8E+FNS1WNvu397/AKDaEf3g0g3uP91OexpF8P8Aj7V+db8XWmkRH71toVkC3/f6bcfyQUAd5dWlvdx+Xd28M6f3ZUDD8jXP3fgTwdO2668L6A7H+J7CEk/jtrJh+Fuiu2/VtR8RaxJ/evtYnI/75RlX9KuRfDLwXH18NabKf708Xmn82yaAHJ8PfAobK+FPDmfawh/+JrY0/wANaFppB07RdMtCO8FrHH/IVlSfDnwY4w3hXRce1nGP5Cqkvwt8IOD5OlyWZPeyvJ7fH/ftxQB21Fefn4e6hY5bw5448S2DD7sV3Ml/CPbbMpbH/AhUM2p/ETw5G0up6bo/iaxjGWl06Q2dyFHVjFISjfQOKAN34g3OzTbe1B5uJQSP9leT+u2uSth0rM1jx/o+u6vZRSm40q68oqlrqcf2eRmJ5C5+Vug+6TWtbjBANeNjG3V1PXwiSpKxo246Vfj6VSgq4hrGJciwlSjpUCGpN1aoyaB6ryGpmaq0rdamTHFEEsmKqvNS3DVRkfmsWzeKJ/M5q1A+ayvM5qf7R5VtJJ/dUkfWhauxVjmdXu2n1K9Dc+XJtX/dAGP61lXDDaPfipL6Rors5/5ap19wef0P6VXY/vQD0A4r2UuVJHfCNkOjTMgbsKv2y4JJGc85qrbf6w56HvVr5hJ8oJTHOKYTZLtBJAZl9gaRi0b/ACDcMZI7ikd1IAX73b2pyHYxDDk9D60GYRguu5j16Yp9pbtLKQNxIOOTwKlsrGSWQnDInvWvFBEjBI8hh94iqUTlrYlR0hqybTIPs8mVfK5wwP8ASq3iB1Fz50ZxlMHFK8oW4EKN8h5/GotQUbaqTtojkw9JynzyMTRp/L1COQ8ASj+dei968uiDfbZNrYGelemwPvgjf+8oP6VwYlbM7sUtUzm/GM+Gjj7BCce5P/1qw9Khy6MxywPFaPjFv9P9gig1V0cEuCe3at6StBGkNKSNfUAgt1DgYyCPY1Xt7zcPL5IB5PpU+of6s7hlSKxIGaN2Kg7SeK2vY53RVSN+p0glWUbV+bHJI7VkX12ULMozjqTV3T5xsYn8vSs/UoNsh3gqpP4VT20OWjGPteWa/wCHI0umVvkfr/CK07C4WQhCzIfY9awwmyYFQMkVIsrROGbOQeMd6lSZ11cNCS91WZuXtnbTKEn4PY1y2raY9vP+5/eRgZ4ro5Cb6wDKriZOQRWFcalJHGqSr8y5BNN26mOEdRP3em6M+zc+ZgjhT1rqtMbdA6nsc1yVq/79t38RzXT6K2S4PXH9a5cSr02ehUWhneMV/wCJFdn0jNcfocnzx89hXb+LYy+h3gH/ADzNcBpTbHT6CuGnsc0tz0rT33QrV0/drI0WTfAOa1j0rGW40YunnZr0g/vIf5iumiNcvBx4gB9VaulhNNiZow9KlI4qGDoKn7UIzZRuVrJuV5Nbc4rLul60FI5/UI+CRXr/AIM1b+2dAt53YG4T91N/vjv+Iwfxryu7TKmtr4XX/wBk8QXFi7YS7jyo/wBtP8QT+VdmEqcs7dznxdPnp37Hq1FFFeseQFFFFABRRRQAUUUUAFFFFABUd1cQ2lvLcXUscMESl5JJGCqijqSTwBWV4s8S6Z4U0h9R1icxxBhHHGi7pJ5D92ONByzk9AP5Vx1n4W1Lx08Wp/EFHg00OJbTw2rfu0A5Vroj/Wv0Oz7q9ME5oAcPF+ueM1kh+HlmttpxO0+IdSjIhYdzbw8NL7Mdq8d60/Dvw50nTb9dV1eW48Qa/wBf7R1MiV4z6RJjZEPZQPqa7RFWNFRFCoowFAwAPSloAKKKKACiiigAoopGOBmgBfauR8eajthj02E/vJcNJjsvYfif5V1NxMltbyTSnCRqWY/QV5lavLquqS3k45kbP0HYUAWBodlqWlGy1Szt7y2k+9FPGHX8j3965+bwTrHhs+d4O1D7Rp68nRtTkLIB6QzctH7Bty/SvRbKDOMU7UZAibaicIzVpK5UZyg7xZwfhnxVY6vdy6fJHPp2tQDM2m3ihJkH95ezp/tKSPpXTq3FcP450nT9fSJL5ZEngbdbXdu/lz27eqOOR9OhrltK8c6/4V1iHSfGMJ1bT5zts9VtY8Sv/svH0Z/YfMewauCrhHHWGx208UpaTPZVapQ3FZelajaarYx3mm3MdzbP92SM5Ge4PcEdwcEd6vKeK5L2Oloe7VVmbrUzniqkxqZMqKKs7cVQlPWrM7VSmPFZG6Rl39+be8tY+MSsQfwGau3s3+hAZ+8f5VzHiOUrqem/9dG/lWxPJvhiHYDNdFCF5ouKuzK1FfP2qpAdfnUn1/8Ar8iqcT+dngqwOMHqD3FWbls5x1xUIi87E0WFmwNy9pB/Q+9eodi0RraUIUYeeRtx3rWgtIHUlOQTnCnpWVpln9sjLQjHln5g3BB9COxrX+1W9vEUSNg/cd81UVpqebiZNztBu/kC6bGr+ZhjnsatRWyF1KooUc/WsqbUp3+XG0kcbaNN815VVmY7epz1pproZTpVORymzc2ISyPgDPA6VQvbj7MW8hQd3B571dnZY42eUgn+Vc5eXLSs+FIPTjoBTbsZ4ek6j12LenEyzB3OTV7UwBHye1UdJAEi4bKgcVe1lQ0YDDioO9q0kjlbcn7WQAcFsg16Ppxzp9sf+mY/lXncGRdbcdDivQdN4062/wBwVy4nZDxWyOX8Xgm+f6L/ACqvpTEOCPu8Zq/4sj/0vPrGD/OsjT5sbRgjsTW1L4UXHWkjob4OYPlUfU1hSMwcoAN3Y10LZmtwEIyB3rDmhZZmLcNjFaMim+g2OR4pEBYYbg1rXUf2uABW56/QVhooYmR2O5TgH0rW02YeWys3QZBBpxfQ58VT2qIy5UMEhYAkdGH9aY5IlR5DhM8e31q/fxFAHck7hzxVZ13pt/hIpPRnTSnzxUizY37W0jbRuQjke9YmqyfaJZJAAu45xV/BVMBgV7Vm3alflz1pX6GlOnFTc1uyCDqD3NdJozDz1x0YGuagAEmB1rf0c7biFe+cVnVV4NF1Voal+QibiAdpDc+xzXJ/Ebw8fDfiYtAP+JfeEzQEdF5+ZPwJ/Iiuvv498br6giuk8faSniH4eCaNN9zbwLdQkdchcsPxGf0rkw0OeMl1PLr1OScX0Z5v4cuAy4zXRg5FcH4ZnIdeeDXbxvlM1y1FZnTEyU/5D6f7rV0cFc3Fzr6/7jf0rpoF5qWDNCDpVjtUEQ4qftTRkyCUcVnXC9a05RxVCcdaBox7hetZcd02m6taXq5zbyrIfcA8j8s1t3K9awdTTKmri7O6KtdWZ78jrIiuhBVgCCO4p1c/4CvDfeE9Pkc5dE8pv+Akr/ICugr3Yy5kmeDKPLJx7BRRRVEhRRRQAUUUUAFY/izxFY+F9Fl1PU2fy1IjjiiXfJPIxwkcaj7zMeAP6VqXE0dtBJPcSLHDEpd3Y4CqBkkn0xXnHg22uPHXiCDxvqySRaRArLoFjIMEIeDdyD++4+6P4VPqaALvgzw3qOoaqPFnjeKM624IsbDIePSoj/Cp6GU8b3/AcDnvqKKACiiigAooooAKKKKACiimXEqW8Ek0p2xxqWY+gFAHJeP9SKxRaZA37yYhpcdk7D8T/KqWlW4REXGK5+51a1l1SfUNSuYYPNbKrI4BC9h+Va2l+JNEmmCpqlpk9A0gX+dS5xTs2axoVZLmjFtejOugAii3Vha1c4RueTWndXcZtg0bqykcFTkGuQ1a73FsmqMjndQuC0hzzzWh4c8O2viiSSy1O3W40wrmdHHB9AO4OeQRyMZFYd0+ZCa9d8CaW2m6FGZRia4/euMdB2H5fzoA8eufD9x4U8Tx6Vf31xYT3D7dG8QJ8wvfS2vF+7JIAMBmwWA4YEGuntvEs2nOtv4utY9MlLCOO+jbdZTsemHPMbH+6+PYtXo3izw/Y+KNAu9J1RC1vOuAy8NE45WRT2ZTgg+orzXw1fXbXF/4S8WrFNrdhGPNdkHl6jbNws4U8c9GXnDZ9a4MTS5feWx2UKl/de51Dniqc561gjQ7/wAPsW8LSpJp3JOkXcjbF/64S8mL/dIKem2n6X4htNWlltgJbTU4RmewuQFmi98dGX0dSVPrXnzj1R3wfRluY9apynrViU9aqTGsjc47xW2NU07/AH2P6VsSEm3UjrgCsLxUc6xp492NblwSsW0egFd+FXU0p7szrk4kwoyAOabAp2blz1zimudrvk981Yt0wntXYdb2NRZ1kSN1LQTgbRMo6j0YfxD/ACKheZoJf9MUIW4EinMb/j2Psf1pWxJHsU8n9KfvdXCFhtYY6ZB+oqr9zmUFF3Q4cvk+nArU05Ps43SDG7kH0rGgtnNysduwUHkRtkp+Hdf1HtWpLfLab1vInt3xwzncjfRhx+eKqK6nLipOVoIh1Gc3FwRE2FXj2JqmjBFIb7/U+9G7Em5SGRznIOeaX703PAA4HrUN3OmnBU4qKLukJ+/U5xnnFXtdbYn3ScDPFVNHQC4xkkLzj0q1rxJjOOuKfQh/xEcvaE/aCzfx8/SvQ7IbbOBfRB/KvPLbCTkyHai8En34r0hV2qF7AYrkxT0Q8T0RjeLFRba3lc4O/wArPrnp/KuS5jkwOOa6Xx8vmaAEyRmVcEdQQDzXH2F4L6Py3IW6j+8p43e49q0w+sC6C/dnTabfh2AXPB+bPatS7tY7pA6NhvauQhlltySwBBPIz0rdsbw7cSfdPbNb3IqU2ndFSa3NszLjIJzg+tMtAnmAnGSefata6gWUb03OwHc9KxwuLhiQVxjg8UbB8cXE19Qhae1BY9Oo9ax5Q235WwOnSug8oz2ygsBGB26msKePyZ8MSVJ4JqpLqcuDqXvEhn5j8uPJaqV58/G0gjk1feTyyA+TnpiqMzEmQ459Kg9GG5RhVTKCCea3dLP76Fv9ofzrCgADYwQ2cGtrTzh+OgYYpS1Viqmx012uAa7fwRKJ/DcCNz5ReIg+gJx+hFcddrlTXQfDmUm2v4D/AASq4/4EuP8A2WuHBStUt3PGxkb0r9jx7UNP/sbxVqViAVSGdtg/2Dyv6EV0lo+6AHPapPi7ZfZfGEF2o+W7txk/7SHB/TbWfpkuYcGs8RHlk0dFCXNBMS0514f7h/pXUQda5eyOdcH/AFzP8xXUwdqwZpIvwjipu1RRdBUx6UzJkMlUZx1rQcVRuRgGkUjNuKxL9cg1tTnrWPe96pDR3Pwiut2n6hZk/wCqlEij2Yf4r+td/XlHwlm26/eRdnt935MP/iq9Xr2MM700eTi1aqwoooroOYKKKKACiiqetana6NpF7qeoSCKzs4Xnmc9lUZP8qAOC+IEkni/xPaeA7ORlsDGL3XpUOCttn5LcHsZWBz32KfWvR40WONUjVURQFVVGAAOgArz74dPBofg+58U+LZ7XS73XJ/7RvZbuZYlhDkLDEWYgDbH5a4PfPrW9H488LTTafFaa7YXh1C5Nnbmzk+0K8wXcULR5Cnbz8xFAHS0VFeXMFlaTXV5PFb20KGSWaVwiRqBkszHgADkk1la74p0XQ/Dy67qV/GmkN5ZW6iVpkcSEBCuwHIJYYI45z0oA2qKqXupWNhLax315bW0l1J5Nuk0qoZpP7iAn5m9hzVugAoorivGXjm30ZntNPCXOoDhs/ci/3vU+w/GonOMFeRvh8NUxM/Z0ldna0V89an4i1fUpC93qE5H9xG2KPoBVAXlypyt1OD6iVv8AGuV41dEe/DhqbXvVEn6f8MfSlecfF/xBcWtkmk6ZIiXM675WPJVM8D2JP8q4vTPGWu6cw8u/kmjH/LO4/eA/ief1rI1O+n1PUJ7y6bdPM2446D0A9h0qKmLUo2jozbB5BKlX5q7Uor8X5nG3XniVjcnD5+Z5G6/iaSLbLxHLDIfRJAx/IVnePLhr/UI7KEbobTKtj+KQ/eP4cD8DWAdKkRQyoQw7iqp5fGUeaUrNnqzxrjLlgtEeiaTruoaNJiznZYz96JuUP4f4V3NrrEWrWIuIxtYcOmc7TXjOjX828Wd+SxPEUrdQf7pPceldNoN5JZ6goyfLl+Rx/I1nFzwtTklszjzDB08dQdWmrTX4+X+R6X4R03+2fEUELjMKHzJP90dvxOBXtoGBgVxvwz0n7FpL3kq4mujlc9Qg6fmcn8q7KvSPigrgfi3od3Nptv4k0GESa/oe6eJB1uYCP30B9dyjI/2lGK76ik0mrMadndHm2l6pa6zpFnqenyeZaXcSzRN6qR39x0I9RWV4h0ex1iOMX0OZYTugnjYpLA3qjjlT+h75qtY2a+FPHOt+G0Oywvc6xpqdkVzieJfTbJhgPSStW4bk14VaLpTaPaoyVSCZyFxe6toLMdUD6rpQ/wCXyCL/AEiAf9NY14df9pBn1XvWpbXltqFnHdWNxFcW0gyksTBlb8RVyViDkGud1HQVe6e+0e4bTNRP33jXdFP7Sx9G/wB4YYetZ3Ut9DWzjtqY3iD954nsI/RST+JFbV4x3ED1zXGT6w6eMbeLXYksbhdkQcNuglYngo/bP91sH61192drEtxmvRw0bRN6DUmyg+GLE9T0q9bgEqW6DtVDH75P7ua0LM/M3BxnrXQdU9i2pLOSnbj61IybnDZ+70pqq53Mi8+lX7GydsSuQB1wRxTSuclSrGmtSTS7faWmkbDgYHHQVDrEjKVCsCp+9u9O1aaDyw6yAfNznsa5+4Aa5cMzbOgBNW9FY46F6lXmZAbGDcXVRE/rCxT+XFOEMjAFbhsejqrf4GlYKkqCNQT3A9KkZFJDbcHI61B6Fy9pSXEZ+V4SPUoRn9aXVzcMhzNEv0jJ/masWoZVJYBQKqagwMbZGaZktZXMO1hBvA0rNK6fMpbgA+uBxXo4f5VPqK87sMm5YDJOea79+AB6CuPFdAxOrRi+NXH9lwD1l/oa89u7faVmiYpKh4YdQa7rxkc2lqvfeW/lXJeXlS3G4k1rhtII2w+kCOw1UTuLe/xHKeFkHAb/AANaiu0DLuYsoPArnrm2Dgkjg9qt6NcEk2cxzIozGzfxD0+oroa6o1cbo7jTLvcxUgj603U4FaYPtwuOvvWVp0jCbLZBXiulAee3HlhW+tJanFV/dvmG2h8xNiudgHNZ+qWnq+QvbHUVoQKHZwT+8Hde1V7aaKSSW3ujvYcLkdvatX2PLptwfNHoYqxqsm5ewx1ziqd2hLs/TjA961r23a0Y/uyEP3cVk3G8KA/TOTisbWPapTU0pIoZbewOM+1aST+RbySddq5X3PQD86zsYkDjkN1q5GnmPbRHop81x7DoPz/lQbTO8n+5z1xWp8PTjUNRXsUjP6tXO6hcYSJd2NwDE+2K6L4cKHuNRmX7u2NR/wCPGvOwn8ZHk4rSiyj8arQvpWm3gHEFwUY+gdf8VFef6ZJxXtHjuwOpeEtSt1XMgiMif7y/MP5V4fpbghTnqK2xsbSuZ4GV4W7GnYjGsIf7yN/Supg7Vylvxq1o3Ykr+YrrIRXAzsZfhPAqftVeI8Cpx0oMmNeqNz3q+3SqVyODTGjHn6msm+6VrXXGayL3lTVIo2/hUCfFUpHQWr/+hLXr1eT/AAkH/FRXh9LU/wDoa16xXrYT+GeVjP4oUUUV0nKFFFFABXnfxaB1u88M+DVyY9ZvfOvQP+fS3xJID/vN5af8CNeiVwmkOuq/GLxBcNyuiadb2EfoHnLTSfjtWGgCH47eHdU8UfDa90nQLY3F/JPbskYkROFmRmOXIXgAnmszx34N8QXupeDmsb+91c2GpS3E95eNbxPbo0JVcCJIwQG54UtyfbHf+KNbh8O6LcandRNLDDjcqzQw8E4zvmdEAGc8sPbJ4rgdN+L+l682gy6MZ4ob7VpdKljmtkmbzI4w5w6T7FGCCHXzAc9O9AHHaPoPxTNnZw3g1qKa28OX9lLJJq0bCe+beYJARKSW+ZAHYArjtjNZni/wP8Rdc0W4sdStNW1ORrHSVswuqxrBDLEqG789DKPMkLgkOQ/sRXsfw1+Idj8QbCa90rSdbs7KNVZJ7+1EUc+WdSI2DMHKlDnHTI79Mvw/8X9D1+01O506zuzDYRvLJ511ZQuQsgTmN7gPHyc5lVBgdckAgGv8QbHX7zUvCL+HnuVgt9Xjl1HybgRA2wR9wYbhvXJX5efpXAfD3wz8QdM13wXea1c6xJGDqKa2lzq32iMISTanYZGBPI5QEjjOK6HTfjV4b1KzD2NtqNxetqA0yKxh8iSSaYqWGx1lMRXAJ3b8e9Xb74p6bp/iWy8P32k6la6vcxpL9nuJrOHYHcqo3POFkbjOIy5wfXIoA6LxzrR0Pw/NcRf8fMh8qH2Y9/wGTXgU8yQxTXFzJtjjUySOeTjufcn+Zr1L40u3k6TH/AWkY/UBf8TXi/jD/kWL0Du0Y/DeK8+t+8rqD2PtMlpqhgnWjvK/4aI5q/8AGGo3MpXS0W0h7MVDyH6k8D8BUEOu+IY28w3zyjqVlRWU/gRVXToQ2OOBW3b22/HHFeg4QguVRRfPKT5mzS0jxRDdukOoRLZzHjzAf3RPvnlf1FbOqXZ0u2Mp4uH4gX1P976Dr+Vche6cjIeMU/w9EtxI8M55iGVJPaud4Wm3zr7jb61UUeRl7RdLV33OM5OST3NdJdaVElmXKDgelYx12xsnCRkyMv8AdHFW5PEVvqFr5ML7X/ung1q+a9zlfZGRpumR3GsAyoDBCPMceuOg/E4rotI0OG81qyhWQQxyTLvLnhVzknP0zTdLtXjsQ4Ulpm3sQOw4A/mfxqwYz0+U57ZBrzsRNyqeSPTw9NKk1ezZ9EW2raThILfULI7QFVFnU4A7da0gcjI6V8xshX7y4+ora0LxNquiMPsV0xhB5hk+ZD+B6fhito43X3keFW4bajejO78/8z6CorF8J+ILfxFpouIBsmT5ZoiclG/wPY1tV2xkpK6PmqtKdKbhNWaPMvjpaGz0jSvFkCkz+H7tZZsdWtZMRzr+RDf8AqtOwPKkMp5BHcV6Rr2mQa1omoaXdqGt723kt5Af7rqVP868T8D3E8/gzSheMWu4Ifss5PXzImMbZ/FK87MIbTO3AT1cTUkOajb7ppzGorhtkLMegFeaj0zg54E1PxDqUMsaSxspjKOu5WAU8EU77Fe6ZCkmjSG7sCgYafcScx5HSKU5IH+y2R6EVP4UHnX93df3nds/U4rUKCLzIOnlMQv+6eR/PH4V62HVoF0Yp69TK0jU7bUnlWLzIriLHm20y7JYj7r6e4yD2NdTpEMBhLzvtGeK5jUNKtNRMclwjLcQ58q4iYpLH/usOce3Q9xT7GfU9LQ/2vG13pa9dRt48vCPWaMdh3dOPUCt0h4iTjD3nbzO2tHjdgkSllPfHIFaLx+VFgPlF5xjtVHS7y1eGE2TxTxyjKzROGRx6gjtSasxjQRo7DdywFXex5XL7SaUev8AVy5JMk0IaE5UjOccVzrfvZSsmMDnjvWzanOl/KcEHisgAs2T29KmR1YSPLKS7f8ABGKpVz5XTvmpIs743bkE9BTQXaQqpXA74q3blEOScleg9Kk62XZHAiGDWJqcwxtUnPerVzdhck/pWRPIHlMr8JjqaB0421Zf8P2/mXcaY6vk/Qc12cn3jXHeAdRiv9Wvlj5EMQ2n1ycGuxcc1wYpvns+hhXd52OV8Zv81qoPIBb9f/rVzjZDFgSI2PStzxgx/tCEdlQfzNY2C2V7ZzXVQ0po6qS9xEEsYJwvTHSsm83wsJU4kiO9a2ZCApHRhyKo3se5c9cjmt0zZG9byl/LmThXQNzXY+HAr226Q/e6VwunMf7LtDx9wCtqzvHhgCpINuMDmknZnHiaTqR5UbLKY75vKyDJ0OOKzr3NteZQEv1z6mrdpehinmc4q3qiW8kaSKw35yKq90cXL7Kqk1o9DHvLqS7Co6kEVk3OVdlZidoyK1LhxuXZ/DWTdEPM27GQOKhnoUYqOiWhRyUGZMbRk59K1LO3MS7pOJZAHI/ujstZsA8yZmIBggYM+f4m7L/U1rwM0shds5PrT2RpNl7XZCgT3iwPrXffDOE/2HJdspU3EnAPoox/PNcRqIjlQiVQwAr1fQLRbHRbK2UYCRLn64yf1riwMeabl2PHx0rQUe5eIDAgjIPBFfPOoWZ0nX76wbpBMyr7qeV/QivoevIfi7prWuv2upoD5V0nlOfR16fmv8q6sXDmhfsc2Cnyz5e5zpbZNBL2Rwf1rr4jXGr+9tiO5FdJplwZrOJyfmxg/WvHZ6jNuE8VYHSqNu+auKeKEQxWqlcng1bc8VSuT1piRk3VZV4PlrVuOprJvTxiqRZ0fwl/5D97/wBe3/s4r1WvK/hMP+J7eH/p2/8AZxXqlethf4aPKxn8VhRRRXScoUUUUAFcB8Ih9pj8W6q3J1DxBdlW9UiIgX9Iq7+uD+Bgz8MNJlI+aeS5nb3L3Ejf1oA6XxR4c0rxRpf9na7a/abUSJMqiR42R1OVZXQhlIPcEVj2Pw48LWM0M1vpsnnQ376oskl3PI32l1CvISzksSAODkd8Zrr6KAMnwz4e0zwxoFvouh2xtNNtwwihEruV3MWPzMS3Vietc/dfC3wjere/2jp1zfveQLazS32oXNzJ5SuJAivJIzIN4DfKRyK3PE2lX+oRQTaPqsunahbEtEceZBLkcpNHkblOOoIYdQRzmhoPivz9RXRfENr/AGRr+CUgZ90N0B1e3kwA47leHXuo6kAqj4Y+ExDcRnTp3ee6S9ed7+4afz0XasgmMm9WA4yGFTXfw98PXxtv7Rj1O+jtnSSOK81e7uIt6nKs0bylWIPdga62vP8AxV8RILGV7XRkS6nXhpmP7tT7Y+9/KonUjTV5HThsJVxU+Skrl34q6W9/4cFxCpaWzfzSB12Yw39D+FeIXtqt9Y3NqxA81CFJ7N1X9QK2tT8Qatqbs17fzurfwK21P++RxWXXmVaqlPnifc5dgp4bD+xqu/p5nNeH/CWt365tNMnaMHBdgEXI68nGfwrvNN8AaoIR9oFtE3oZM/yFdf4Su54NKhSUbto4DdQM10aapFj57c/g1eTW4glKcoJqNn2bPJrVKtObjFXSPOZ/h7dSoR9ptR+Df4Vh3Hwo1Qu5g1CyVX4P3wcflXs41G0P3o5B+ApwvLFv42H1U1Mc4rfZqx/A53ia3VfgeKJ8KdUQYFzYn/gTf/E1TvPhXrrYMDWJcdCJSP6V7yJrEn/XqPqCKeGsj0uIvzrSObYndTi/u/zE8XU6r8D56vfh74sl/wBbbRSAcYjuFx+pFUJfh/4ihUl9Klb/AHCrfyNfShS2PS4i/wC+qYUtx/y8Rf8AfQrX+2MSt1H+vmNYyXY+W2s9Z0abeY7u1YcESIQp9iDwa39E1YaiGinRYrtRnC/dkHcj0PtX0DL9lKFXmiZT2JyDXI+INB8NzSLciKO3u4jvWa3Gw8eoHBH1qnm9KorVo2fdO52YbHyjJWTOe8D6u+jeI7WbcRBKwhmHYqxxn8Dg177XzLGC8qrHnczAL9c8V9MoCEUNywHNetgpOzRy8S0oqcKi3d/wt/mLXg2k5g13xlYMNv2bW53Ueiyqkw/VzXvNeG6iPJ+KnjiMcCRrGf8AE2+3/wBkqsar0meJgnaqiyx5rG8VXYtdHnfOCVwPqa12PNcZ49n3m0tB/wAtH3H6CvIgrs9iWiLHhCLy9OLEckCrmogkR3GcD/Uv/NT/ADH407R08rTf8+lLIAymKX/VSDa2PT1/CvWo/AjekrJFYAMARUV5rd7DdppWhLHJqMiiSR5SfKtUPAd8cknBwo5OOw5qWHcsrxMQZI+pHRh2YfWqfgqOOSfWbl2/fTanKkjEchUwij8FAP41qtArtNWLHh3wNPFf3N6niHU7a7lG6WS1jhiiZvXythUn3OT705tS1HTtVisfEM0VzDcOIrXUYo/LDv2jkTJCsccEfKenB4PdIz/IkRSZVIiQqQu7vyOtcL8Qkjk8Ma2JNsTRwPMpz9x0+ZSPcMoqntY8yg+abnHojrbBwLRwqjOe9ZR+c5IwoqGC+YW0RbIZ0DNj1I5qNro42oOKhs76VBxlKXcnYqCBExB7mo5bpApQfe9qqzSbQXmkWJe+Tiud1LxLa2xaOzU3EvTd2pxi5bG9ktzeuLhIo2e4lVI16k1yOsavJqb+TaZW2XjI6tVCZ7vU5A94xCdQg6VajjCqFRQprZRUPUL3O1+EEGy/1BsdIVX82/8ArV6TIK5T4bWBs9JluZBhrlgVz3UdD+JJrqpG4ryMVLmqNnFV1m7HCeLXL6s6DoAo/SsGa8ht8ia4SM+mc10Xiyxu5JZ5LWNmMi8Oozg9OlecXGmSxyYlDbycneCP5134dRlBandCfuJI2zrWnqP+Pgk/7ppg1fTnGPPx7EGsMWH+xk+xpDp+eSuPaujkgPmkdbo2o2ktqtv9oQSxkgAnhhngitBMp8wCtnuK8+bTxn5Tz7VYga+tgPJuJAPQnNDpxezJu+x3sVwQPmJHcCrX2sSKPmwRXBjX9QhAEqRye5GKsReJg+FlgSMnvk1DpS6C91nZPMWXdnb+NZlxIzyNHGVac9SekY9T/hVS1n+3JiG9ix3WIYb8z/hU6xeSQsa7MdT1yff1qGrblpLoSRjZGkMf+qjP4se5PvWxaD957cVmWylu31rZtBl8DoKzqStFsmeiL9pCb3UbW2/56yqh+mef0r2UcDivLfBkHneJ7XIyI1eT8hgfzr1KowEbQbPBx8rzS7BWX4m0eLXdFuLGbALjMb/3HHQ/nWpRXa1dWZwptO6PniJZbS5ktrpCk8TFHU9iK29KYIrKDwTkCuv+I3hZr1Dq2nJm7iX97Go5lUdx7j9RXA6Zchsc814uIpOnKx7lCqqsbo6iB8GtBGyKxIJM4rRik4rnKaLLvxVK4bINTu2RVK5bAqkKxSuGABrHuTuzV66kzWdO2cCqGjtvhLATeanP2VI4/wAyT/QV6TXJfDOzFt4bE5HzXUjSfgPlH8s/jXW17OHjy00jx8TLmqthRRRWxgFFFFABXCfAxs/CnQB3WORD9RK4/pXd1wPwVPleEr3Tj97TdX1C0YemLmRh/wCOutAHfUUUUAFZ2vaLp+v6c9jq1qlzbMQwByGRh0dWGCrDswII7GtGigDwv4h+Jtb8II+gXN7JqmlFQzagF/0u3jOf3cwH3xjH7xcHH3h1Y8pbyx3EMctu6SxSAFHQghh6gitTxHdNe+INRuHJJe4f8ADgD8gK5lNHuLS8a60Bo43Zt0tlIcQTE9SMf6tj/eAwe4PWvExddWlN9D9AwWHeBoJRV+r73/X8/wAjqtO0s3GN2T7DpXQWegxxkHYAaf4L1G11G2ZPJmtbu3IW4tp12vET09iD2YEg12iSWiKBgV8lUq168mqk7eRw4jHzfw6ow4YRCm1RT615VtpV4wDWbJHtcheRXBWoOnre5zQq8+5FS4zUojOKljhyeazjTbG5pECoTTvKqy5SMe9VnmzVyhGG5Kk5bDGAFRO6oMsRSSv8px1rl9a1NoZDGSd3oKVKjKtLlgrs6aVJ1HZGtf6okSkKRmuV1PUXn3IG+9wfp6VQmnklJ3E1d0LQ7/XbrydOhL4PzyHhE+p/p1r6PA5T7OSlPV9j06eHhQXtKrskanw80ZtY8RwFlJtrUiaU9uD8o/E/oDXu1ZHhjQ7fQNKjtLfDP96WXGDI3c//AFq16+voUvZxs9z47Ncd9cr80fhWi/z+YV4drLbviz4yx/BDYIfr5Tn+te414Is32vx947vB91tTjtlP/XK3jU/qTUY1/uWc2CX71F5q4PXT9r8UqgyRCgH9a7qRgqMx6KMmuPmi2eJr0MPmjCI3+9tBP6k15NNbs9iW6RvWi4swvqcVDNy3OOKswf8AHsPzrnfEOsxaeuD88rdFFepQTlBJHVT2L8uWClCEdc7XHb2I7iudm1NvDesTXjo5068KvdCIb/JlAA81R1KkABh1GAeeaxLjUtTvyShMcftxWXdhoJUjllklu5BlII+Xb39h7nArrVK27FVcWj1UeLrS8t2nj1bT3RsN5wlQEY988VyepanaeI5hZwXStpCuGvLsn5ZsHPkx/wB7JA3MOAOOSeOUtvC5u5VudV8jeDlIEUFUPqTjLN+nt3roLPw/LcuBBDNcHoBGpbFJxitWzGELLRJL8/8AI37zxNpsOREWmf0UcVi3Pia+nJFpEsQPcjJrcsPAepyFT9migU/xTOOPwGTXS2Pw9jXBvb92/wBmFAv6nP8AKsnWow6mkqyW7PL5Y72+YNeXDEHtmrFvZxRsFiTzHPGF5NeyWnhHRbYg/YxMw/imYv8Ap0/StqCCG3ULBFHEB0CIF/lWUsctoozdeK2R4/Y+HdVu8GLT5lXs0n7tf1rqNF8ErG4k1eRJMHPkxE7T/vN3+grum5qJx6VzTxU5aLQh1pPbQFIRQqgKqjAAGABUcsnFKahl6VyszRC8nOc08YkGHAYe/NV296nhwRUlMik0yym/1lnbt7mMVWk8OaW55s0X/dJX+RrZjp5WqU5LZi5mjnH8IaU6kLHNGT3WQn+eaz7rwKpBNrec+kqf1H+Fdoq1IFrSOIqx6lKrJdTyu+8I6lBkm389R3iO79Ov6Vzt1p/luyTRlGHZhg17qRVe5giuEKXESSoeodQa6IY6S+JGir90eAz2TwsHgZlI6EVcsfEN5ZsEu186L/a6/nXpuq+D7K4UtZk2z9dv3kP4dRXFa14YvbYkyQFo/wDnonzL/iPxrtp4qnV0ZrGUZfCzc0e9tb6LzLVwfVT1FblmoQMfavOPDljdWurxugIi5DHPBFekYMcADcMeTXPjGoRsuopvTU6/4cxiTVLyb+5Cqj/gRz/7LXoFcP8AC9P3OpS+rov5An+tdxW2EVqSPn8W71WFFFFdBzBXE+K/A0WoSveaQyWt6TudD/q5T/7Kfeu2oqJwjNWkXTqSpu8WeJXEV/pEwh1S2kgboGIyrfRhwa0Le5DAEGvWp4Y7iJop40kjYYZXGQfwrg9c8EyQs0+gtleptZG/9BY/yP5151bBNaw1PRpY2M9J6GYJNwqpdqzdKqG5ms7gwX0MlvMP4ZFwfw9auLcoy5yK4rOLszs32MyWFu9VktJLq6htof8AWzSLEvsScZ/DrWncSA5xXQ/DvSmuL9tVlT9xCCkBP8TnhmHsBx+J9K1owdSaiRVmqcHJnfWVtHZ2kNtANsUSBFHsBipqKK9w8IKKKKACiiigArgfAiNpvxB8faURiKW5ttWh9xPFsf8A8fgb8676uA8UzHQ/ir4U1QjbaatDNotw56CT/XQZ/FZVH+9QB39FFFABRRRQB87+KLRrDxHqVuwI2zsRnuCcj9CKo2r7JQfevSfi7oRZYtZt1+6BFcY9P4W/p+VeY9K8DHYfnjKl3P0bAYhYvDRmt7Wfqj0HSbgSW6jNaOc1wmk6i0LhSeK62zuxKBg18LWpSpycZI4cRh3B3RoAnsasRJkZNV4iGNXVYKlOlFPVnn1HbQTgUx5cDApjydahZiacqltEJQvuKzFjTlgd+i1GOoq7DcMmKmmoyfvsqTcV7pVktnQcqa5HxNpjSSGeIfOByPUV6FHdJINsgFZmqW8ZJ24INdcf9lkq1GVy8NiZQnrueUoxR1bapKnOGGQfYiva/h54js9XsTaxW0NldQDLQRAKrD+8o/n6V5Xr9gIJDLGPlJ5qlo+oz6RqdvfWzESQtnH94d1P1HFfX5fjVUiqkdup6mOwkcxoafEtvU+kKKitJ0urWG4iOY5UDqfYjIqWvfPgGmnZiMwVSzEBQMknsK+ePCFyL/SZtWxj+1b251D/AIDJKxT/AMcC16h8atal0X4caq1m2NQvlXT7QA8maY+WMfQMW/4DXAWFlFpmnWlhbDENrEkCfRQB/SvPzCdoqJ35fC8nIvWlv9svbW0/57yrGfoTz+ma41ZPtWt6pdD/AJbXUjj6Fjj9K9D8LqRqU1xji0tJZ8+h24H8zXnGjriLJ6k5NccVanfud6d6j8jfiz9mOO1cLq2nvNqU08xBjAyCTgAD1rs7nVrXSliEu+a6m4gtIRummPoq+nqxwB3Iqa08PTay/n+KY7fycho9Lg5hTHIMr9ZW9uE9j1rehiXSjqjZVVH3bXPPdN0/VteO3w7bt9jHB1CVMRk/9Mwcb/8Ae+79a7LQPhslmpe5u/30h3Suo3ySH1Zz/IDA7V6FGoAAUAKBgADAA9KsIlKeMqS20M3Ule/UxrDwxpdqQRbCVx/FMd/6dP0rcjiWNAsahVHZRgVIqVMqc9KxcpS+JmUpt7kAQ+lPVKnCUuwUWIuVylN2VZKe1NZaATK5FMZKsFfamstIdyk4xVaU1dlHWqcgqWWilKealtzUUo60sB5qDV7GnEal4NQw9KmHWqMhyipFFMWpVpCY0rUTrVgjio2FDBMrMKicVaYVC60ijMktLYSeaIIhIOQwUZqjd9615hwayLvrQ23uax1O/wDhmgXRLh+7XB/RVrrq5j4dDHhzPrM5/pXT17mH/hR9DwsQ71ZeoUUUVsYhRRRQAUUUUAV72ytb6Lyry3inj/uyKGxWBP4H0aRiYo54PaKY4/I5rp6KmUIy+JFxqSj8LscvB4H0iNw0v2m4A/gll+U/UDGa6WKNIYkjhRY40GFVRgAegFPoojCMPhVglOU/idwoooqiAooooAKKKKACuW+J3h6bxN4Lv7GxYJqcYW6sZM42XMTB4jnt8ygfQmupooAwvA/iCLxV4T0zWYUMRuosyRMMGKUErIh91cMPwrdrzjSZm8GfEy60a4wuieJZHvtPfosN4APPh/4GB5g994r0egAooooAjuIY7mCSGdFkikUq6sOCD2rwrxv4abw5qSqjb7OfLQMT8wA6qfpkc969u1a/h0vTbm9uTiKFC5x1PoPqTxXgHiDWbrXdSkvLxuTwkYPyxr2Uf55rixjjZJ7n0vDkK3tJSi/c6+b6WM5SVII6iuv0AF4kb1Ga57TbI3Ei5UtnoO1eiaForCIMxCr618dmc44map0leS6nu4/EQpxsx0fygU55M1ens4kyBICRWcww2K8WrCdL3ZHjRkp6oOTSU4U5kIGcVla5dyPOOtAcHo1ZWsX62iEucCsOPXFL9WX/AHq2p4WrUjzwi2jpp4aU48yO1WTHWmSvnJPSuaj1nj73FNm1xdpGajkm/dsJYWVxfEDL9mfPfNcieBmtDUdQa54HSpvCukPrmuW1moPlk75WH8KDr/h+NfVZRh6lOm1Jatnq0rYek51NEtT3DwnG8PhnSo5Bh1to8j/gIrWpFUKoVRgAYAHasLxz4ltfCPha/wBZvVMi26fu4V+9NIThI192YgV9elZWPzmpP2k3Luzzb4lXf9vfErTtOjYPY+HYTeXAHT7XKCsSn3WPc3/AxUDctWb4Z0+6sdPmuNWcSazqMzXt+46ec/8ACP8AZUYUey0avq9tpax+eWkuZ22W9tEu+Wd+yovf3PQdyK8PEVHWqaHtYamqNP3juNGt/I8E+Ib84BlhdFJ4+VVPP5lvyrxa01C61GPyvDwj8kkq+oSrmJPXy1/5aH3+77npXrmoeFdV1HwTMPFUiW9jb2jMui2shZGcAndcSjHmnPOwAJnrv4NcJYqFRFAAUDAAGAB6V1Vo+zjGPkY4eTqynLzL3hbSbXTFkeINLdzcz3Up3SzH/ab09FGAOwrq4KwrH5GFbcJrgk23dnVa2iL8fNW4lqnCauRGhESJ1WpFFMSplrVGLFC0u2nAUVZNxhFRtUxFRNSHcjNRPUx6VXlPFIpFaSqz1O5qB+tQzRFOfvUcPWnz9TTIetSadDSg6VP2qCDpU46UEMelTLUS1KnSmQOI4qNhU2OKawoYkV2qF6sOKgepLRUnHBrHvBzWzN0NY95yaRrBno3w9GPDUR9ZZP8A0I10tc/4DXb4Wsz/AHi5/wDH2roK9+irU4+iPCru9SXqwooorQyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5/xz4Zg8V+HptPlka3uVZZ7O6T79tcJzHKvuD+YyO9U/hz4pk8R6VNBqkItPEOmyfZdTs/+ecoH3l9UcfMp7g+xrrK4bx54fvotTtfF3hSFZPENinlTW2/Yuo2uctCx6bh95GPRuDwaAO5orF8I+JdO8V6NHqWkyM0ZYxyxSLslgkXho5FPKuDwQf5VtUAcR8XbhovC8cKnHn3Cq30ALfzArxsda9s+KVi154WeRBlraVZfw5B/n+leKONrYry8Ynzn3HD7i8JZb3Z2XhaJPK8wgE11X21wmxeFrzvQ9VNp+7c8V0serxMucivz+qqtGbWzJxOHlKd2rmu8hPU0xWGaxLjVU7NxUdtr0LPszWKpzknJLYhYadtEdCTzV55EOnDp5gNY8N5FIuQwpZrlFQ80Qm4XVtzCVJyaRyvixy7Ic/xf0rDtLWe8l8q1heaXaW2IMkgdeO9aGvziWbaDkZq78OpDH4z00j+JmU/ijV9bk6vQjF9z21N0cM5papN/cc6wZGKsCrDqCMEUh9zX0bqOj6dqXN/Y287dmdAT+fWqlt4V0K2cPDpVqGHdk3fzzXuPBO+jPHjxJS5byg7/L+vwPD9F0TUdZnWLT7Z5M9ZCMIo9S3SvafBvhmDw5YlFYS3cuDNNjGfYegFdAihFCooVRwABgClrpo4eNPXdnj5hnFXGLkS5Y9u/qBOBk9K8L17Wz498XfaIGDeFNDlYWxP3b28GQ0w9Uj5VT0LEnsKsfGDx/FeXM3hHRLqSNWk+z6pdwKWkwRza26jl5mBwxHCKckg9MKLQrjUreG31a3i0/Q4FCQaNbvkFR089x94f7C/L6lqyxdblXInucmEo8z52tht7rVzqkz2vhkRSKh2zalKN0EJ9EA/1r+wO0dz2rd8AeG7ZPEds58y5vH/AHlzeTndLIqcgE9FXdj5VwPahkVEWONVSNBtVVGAoHQAdhXafDSz+a+vWH92BD9Pmb+a/lXDh1z1FFbHoV37Ok5Pc6rxDH5ug6in962kH/jprwG2GAuPSvZfiPqx0zw1MsTbbi5/cpjqAfvH8v5145ajIT6V042S5kjDARag2zZtOQDWxD0FYtn8rAVuwDKivPZ2stRdKtxmq0QqwlJEMtRtVhDVRKsJWkWZSRYU0tNWnitUZMaaiapjUT0MEQt0qtN3q09VpRUloqtyTUMnSpm61DJUM1RSmHJpkX36kk5NMj+/UGnQ0IPuirAHFVoelWQeKZmPWpUqJakSmhMmFI1KKRqGSiB+tVpOtWZKrS96ktFeb7prHu+ta8v3TWRddDQaQPUPBi7PC+nD1jz+ZJrarN8NJ5fh7TV/6d0/9BFaVe/TVopHg1HebYUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwfifw1qema1P4p8DLCNVkUDUNMlOyHU1Xplv4JgMhX79G46bvgzxVYeK9Oe4shLBdQN5V3Y3C7J7SUdUkTsfQ9CORW/XIeLfA9vrF9/bGkXcuieJo02R6nagZdR0SZD8sqdOG5HYigDrJ4knhkimUPHIpVlPQg9RXhfjTw3NoF/jDPZyE+TL/wCyn3H612mlePrnSb2LSPiNYpot+52Q6jGxbT7w/wCxIf8AVsf7j4PoTmu7ube21C0MVxHHcW0g6MAysPWsa1FVV5no5bmMsDUvvF7o+bMU9JXXoTXrOrfDSwuHZ9OuZLTP/LNh5ij6dD+prIj+Ft3v+fU4AnqIiT/OvKq5f7R+/G59XHOcFUjeUreqZ548jvwzHHpTAcHIODXselfDbSbVg99JNesP4W+RPyHP61V8Z+AIrpPtegxpDcKPmtxwkgHp6H9DWiwLhC0UrdiYZ5hHUVNbd7aHmtvqUsIqSXVZJBg5FUrq1uLSQpdwSwODgiRCvP41BkeoryJ5XQcr2aPUVKEveQ+RzIxY12Xwo057rxMLvbmG0QszdtzDAH15J/Cs/wAMeD9S12VWEbW1nn5p5Fxkf7I7n9K9o0PSLPRbBbSwj2RjlieWc+pPc17OEw3LaytFHjZxmdKjSlh6bvJ6ehoUUVg+LfFuieE7MXGuX0cBfiKBfnmnbsscY+ZifYV6p8Ub1eQ+MvHGq+Jrm60D4dTRRwxkw3/iBvmjtm7xwD/lpJjuOF9c9KeoXHiTx+5/tpJ/D/hZhxpccm28vB/08Ov+rQj/AJZqcnOCa37KyttPsYbOwt4ra1hXZHDEoVUHoBXDXxij7tPVnZRwrlrPY5Xwl4N0vwlZhLJXuLxlIlvbg7pZMnJ5/hBPOB9Tk81qTHrWjcKT2rPnRgDxXlybk7s9SCUVZFNuTXp/gi3EHhq0OMNKDMf+BHP8sV5fKreW20HcRgfU9K9Y1OZdF8MzOpx9mt9qY9QuB+uK7cArOU30OXHu6jBdTzDx9qZ1fxBLEjZtrTMKY6Fv4j+fH4Vz1pEVGD2NSWiE43HLHkk9zWilvnBxXLUm5ycmdlOKpxUUFunIrctl+UVRihxjitK2XFQEmWEWpkFNQVMgoRm2PQVYQVEgqdRxWkUZSY9aeKatOFWjMDUbCpDTWpgV3qrJ1q3L0NU5OtSy4ldupqtLVhupqvKOag1RVY8mmx/epW+9SwjmpNOhchqwOlVoutWR0pkDxUiVEKkShEssLTXpRTX6U2SiJ6qy9asvVaXrUForS/dNZV7xE59Aa1Zj8prLuhvGwdW+X8+KEXHQ9e0pPL0uzT+7Ci/koq1SIoRFUdAMUtfQrRHgN3dwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC+tLa/tJbW+t4bm1lXbJDMgdHHoQeCK4Bvh/qPht2m+G+tf2XESWbR78NcWDn/ZGd8P8AwA4/2a9GooA8/PjzVNEiA8aeFNSs9v3r3S1+32uO7HYPMUf7yfia6Hw54z8N+JQP7B1zT75+8UU6+Yv1Q/MPxFb9c74i8D+GPEjFtb0HTryU/wDLZ4AJR9HGGH4GgDoqK4AfC7TrXjRNe8U6Og6R2urSPGP+Ay7x+lSx+D/EkHEHxD1soOgns7OQ/n5QoA7eaKOZCk0aSIeqsMiqkWk6dFJ5kWn2iP8A3lhUH+Vcw/hfxUwx/wAJ/qC+66baA/rGart4C1G4P/Ey8eeK5x/dglgtR/5DiB/WlZMpTlFWTO5ubiG1haW5ljhiUZZ5GCqPqTXE6h8VPC8FybXTLqfXL0HH2fSIWuiPqy/IPxYVCPhb4ZZxJe2c2pTDnzNSuZLpifX94SP0rft9Bt7OERWkMcMQ6JGgVR+A4qJymvhQ4qL+JnEalrvjrxC3lafDa+E9PbrPMVu71h/soP3cZ+pameHvB+naLcyXsaTXmrTf67Ur1zNcy/Vz90ey4HtXe/2cBThYYFcVSFappLY66c6UNYmCICaf9nra+xUos/Y1ksKzR4hGC1rntUTaaZM4WunWzHpU0dqo6ito4TuZvFW2OUttBZrm3LAbRKjN9AQf6Vr+Pg0+g+RHnMsig/Qc/wCFbqRBe2KivbdbhArDgdK6FQUIOMepi67lNSl0PIUsXjbkVoQQ/LyK7G60ZecLVB9LKdBXnVMPKJ6EMTGRjRx4q1EuKsPaMp6U1YyvauZxaNuZMcgqZBzUYqRTQiWToKmUVClTLWqMpDqUUlLVIgKaadTGqhkEvSqch5q3MeDVKSokXEhPU1Xlqw1VpT1qDZFVupp0XWmt606OpLLUXWpwarxdasDtQQSLUiVGKkWmiWTA8U1zQDxTWpslEbVBL1qc1C6kmoLKVweKqWMfn6tYxdd9xGP/AB4GtN7V5OADV/w7pJGs2srjiNi/5A1rSpuUkTOoowZ39FM3+tPByK908QKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArD8X+K9G8Iafb3viG7e1t7i4W1iKQSTF5WBKqFjVjkhT2rcryP9pTSdU1jwt4ch0Syubu5i1+1mYQ27z+UoWTLsq87QSMnI69RQB6B4Z8WaN4me9j0e7aS4snEd1bzQSQTQMegeORVZc4OMjnFblfN/xs+GWpw+CPFWqwtc+IfE+uXto8y2Fi6qkcXyqqRBnbAHUlj0HTvR8V+EfFsGv/Fay8D6df2Fpe2tlJbrAjQxXLbYzOIm4UuQXzg5PzDqcUAfT1FfKuqeCNRu/BXjWPw7baiDqOmWrnR4fDlxpduksU0ROxZZGLzbEbOwHd1zk8t17Q9c1XVfFN1aaBrfkz+CIbKIyadNGZJ1eHMQDKCXG1uOvBPTmgD6soxXyyPA18mrW0a+Gr0Wdx8PlW6X7E/lyagsTBVcYwZhhcA/MDjFWdP0HWGj8Az+OtC1jVvDlv4fltpLFrGW6eC9y4BkhClgSmxVYjg45HWgD6dwKxNa1z+y9Y0fT/7K1a8/tJ3T7TaW3mQ2u0DmdsjYDng85wa+dfCngjxNP4m+E9v400i8v7aCxvor0zwtNHDG6y+XHM+CoOCowT6Co/h94d8TRWfwkTUNH1lDpur3xmFxbSj7LCQmzdkfIp5xnA9KAPqYrim7B6V8r+G9J8Sy+PfCGty+Hb7SNV/tmZNTt9P0L7JbW9uxABMyxgzKw3ZZnYfTOT9W0AQlB2o2VLgUtAEQSnhMU6igBpHPFNIp5FJigCNlBFQvAp7VaxRtpNXGnYzZLJWzxVWXTlPQVt7aQr6is5UYyNI1ZRObk00joKhNiynpXUGMGomtwelc8sJHobLEs50WzDtThEw7Vtm19KY1ufSoeFsV9YuZGw0hBHatYwe1Ma1BqHQZSrIy6Y5rSe0qF7Q1PsZIpVImVMeKpyVsyWJaoG01j0rN0pdjSNWJkvVWUVvnS3NMOkMetT7Gb6GntoLqc04OKkjU46V0Q0UY5FSx6MoxT+rzD6zA5+MHPSrCq3pW+mlKO1TppyDtVfVpEPExOeWNjjg1MkDk9DXQrYqP4alW1HpWiwrM5YlGCtq57GpFsWPaugS2HpUyQADpWqwncyeJ7HOrppPUVPFpij+Gt4QrThGo7VpHCxRm8RJmVHYKP4RV60tliYsAM4xVkL7U4LW8aajsYym2JjNPAxRRWhAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJgUbaWigBu2grTqKAIyntSbB6VLRQBCYwe1NMIqxRRYLlbyE9KTyF9KtYFJtFKyHdlfyV9KXyVqfaKNoosguyAQp6UvlL6VNtFG0UWQXZF5a+lKEUdqk2ijaKdhXI8D0pcCpMD0owPSgCPFOxTsUUAN20oFLRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Alveoli\" are air sacs in your lungs that are surrounded by tiny blood vessels called capillaries. The air sacs have thin walls that allow the exchange of gases. When blood flows through the capillaries around the air sacs, it picks up oxygen that you have breathed in and dumps off carbon dioxide that you then breathe out. But if you have pneumonia, your alveoli swell and fill with fluid. This makes you cough and makes it hard to breathe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10294=[""].join("\n");
var outline_f10_3_10294=null;
var title_f10_3_10295="The pediatric physical examination: The perineum";
var content_f10_3_10295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pediatric physical examination: The perineum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10295/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/3/10295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the perineum in children will be reviewed here. Other aspects of the pediatric physical examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link\">",
"     \"The pediatric physical examination: General principles and standard measurements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link\">",
"     \"The pediatric physical examination: HEENT\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link\">",
"     \"The pediatric physical examination: Chest and abdomen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENITOURINARY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination of an infant, toddler, or child should be performed in the presence of a parent or guardian; if the parent&rsquo;s presence may interfere with the examination (eg, suspected child abuse) a chaperone should be present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/1\">",
"     1",
"    </a>",
"    ]. The use of a chaperone for the examination of the anorectal and genital areas of adolescent patients should be a shared decision between the patient and the clinician after the clinician has explained the reason for the examination and described how the examination will proceed. The sex of the chaperone should be determined by the patient&rsquo;s wishes and comfort (if possible). If a patient is offered the use of a chaperone and declines, this should be documented in the chart.",
"   </p>",
"   <p>",
"    The physical findings and approach to examination of the genitourinary system depend upon the age and sex of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Males",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neonatal examination should focus upon congenital anomalies. Attention should be paid to penile length (",
"    <a class=\"graphic graphic_figure graphicRef66323 \" href=\"UTD.htm?7/4/7246\">",
"     figure 1",
"    </a>",
"    ), foreskin anatomy, location of the urethral meatus, scrotal anatomy (including rugae), the presence and location of the testes (",
"    <a class=\"graphic graphic_picture graphicRef51355 \" href=\"UTD.htm?4/46/4832\">",
"     picture 1",
"    </a>",
"    ), and the presence of abnormal scrotal or inguinal masses. The precipitation of uric acid crystals in the diaper (secondary to increased urinary uric acid excretion in infants) may be misidentified as blood (",
"    <a class=\"graphic graphic_picture graphicRef65328 \" href=\"UTD.htm?38/56/39808\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tightly adherent foreskin should be gently retracted to reveal the urethral meatus in its normal anatomic position at the tip of the glans penis. Forceful retraction is never indicated, particularly in the infant. Care of the uncircumcised penis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H9377172#H9377172\">",
"     \"Care of the uncircumcised penis\", section on 'Routine care and hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A hooded foreskin and chordae generally are present if the urethral meatus is found on the ventral surface proximal to the glans (hypospadias) (",
"    <a class=\"graphic graphic_picture graphicRef58046 \" href=\"UTD.htm?0/44/710\">",
"     picture 3",
"    </a>",
"    ). Epispadias is diagnosed when the urethral meatus is found on the dorsal surface of the penis. Additional evaluation and management of infants with hypospadias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"     \"Hypospadias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attention to the development of scrotal rugae helps determine the gestational age of male neonates. Poorly developed shallow rugae are found in significantly preterm infants. Fully developed deep rugae are evident in the term infant.",
"   </p>",
"   <p>",
"    The clinician's hands and fingers must be in the proper position for an appropriate examination of the scrotum to identify the testes and other normal and abnormal masses. Ideally, the index finger",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    middle finger of the examining hand are placed over the posterior aspect of the scrotum, with the thumb of that hand positioned over the anterior aspect of the scrotum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H10#H10\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the scrotal sack is empty, each inguinal canal should be examined for retained testicular tissue. The infant or young child should be in a supine position. With the index and middle finger of the examining hand positioned over the inguinal canal, the examiner should palpate the length of the canal and attempt to gently express any retained testicular tissue into the scrotum. At the same time, the middle finger, index finger, and thumb of the opposite hand should be properly positioned to palpate the ipsilateral proximal scrotum for any testicular tissue entering from the inguinal canal.",
"   </p>",
"   <p>",
"    Even if previous examinations have revealed the presence of scrotal testes, it is important to reexamine the scrotum at each subsequent well child visit. Some boys have palpable testes in the scrotum on one visit, but months to years later the examination reveals that the testes have spontaneously ascended into the inguinal canal or into an intraabdominal position [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/2\">",
"     2",
"    </a>",
"    ]. The evaluation and treatment of undescended testes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H21#H21\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, palpation of the scrotum reveals unilateral or bilateral fullness in addition to the normally palpable testis. Transillumination of the area using a narrow-beam, bright-light source frequently reveals either a fluid-filled hydrocele or an indirect inguinal hernia. Hydroceles generally spontaneously regress during the first 12 to 18 months of life. Occasionally, they are accompanied by hernias, sometimes making it difficult to distinguish between the two. Hernias usually fill the inguinal area and the upper two-thirds of the scrotum, whereas hydroceles may be confined to the scrotal area alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of inguinal hernia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Older males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genitourinary examination of the older infant and toddler requires the same meticulous evaluation as does that of the neonate, the findings may be somewhat different. If the examiner has difficulty palpating scrotal testes, the patient should be placed in a sitting knee-chest position to help force the testes into a dependent position. Testicular palpation may be enhanced further by having the patient assume that same position in a warm tub of water.",
"   </p>",
"   <p>",
"    Penile length should be assessed (",
"    <a class=\"graphic graphic_figure graphicRef77025 \" href=\"UTD.htm?19/26/19875\">",
"     figure 2",
"    </a>",
"    ). The foreskin of an uncircumcised penis may be difficult to retract. Fusion of the inner epithelium of the prepuce and the epithelium of the glans accounts for the nonretractability. After the first few years of life, squamous cells eventually keratinize, and the prepuce separates from the glans, allowing for normal retraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H86214258#H86214258\">",
"     \"Care of the uncircumcised penis\", section on 'Benign conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, the glans becomes traumatized or infected, producing erythema and swelling (balanitis). Foreskin that has been forcibly retracted and not returned to its normal anatomic position may create a ligature around the penile shaft (paraphimosis) that requires immediate medicosurgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410326#H172410326\">",
"     \"Care of the uncircumcised penis\", section on 'Pathologic conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Preadolescent and adolescent males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate adolescent Tanner staging is determined by assessing penile and testicular size and the extent of pubic hair development (",
"    <a class=\"graphic graphic_table graphicRef76165 \" href=\"UTD.htm?31/46/32491\">",
"     table 1",
"    </a>",
"    ). As the male approaches adolescence, at an average age of 11 to 12 years, the first sign of pubertal onset is testicular enlargement (Tanner stage 2) (",
"    <a class=\"graphic graphic_figure graphicRef68452 \" href=\"UTD.htm?19/32/19970\">",
"     figure 3",
"    </a>",
"    ). In addition to testicular growth at this stage, pubic hair becomes evident, at first long and straight and later curling (",
"    <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testicular length before puberty is normally 1.5 to 2 cm (",
"    <a class=\"graphic graphic_table graphicRef76651 \" href=\"UTD.htm?39/57/40859\">",
"     table 2",
"    </a>",
"    ). Testicular length can be determined using a measuring tape or calipers; alternatively, testicular size and volume can be determined with the use of orchidometer beads. When testicular growth is questionable, ultrasound measurements should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/3\">",
"     3",
"    </a>",
"    ]. Although somewhat smaller than the right testicle, the left testicle tends to be positioned lower in the scrotum.",
"   </p>",
"   <p>",
"    Penile enlargement begins in stage 2 and continues through stage 5. Accurate measurement of penile length is best achieved by using a ruler, retracting the pubic fat away from the proximal shaft, and stretching the penis to its full length. By Tanner stage 4, pubic hair becomes more abundant, spreading to involve the symphysis pubis and eventually the thighs. Prolonged onset of male puberty generally is attributable to constitutional delay and warrants close follow-up.",
"   </p>",
"   <p>",
"    Examination of the adolescent male should include visualization of the urethral meatus for any discharge and the penile and scrotal skin for unusual lesions. The clinician also should palpate the scrotum for testicular position, hernias, and abnormal masses (such as a varicocele). The normal testicular surface feels smooth; an adjacent varicocele feels like a clump of worms. Most varicoceles collapse when the patient assumes a supine position. Adolescent varicoceles (dilatation of spermatic cord veins) can be detected more frequently if the patient is examined while standing. Testicular self-examination is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28261?source=see_link&amp;anchor=H20186674#H20186674\">",
"     \"Screening for testicular cancer\", section on 'Testicular palpation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to examining the genitalia, the clinician should inspect the perianal area for fissures, hemorrhoids, or abnormal lesions. If any abnormal findings are present, the adolescent should be appropriately informed and counseled. Normal findings also should be communicated to the patient, particularly to those who have been somewhat apprehensive during the examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Females",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neonates and infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genitourinary examination of female neonates requires careful inspection of anatomic structures. Proper visualization should be done with the infant in a supine position, legs flexed and abducted at the hips.",
"   </p>",
"   <p>",
"    Normally, no visible distinction is found between the labia majora and labia minora in the young girl. Gentle separation of the labia will reveal the clitoris, vaginal introitus, and urethral meatus. If the clitoris is large and posterior labial fusion is noted, virilization secondary to congenital adrenal hyperplasia should be ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of the infant with ambiguous genitalia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inferior to the clitoris is the urethral meatus and, inferior to it, the vaginal introitus. Patency of the vaginal introitus should be established. Many infants have vaginal tags, which are of no significance and eventually spontaneously regress. In the first few days after birth, a transient, blood-tinged, mucoid vaginal discharge may be seen secondary to maternal estrogen withdrawal. The precipitation of uric acid crystals in the diaper (secondary to increased urinary uric acid excretion in infants) may be misidentified as blood (",
"    <a class=\"graphic graphic_picture graphicRef65328 \" href=\"UTD.htm?38/56/39808\">",
"     picture 2",
"    </a>",
"    ). A unilateral soft tissue mass in the inguinal or labial areas may represent a direct inguinal hernia.",
"   </p>",
"   <p>",
"    Female infants and toddlers are best examined in the supine position with the legs abducted at the hips. Gentle posterolateral retraction of the skin surrounding the inferior vulvar rim provides optimal visualization. Anatomically and physiologically, generally little change occurs in this area from the time of birth.",
"   </p>",
"   <p>",
"    Occasionally, a thin tissue membrane adherent to labial skin (labial adhesions or agglutination) but not impeding urethral flow will obscure visualization of the underlying vulvar anatomy. This membrane may develop as a result of poor hygiene. Management of this condition consists of instructions to the caregivers regarding appropriate cleansing of the area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    daily application of a thin layer of estrogen cream for two to three weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H23#H23\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Labial adhesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Older females",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must understand individual sensitivity issues regarding the genitourinary examination of the older child. The admonition from parents, teachers, and guardians that a child should not allow anyone to see or touch her private areas without her permission causes some children to become apprehensive and uncooperative. Thus, the clinician who is about to begin an examination of the genitalia should explain to the patient why examination of the area is needed and how the examination will be performed, including what instruments, if any, will be used. Appropriate gowning",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    covering should be provided. Careful attention should be given to making sure the procedure is painless.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Preadolescent and adolescent females",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital examination of the preadolescent female is best conducted with the patient either in the supine position with legs in a frog-like position, flexed and abducted at knees and hips, or with the patient prone in a knee-chest position. Vaginal mucosa in the preadolescent is thin, moist, and somewhat red. The examiner should look for any signs of trauma, irritation, or discharge. In early puberty, a normal watery, non-foul-smelling vaginal discharge may be present. The presence of blood, purulent discharge, or foul odor requires investigation. Evidence of trauma or blood should raise the possibility of sexual abuse. In the younger child with genital blood or foul odor, the examiner should consider the possibility of a vaginal foreign body. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H13#H13\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Foreign body'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clitoral size should be determined by the clitoral index, a measurement expressed in square millimeters and calculated from the product of the length and width of the clitoris; charts indicating the normal clitoral index by age are available. Causes of androgen stimulation, including congenital adrenal hyperplasia and abnormal karyotype (",
"    <a class=\"graphic graphic_table graphicRef78311 \" href=\"UTD.htm?4/7/4222\">",
"     table 3",
"    </a>",
"    ), should be sought when measurements indicate clitoral enlargement for age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the infant with ambiguous genitalia\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unusual soft tissue masses may be seen in the vulvar area in preadolescent females. An edematous, violaceous, nontender, donut-shaped mass may be noted surrounding the urethral meatus, particularly in black females younger than age 10 years. This abnormality is the result of urethral prolapse with eversion of the mucosa through the external meatus. Bleeding from this area may be the presenting complaint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H19#H19\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Urethral prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lesion found predominantly in white preadolescent girls is a prolapsed ectopic ureterocele, which protrudes through the urethral meatus. Other vulvar lesions include paraurethral cyst, imperforate hymen (leading to hydrocolpos or hydrometrocolpos), and rarely a grapelike cluster (caused by sarcoma botryoides) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally, the first sign of puberty (Tanner stage 2) for girls is breast development (",
"    <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 5A",
"    </a>",
"    ), followed shortly thereafter by the growth of pubic hair (",
"    <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"     picture 5B",
"    </a>",
"    ). The definitions of and evaluation for precocious puberty and delayed puberty are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed puberty in girls requires a thorough investigation to rule out significant organic causes; it cannot be explained on constitutional grounds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid growth in girls begins during Tanner stage 2 and slows considerably after the onset of menses (usually in Tanner stage 4). Females usually grow only 1 to 2 inches thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An adolescent female should be examined in the same position as described for the preadolescent. Tanner staging should be assessed and attention given to looking for abnormal vaginal discharge and vaginal or vulvar lesions. Estrogen stimulation of the vaginal mucosa produces a thickened, dull-pink mucoid surface. A thin, white, non-foul-smelling liquid discharge (leukorrhea) normally is present in the otherwise asymptomatic patient.",
"   </p>",
"   <p>",
"    Indications for pelvic (speculum and bimanual) examination include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent vaginal discharge",
"     </li>",
"     <li>",
"      Dysuria or urinary tract symptoms in girls who are sexually active",
"     </li>",
"     <li>",
"      Dysmenorrhea that is unresponsive to nonsteroidal antiinflammatory drugs",
"     </li>",
"     <li>",
"      Amenorrhea",
"     </li>",
"     <li>",
"      Abnormal vaginal bleeding",
"     </li>",
"     <li>",
"      Lower abdominal pain",
"     </li>",
"     <li>",
"      Contraceptive counseling for an intrauterine device or diaphragm",
"     </li>",
"     <li>",
"      Performance of Pap smear",
"     </li>",
"     <li>",
"      Suspected or reported rape or sexual abuse",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bimanual examination of the uterus in a supine preadolescent or adolescent female can be accomplished by palpating the anterior rectal wall with the gloved index finger of one hand while palpating and applying pressure to the lower midline abdominal area with the other hand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H3#H3\">",
"     \"Gynecologic examination of the newborn and child\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANUS AND RECTUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the anus and rectum is relatively standard for all age groups. Inspection of the perianal area under normal circumstances should reveal an intact, symmetrically wrinkled area of pigmented skin. Aside from the rare finding of an imperforate anus or an anteriorly placed anus, anatomic abnormalities in the pediatric age group are unusual.",
"   </p>",
"   <p>",
"    Infantile perianal pyramidal protrusion (IPPP) is a perianal lesion, previously described as a skin tag or skin fold, reported almost exclusively in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Some authors propose that the lesion be called \"infantile protrusion\" since it is not always pyramidal and may be perineal rather than perianal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/10\">",
"     10",
"    </a>",
"    ]. The lesion is typically located in the midline, just anterior to the anus, although posterior lesions have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/11\">",
"     11",
"    </a>",
"    ]. It is described as a pedunculated pyramidal protrusion with a tongue-like lip that is covered with smooth red or rose-colored skin (",
"    <a class=\"graphic graphic_picture graphicRef62735 \" href=\"UTD.htm?14/57/15248\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/8,9,12\">",
"     8,9,12",
"    </a>",
"    ]. Tenderness is not reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/8\">",
"     8",
"    </a>",
"    ]. Treatment generally is not necessary. The clinical course is one of recurrent swelling and eventual resolution. Constipation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lichen sclerosis may be associated findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ]. Resolution of the lesions with treatment and resolution of constipation is an inconsistent observation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The history of swelling and resolution and characteristic appearance distinguish this lesion from condyloma acuminata, trauma, skin tags, rectal prolapse, and granulomatous lesions of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10295/abstract/12\">",
"     12",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    External hemorrhoids and prolapsed internal hemorrhoids are found primarily in older patients. Perianal fissures caused by straining during defecation and passage of hard stools or by dry irritated skin are seen in all age groups, particularly infants. Careful attention to bruises, tears, and lacerations in patients suspected of having been sexually abused should be noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Perianal area'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Digital rectal examinations are not performed routinely as part of the regular physical examination of children. When digital examination becomes necessary, the examiner should remain sensitive to the potential embarrassment and discomfort for the patient. The patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guardian should be given an easily understandable explanation of why the examination is being done and what discomfort might be experienced. The examination is performed best with the patient lying on his or her left side and legs flexed at the hips and knees. Gloves and an appropriate lubricant should be used.",
"   </p>",
"   <p>",
"    In the child with a lower abdominal mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    history of constipation or infrequent passage of stools, a rectal examination may help to make the diagnosis. A smooth-walled rectal vault with soft stool in the rectal ampulla is the normal finding. A palpable abnormal mass or blood-tinged stool on a gloved finger requires more extensive investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link&amp;anchor=H23#H23\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Digital examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184025048\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of a chaperone for the examination of the anorectal and genital areas of adolescent patients should be a shared decision between the patient and the clinician after the clinician has explained the reason for the examination and described how the examination will proceed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genitourinary system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The important physical findings and approach to examination of the genitourinary system depend upon the child&rsquo;s sex and age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genitourinary system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genitourinary examination of newborn male infants focuses on congenital anomalies including microphallus (",
"      <a class=\"graphic graphic_figure graphicRef66323 \" href=\"UTD.htm?7/4/7246\">",
"       figure 1",
"      </a>",
"      ), abnormal location of the urethral meatus (",
"      <a class=\"graphic graphic_picture graphicRef58046 \" href=\"UTD.htm?0/44/710\">",
"       picture 3",
"      </a>",
"      ), undescended testicles (",
"      <a class=\"graphic graphic_picture graphicRef51355 \" href=\"UTD.htm?4/46/4832\">",
"       picture 1",
"      </a>",
"      ), and abnormal scrotal or inguinal masses. In older boys, it is important to assess the position of the testicles, penile length (",
"      <a class=\"graphic graphic_figure graphicRef77025 \" href=\"UTD.htm?19/26/19875\">",
"       figure 2",
"      </a>",
"      ), and retractibility of the foreskin (if the boy is uncircumcised). The evaluation of preadolescent and pubertal males focuses on staging pubertal development (",
"      <a class=\"graphic graphic_figure graphicRef68452 \" href=\"UTD.htm?19/32/19970\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"       picture 4",
"      </a>",
"      ), urethral discharge, and scrotal palpation (for testicular position, hernias, and abnormal masses). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Males'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genitourinary examination of female newborn infants also focuses on congenital anomalies including clitoral enlargement, patency of the vaginal introitus, and direct inguinal hernias. The examination of preadolescent and adolescent girls focuses on staging pubertal development (",
"      <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72038 graphicRef79782 \" href=\"UTD.htm?39/9/40088\">",
"       picture 5A-B",
"      </a>",
"      ) and signs of trauma, irritation, or discharge. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Females'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The perianal area should be examined for fissures, hemorrhoids, or abnormal lesions. Digital rectal examinations are not performed routinely as part of the regular physical examination of children. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anus and rectum'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/1\">",
"      Committee on Practice and Ambulatory Medicine. Use of chaperones during the physical examination of the pediatric patient. Pediatrics 2011; 127:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/2\">",
"      Gracia J, Navarro E, Guirado F, et al. Spontaneous ascent of the testis. Br J Urol 1997; 79:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/3\">",
"      Walc L, Bass J, Rubin S, Walton M. Testicular fate after incarcerated hernia repair and/or orchiopexy performed in patients under 6 months of age. J Pediatr Surg 1995; 30:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/4\">",
"      Sane K, Pescovitz OH. The clitoral index: a determination of clitoral size in normal girls and in girls with abnormal sexual development. J Pediatr 1992; 120:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/5\">",
"      Lowe FC, Hill GS, Jeffs RD, Brendler CB. Urethral prolapse in children: insights into etiology and management. J Urol 1986; 135:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/6\">",
"      Nussbaum AR, Lebowitz RL. Interlabial masses in little girls: review and imaging recommendations. AJR Am J Roentgenol 1983; 141:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/7\">",
"      Braverman PK, Breech L, Committee on Adolescence. American Academy of Pediatrics. Clinical report--gynecologic examination for adolescents in the pediatric office setting. Pediatrics 2010; 126:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/8\">",
"      Fleet SL, Davis LS. Infantile perianal pyramidal protrusion: report of a case and review of the literature. Pediatr Dermatol 2005; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/9\">",
"      Konta R, Hashimoto I, Takahashi M, Tamai K. Infantile perineal protrusion: a statistical, clinical, and histopathologic study. Dermatology 2000; 201:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/10\">",
"      Cruces MJ, De La Torre C, Losada A, et al. Infantile pyramidal protrusion as a manifestation of lichen sclerosus et atrophicus. Arch Dermatol 1998; 134:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/11\">",
"      Patrizi A, Raone B, Neri I, D'Antuono A. Infantile perianal protrusion: 13 new cases. Pediatr Dermatol 2002; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/12\">",
"      Kayashima K, Kitoh M, Ono T. Infantile perianal pyramidal protrusion. Arch Dermatol 1996; 132:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10295/abstract/13\">",
"      M&eacute;rigou D, Labr&egrave;ze C, Lamireau T, et al. Infantile perianal pyramidal protrusion: a marker of constipation? Pediatr Dermatol 1998; 15:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2858 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10295=[""].join("\n");
var outline_f10_3_10295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H184025048\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENITOURINARY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Older males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Preadolescent and adolescent males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Females",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neonates and infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Older females",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Preadolescent and adolescent females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANUS AND RECTUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184025048\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7246\" title=\"figure 1\">",
"      Penile length in newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/26/19875\" title=\"figure 2\">",
"      Penile length 0 to 5yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/32/19970\" title=\"figure 3\">",
"      Tanner rating genitalia boys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2858|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/46/4832\" title=\"picture 1\">",
"      Bilateral cryptorchidism2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/56/39808\" title=\"picture 2\">",
"      Urate crystals diaper",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/710\" title=\"picture 3\">",
"      Hypospadias composite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/26/33187\" title=\"picture 4\">",
"      Sexual maturity rating of pubic hair in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 5A\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30227\" title=\"picture 5B\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/57/15248\" title=\"picture 6\">",
"      Infantile perianal pyramidal protrusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/46/32491\" title=\"table 1\">",
"      Tanner stages of male puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/57/40859\" title=\"table 2\">",
"      Normal testicular size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/7/4222\" title=\"table 3\">",
"      Causes clitoromegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/1/8220\" title=\"table 4\">",
"      Sexual maturity rating of secondary sexual characteristics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=related_link\">",
"      Care of the uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28261?source=related_link\">",
"      Screening for testicular cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_3_10296="Initiation of positive airway pressure therapy for obstructive sleep apnea in adults";
var content_f10_3_10296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10296/contributors\">",
"     Nilesh B Dave, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10296/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10296/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10296/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/3/10296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. Potential consequences of OSA include excessive daytime sleepiness, impaired daytime function, metabolic abnormalities (ie, glucose, insulin, lipids, leptin), and an increased risk of cardiovascular disease and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a patient has been diagnosed with OSA, it should be determined whether treatment is indicated and, if so, which type of therapy is most appropriate. These decisions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive airway pressure is a first-line therapy for OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. Its initiation requires selection of a mode of positive airway pressure and a patient-device interface. The optimal amount of positive airway pressure must also be determined. These issues are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MODES OF POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major ways in which positive airway pressure is delivered to patients with OSA, as continuous positive airway pressure or bilevel positive airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. Continuous positive airway pressure is generally preferred for most patients because it has been well studied, is simpler to use, is less costly, and there is a lot of clinical experience using it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Continuous positive airway pressure (CPAP)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fixed CPAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed CPAP delivers positive airway pressure at a level that remains constant throughout the respiratory cycle. The positive airway pressure splints the upper airway open, preventing upper airway collapse during sleep. No additional pressure above the level of CPAP is provided and patients must initiate every breath. The benefits of fixed CPAP therapy in patients with OSA are well established and described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Autotitrating CPAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autotitrating CPAP delivers an amount of positive airway pressure that varies during the night. The variation is related to whether the device algorithm detects upper airway obstruction or patency. In the presence of upper airway obstruction (indicated by increased airway resistance), the delivered pressure gradually increases according to the algorithm until adequate patency is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. After a period of sustained upper airway patency, the delivered level of pressure gradually decreases until the algorithm identifies recurrent upper airway obstruction, at which point the delivered pressure increases. The result is that the delivered pressure varies throughout the night in an effort to provide the lowest pressure that is necessary to maintain upper airway patency.",
"   </p>",
"   <p>",
"    The algorithms used to detect upper airway obstruction and to change the level of positive airway pressure delivered vary considerably among manufacturers. Thus, it is likely that performance of the autotitrating CPAP devices is also highly variable. Autotitrating CPAP may not function properly if a significant leak exists, since leaks can change airflow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that autotitrating CPAP should be used selectively in patients with OSA because its performance may be highly variable, the body of evidence supporting its efficacy is more limited than that of fixed CPAP, and direct comparisons with fixed CPAP have not identified definitive benefits (as discussed in the next section).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small randomized trials and observational studies initially found that autotitrating CPAP was associated with improved sleep architecture and continuity compared to fixed CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, more rigorous studies indicate that autotitrating CPAP has little or no benefit over fixed CPAP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis (nine randomized trials, 282 patients) found that autotitrating CPAP and fixed CPAP equally improved daytime sleepiness and the apnea hypopnea index [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/7\">",
"       7",
"      </a>",
"      ]. Adherence was similar in both groups.",
"     </li>",
"     <li>",
"      A crossover trial randomly assigned 200 patients with treatment-naive OSA to receive either autotitrating CPAP or fixed CPAP for six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/8\">",
"       8",
"      </a>",
"      ]. OSA was defined as subjective daytime sleepiness plus an apnea-hypopnea index (AHI) &gt;15 events per hour of sleep (mean AHI was 33 events per hour of sleep). The trial found no difference in patient preference for a device, despite the autotitrating CPAP group having a marginally longer duration of use (4.2 versus 4.0 hours per night) and less subjective daytime sleepiness (Epworth Sleepiness Scale score of 9.5 versus 10.0). It is uncertain whether such small changes are clinically important. There was also no difference in the quality of life, objective measures of sleepiness, or psychomotor vigilance testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link&amp;anchor=H14#H14\">",
"       \"Quantifying sleepiness\", section on 'Epworth sleepiness scale (ESS)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bilevel positive airway pressure (BPAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPAP delivers positive airway pressure at different levels during inspiration and expiration. The level during inspiration is called the inspiratory positive airway pressure (IPAP) and the level during expiration is called the expiratory positive airway pressure (EPAP).",
"   </p>",
"   <p>",
"    BPAP splints the upper airway open like CPAP. However, it provides additional ventilatory support because it augments the tidal volume. The tidal volume is directly related to the difference between the IPAP and EPAP. As an example, the tidal volume is greater when the IPAP is set at 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), than when the IPAP is set at 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O).",
"   </p>",
"   <p>",
"    With most BPAP devices, it is possible to set a backup respiratory rate. This is the number of breaths initiated by the BPAP device per minute. The backup respiratory rate is generally not used or set to initiate only a few breaths per minute, since most patients with OSA initiate a sufficient number of breaths without assistance. Higher backup respiratory rates are usually reserved for patients who require BPAP for reasons other than OSA.",
"   </p>",
"   <p>",
"    BPAP has not been as well studied as CPAP in patients with OSA alone. Studies of the efficacy of BPAP in patients with OSA have been predominantly performed in patients with coexisting OSA and obesity hypoventilation syndrome, which is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BPAP should not be considered synonymous with BiPAP",
"    <sup>",
"     &reg;",
"    </sup>",
"    . The latter is the proprietary name of a portable respiratory assist device manufactured by Respironics Corporation and is just one of many commercially available devices that can deliver BPAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SELECTING THE MODE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed CPAP is first-line therapy for most patients with OSA because its efficacy is well established and supported by extensive clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. BPAP may be a preferable initial therapy in certain subgroups of patients with OSA, including patients with coexisting OSA and chronic hypercapnic respiratory failure, patients with OSA plus obesity hypoventilation syndrome whose alveolar hypoventilation failed to improve despite CPAP therapy, and some patients with OSA plus significant central sleep apnea. A trial of BPAP or autotitrating CPAP may also be worthwhile for patients who do not tolerate fixed CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1,9-11\">",
"     1,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT-DEVICE INTERFACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proper fitting interface between the patient and the device optimizes efficacy (by ensuring delivery of the target airway pressure) and adherence (by optimizing patient comfort and convenience). Patients may be encouraged to try several different interfaces at the same time that the optimal level of positive airway pressure is determined, so that the interface that offers the best mix of comfort and efficacy is determined (ie, the most comfortable mask is not always the best fitting and the best fitting mask is not always the most comfortable). However, trials of different interfaces may be necessary even after the optimal level of positive airway pressure has been determined.",
"   </p>",
"   <p>",
"    Interface options include nasal masks, nasal pillows, and facemasks (ie, oronasal masks). The optimal interface varies from patient to patient. Common issues to consider when selecting an interface include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Claustrophobia &ndash; Claustrophobic patients may find nasal pillows less confining than other interfaces. Alternatively, desensitization to a nasal mask can be attempted [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/12\">",
"       12",
"      </a>",
"      ]. One approach to desensitization is to have the patient wear the mask during the day, for progressively long periods, while reading or watching television. The goal is to increase the patient's tolerance of the mask and positive pressure.",
"     </li>",
"     <li>",
"      Nasal congestion &ndash; Nasal congestion is a common problem that may preexist or be precipitated by positive airway pressure therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/13\">",
"       13",
"      </a>",
"      ]. Airflow resistance is higher when nasal congestion is present, which can impair comfortable breathing through the nose and negatively impact adherence. It may also impede the transmission of enough positive airway pressure to the upper airway, impairing its ability to prevent upper airway collapse during sleep. Nasal glucocorticoids, nasal antihistamines, oral non-sedating antihistamines, or nasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      may improve nasal congestion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/14\">",
"       14",
"      </a>",
"      ]. A facemask that covers both the nose and mouth may also be helpful, allowing the positive pressure to be delivered through the mouth and the nose [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. However, a significant number of patients find facemasks less tolerable than nasal masks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"       \"Chronic nonallergic rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mouth breathing &ndash; Patients who breathe through their mouths while asleep are likely to develop a mouth leak when positive airway pressure therapy is initiated. A mouth leak exists when the airflow delivered through the nose exits through the mouth instead of reaching the more distal pharyngeal airway. A chinstrap that holds the mouth shut may be sufficient to eliminate a mouth leak. Some patients continue to have a mouth leak despite a chin strap, in which case a facemask may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DETERMINING THE AMOUNT OF POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal amount of positive airway pressure is determined by titration. The goal of titration is to identify a level of positive airway pressure that is acceptable to the patient, prevents recurrent upper airway obstruction during sleep, and maintains both sleep continuity and an acceptable oxyhemoglobin saturation during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fixed CPAP &ndash; Starting at a low level (eg, 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O), the amount of CPAP is serially increased (usually in increments of 1 to 2 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) until evidence of upper airway obstruction is eliminated. The minimal amount of CPAP that consistently prevents upper airway obstruction becomes the fixed CPAP setting. Evidence of upper airway obstruction includes snoring, apneas, hypopneas, respiratory effort related arousals,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      episodic oxyhemoglobin desaturation. The recommended maximum level of positive airway pressure is 20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O for adults; transition to BPAP should be considered if there is still upper airway obstruction at this level.",
"     </li>",
"     <li>",
"      Autotitrating CPAP &ndash; Patients who plan to use autotitrating CPAP for ongoing therapy do not need to undergo formal titration because the mode is self-titrating. However, autotitrating CPAP can also be used to determine the optimal amount of positive airway pressure patients who plan to use fixed CPAP for ongoing therapy. The patient is given autotitrating CPAP and the level of pressure that eliminates all evidence of upper airway obstruction for more than 90 percent of the time then becomes the fixed CPAP setting.",
"     </li>",
"     <li>",
"      BPAP &ndash; The titration of BPAP differs from CPAP because two levels of positive airway pressure need to be adjusted: the inspiratory positive airway pressure (IPAP) and the expiratory positive airway pressure (EPAP). Generally speaking, the IPAP and EPAP are simultaneously titrated as described above for CPAP. Once partial and complete upper airway obstruction are eliminated, the IPAP alone is increased if additional ventilation is required. The recommended maximum IPAP level is 30 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O for adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Titration of fixed CPAP and BPAP should be performed during a sleep study, since a sleep study is the only way to confirm that the positive airway pressure has eliminated upper airway obstruction. The sleep study may be full-night in-laboratory polysomnography, split-night in-laboratory polysomnography, or unattended in-home portable monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Full-night studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titration during a full-night, attended, in-laboratory polysomnogram is the preferred approach to which other titration strategies are compared. This approach is appropriate for the initiation of CPAP, BPAP, or autotitrating CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Split-night studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split-night studies are attended, in-laboratory polysomnograms during which the first part of the night is the diagnostic portion of the study and the second part of the night is the titration portion. Titration is performed only if the diagnostic portion of the study identified OSA conclusively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link&amp;anchor=H5#H5\">",
"     \"Polysomnography in obstructive sleep apnea in adults\", section on 'Split night studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Split-night, attended, in-laboratory polysomnography is appropriate for titrating fixed CPAP. However, it is not recommended for autotitrating CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1,19\">",
"     1,19",
"    </a>",
"    ] or BPAP because there is insufficient evidence that split-night studies effectively guide the titration of these modes.",
"   </p>",
"   <p>",
"    Titration during split-night studies is less costly, timelier, and more convenient for patients than titration during full-night studies. However, there are important drawbacks to this approach that are related to the shorter duration available for diagnostic study and titration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. Specifically, the likelihood of observing the patient when the risk of OSA is highest (ie, rapid eye movement sleep in the supine position) is reduced, opportunities for patient education are fewer, and a higher degree of technician skill is required. Such drawbacks may explain why one study found that split-night studies may tend to derive a positive pressure level that is lower than that derived from full-night studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     In-home studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titration guided by unattended, in-home portable monitoring is not standard care and has been mainly performed as part of research studies. Before it becomes routine clinical practice, there needs to be better evidence that it is effective in various patient populations. This is based upon widespread recognition that both patient demographics and coexisting medical or psychiatric disorders influence the outcome of an approach. In other words, the experience of one sleep center with unattended, in-home positive airway pressure titration may not be applicable to centers that serve different patient populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fixed CPAP is titrated at home by having the bed partner serially titrate the positive airway pressure level as needed to eliminate snoring. Following the titration, the in-home study is reviewed by a clinician with expertise in the management of sleep disorders in order to confirm that an adequate titration was done and an optimal positive pressure level was identified [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autotitrating CPAP is self-titrating and, therefore, no manual adjustments are necessary. The need to perform in-home portable monitoring in this setting has diminished due to the data management software that exists within many autotitrating CPAP devices. This software provides information about the apnea hypopnea index, hours of use, and presence or absence of a mask leak. In the absence of such software, an in-home study can be performed and reviewed following the titration, in a fashion similar to that described above for fixed CPAP.",
"     </li>",
"     <li>",
"      BPAP titration is more complex and should not be guided by unattended, in-home portable monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several randomized trials suggest that in-home titration is as effective as full-night, attended, in-laboratory titration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. In one trial, 200 consecutive patients who had been diagnosed with OSA via attended, in-laboratory polysomnography were randomly assigned to have their positive airway pressure level determined by either one night of in-laboratory fixed CPAP titration or three nights of in-home autotitrating CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/23\">",
"     23",
"    </a>",
"    ]. The latter group was then transitioned to fixed CPAP at the level at which the autotitrating device eliminated upper airway obstruction. At three months, there were no differences in quality of life, daytime sleepiness, or hours of CPAP use. The generalizability of these results may be limited because patients with a cardiorespiratory disorder were excluded.",
"   </p>",
"   <p>",
"    The primary advantage of in-home titration is that a sleep laboratory is not necessary. This may reduce both the costs and wait until titration can commence, although this needs to be confirmed. In-home titration may also extend care to patients in areas that lack sleep laboratories.",
"   </p>",
"   <p>",
"    The major disadvantage of in-home titration is the absence of a technologist or clinician with expertise in the management of sleep disorders who can choose, adjust, and adjudicate the patient-device interface. The growing variety of nasal pillows, face masks, and hybrid interfaces that are available makes this limitation increasingly pertinent. Additional disadvantages of in-home titration include the inability to determine the effect of positional changes (ideally, titration should encompass supine and non-supine sleep) and the effect of humidification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACCESSORY FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pressure relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expiratory pressure relief is a feature that briefly lowers the delivered positive airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. The pressure is lowered during early expiration with CPAP, whereas it is lowered at end-inspiration and early expiration with BPAP. The purpose of pressure relief is to improve adherence by reducing the uncomfortable sensation of breathing against high pressure.",
"   </p>",
"   <p>",
"    A beneficial impact of pressure relief on adherence has not been proven in randomized trials, when compared to either conventional CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/27\">",
"     27",
"    </a>",
"    ] or autotitrating CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/28\">",
"     28",
"    </a>",
"    ] without pressure relief. This was best demonstrated by a meta-analysis of seven randomized trials (514 patients, mean AHI &gt;30 events per hour of sleep) that compared CPAP with pressure relief to conventional CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/27\">",
"     27",
"    </a>",
"    ]. The meta-analysis found no differences in adherence, sleepiness, or vigilance.",
"   </p>",
"   <p>",
"    Despite the lack of evidence that routine administration of pressure relief improves adherence, a trial of pressure relief may be worthwhile for those patients who do not tolerate CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. This is especially true if the patient's intolerance may be related to discomfort caused by exhaling against positive airway pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Humidification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor mouth leaks allow unidirectional nasal airflow, which tends to dry the nasal mucosa and increase nasal resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Heated humidification decreases the nasal resistance approximately 50 percent, whereas cold humidification has little impact [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/30\">",
"     30",
"    </a>",
"    ]. In theory, reduced nasal resistance may improve the comfort and effectiveness of positive airway pressure delivered via nasal mask or nasal pillows. However, clinical studies have not found such benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Sleep Medicine advocates heated humidification for all patients who receive CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in our clinical practice, we restrict our use of heated humidification to those patients who are older than 60 years, have symptoms of rhinitis, or have had an uvulopalatopharyngoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pressure ramp",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pressure ramp initiates positive airway pressure delivery at a low level (usually 4 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) and then progressively increases the positive airway pressure to the prescribed level over a duration designated by the clinician (usually 5 to 45 minutes). This feature serves as a comfort measure, allowing the patient to fall asleep before reaching the higher pressures. The pressure ramp can be restarted at any time and is available with CPAP, BPAP, and APAP.",
"   </p>",
"   <p>",
"    There are no published data indicating that a ramp feature augments acceptance or adherence with CPAP, although many clinicians routinely prescribe a pressure ramp. Ramp abuse refers to repeated activation of the pressure ramp feature, which can diminish the effectiveness of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/34\">",
"     34",
"    </a>",
"    ]. It can be addressed by increasing the starting pressure to a level just below the therapeutic pressure. Alternatively, repeat titration may be worthwhile if there is suspicion that the ramp abuse is indicative of a therapeutic pressure target that is too high. Changing from a nasal mask to a facemask may be worthwhile if there is suspicion that the ramp abuse is indicative of discomfort associated with the stronger force of flow from a nasal mask.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Altitude compensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies performed using a decompression chamber demonstrated that a level of positive airway pressure that is effective at one altitude may not be effective at other altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/35\">",
"     35",
"    </a>",
"    ]. This may be clinically important for patients who are studied at one altitude, but travel or live at a different altitude. Such patients may complain of recurrent symptoms despite a seemingly appropriate level of positive airway pressure. Recent generations of positive airway pressure devices include an altitude compensation feature [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10296/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EARLY PATIENT EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's early experience with positive airway pressure therapy appears to influence long-term acceptance and adherence. Contributing factors probably include patient education, close follow-up, treatment of complications, comfort of the patient-device interface, subjective success of the patient's first night using positive airway pressure at home, and support of the patient's bed partner. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive airway pressure is the mainstay therapy for obstructive sleep apnea (OSA), a disorder that is characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initiation of positive airway pressure therapy requires selection of a mode of positive airway pressure and a patient-device. The optimal amount of positive airway pressure must also be determined. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient-device interface'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Modes of positive airway pressure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Determining the amount of positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fixed continuous positive airway pressure (CPAP) is first-line therapy for most patients with OSA. For patients who do not tolerate fixed CPAP, we suggest a trial of an alternative mode of positive airway pressure before abandoning positive pressure therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bilevel positive airway pressure (BPAP) and autotitrating CPAP are acceptable options. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Selecting the mode'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BPAP may be preferred initial therapy in certain subgroups of patients with OSA. These include patients with coexisting OSA and chronic hypercapnic respiratory failure, patients with coexisting OSA and significant central sleep apnea, and patients with OSA plus obesity hypoventilation syndrome whose alveolar hypoventilation failed to improve despite CPAP therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Selecting the mode'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appropriate amount of positive airway pressure is determined by titration. This is performed during a sleep study, in order to confirm that the derived amount of positive airway pressure effectively eliminates upper airway collapse. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Determining the amount of positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient's early experience with positive airway pressure therapy appears to influence ongoing acceptance and adherence. Contributing factors include patient education, close follow-up, treatment of complications, comfort of the patient-device interface, subjective success of the patient's first night using positive airway pressure at home, and support of the patient's bed partner. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Early patient experience'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13132679\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Patrick Strollo, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/1\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/2\">",
"      Berthon-Jones M, Lawrence S, Sullivan CE, Grunstein R. Nasal continuous positive airway pressure treatment: current realities and future. Sleep 1996; 19:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/3\">",
"      Behbehani K, Yen FC, Burk JR, et al. Automatic control of airway pressure for treatment of obstructive sleep apnea. IEEE Trans Biomed Eng 1995; 42:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/4\">",
"      Berthon-Jones M. Feasibility of a self-setting CPAP machine. Sleep 1993; 16:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/5\">",
"      Scharf MB, Brannen DE, McDannold MD, Berkowitz DV. Computerized adjustable versus fixed NCPAP treatment of obstructive sleep apnea. Sleep 1996; 19:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/6\">",
"      Meurice JC, Marc I, S&eacute;ri&egrave;s F. Efficacy of auto-CPAP in the treatment of obstructive sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1996; 153:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/7\">",
"      Ayas NT, Patel SR, Malhotra A, et al. Auto-titrating versus standard continuous positive airway pressure for the treatment of obstructive sleep apnea: results of a meta-analysis. Sleep 2004; 27:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/8\">",
"      Vennelle M, White S, Riha RL, et al. Randomized controlled trial of variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS). Sleep 2010; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/9\">",
"      Ballard RD, Gay PC, Strollo PJ. Interventions to improve compliance in sleep apnea patients previously non-compliant with continuous positive airway pressure. J Clin Sleep Med 2007; 3:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/10\">",
"      P&eacute;pin JL, Muir JF, Gentina T, et al. Pressure reduction during exhalation in sleep apnea patients treated by continuous positive airway pressure. Chest 2009; 136:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/11\">",
"      Nilius G, Happel A, Domanski U, Ruhle KH. Pressure-relief continuous positive airway pressure vs constant continuous positive airway pressure: a comparison of efficacy and compliance. Chest 2006; 130:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/12\">",
"      Edinger JD, Radtke RA. Use of in vivo desensitization to treat a patient's claustrophobic response to nasal CPAP. Sleep 1993; 16:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/13\">",
"      Indications and standards for use of nasal continuous positive airway pressure (CPAP) in sleep apnea syndromes. American Thoracic Society. Official statement adopted March 1944. Am J Respir Crit Care Med 1994; 150:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/14\">",
"      Strollo, PJ, Sanders, MH, Stiller, RA. Continuous and bi-level positive airway pressure therapy in sleep-disordered breathing. Atlas Oral and Maxillofac Surg Clin North Am 1995; 7:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/15\">",
"      Prosise GL, Berry RB. Oral-nasal continuous positive airway pressure as a treatment for obstructive sleep apnea. Chest 1994; 106:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/16\">",
"      Sanders MH, Kern NB, Stiller RA, et al. CPAP therapy via oronasal mask for obstructive sleep apnea. Chest 1994; 106:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/17\">",
"      Mortimore IL, Whittle AT, Douglas NJ. Comparison of nose and face mask CPAP therapy for sleep apnoea. Thorax 1998; 53:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/18\">",
"      Kushida CA, Chediak A, Berry RB, et al. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med 2008; 4:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/19\">",
"      Morgenthaler TI, Aurora RN, Brown T, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep 2008; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/20\">",
"      Strollo PJ Jr, Sanders MH, Costantino JP, et al. Split-night studies for the diagnosis and treatment of sleep-disordered breathing. Sleep 1996; 19:S255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/21\">",
"      Sanders MH, Kern NB, Costantino JP, et al. Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial. Am Rev Respir Dis 1993; 147:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/22\">",
"      Lloberes P, Ballester E, Montserrat JM, et al. Comparison of manual and automatic CPAP titration in patients with sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1996; 154:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/23\">",
"      Cross MD, Vennelle M, Engleman HM, et al. Comparison of CPAP titration at home or the sleep laboratory in the sleep apnea hypopnea syndrome. Sleep 2006; 29:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/24\">",
"      Masa JF, Jim&eacute;nez A, Dur&aacute;n J, et al. Alternative methods of titrating continuous positive airway pressure: a large multicenter study. Am J Respir Crit Care Med 2004; 170:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/25\">",
"      Antic NA, Buchan C, Esterman A, et al. A randomized controlled trial of nurse-led care for symptomatic moderate-severe obstructive sleep apnea. Am J Respir Crit Care Med 2009; 179:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/26\">",
"      Skomro RP, Gjevre J, Reid J, et al. Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. Chest 2010; 138:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/27\">",
"      Bakker JP, Marshall NS. Flexible pressure delivery modification of continuous positive airway pressure for obstructive sleep apnea does not improve compliance with therapy: systematic review and meta-analysis. Chest 2011; 139:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/28\">",
"      Kushida CA, Berry RB, Blau A, et al. Positive airway pressure initiation: a randomized controlled trial to assess the impact of therapy mode and titration process on efficacy, adherence, and outcomes. Sleep 2011; 34:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/29\">",
"      Hayes MJ, McGregor FB, Roberts DN, et al. Continuous nasal positive airway pressure with a mouth leak: effect on nasal mucosal blood flux and nasal geometry. Thorax 1995; 50:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/30\">",
"      Richards GN, Cistulli PA, Ungar RG, et al. Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance. Am J Respir Crit Care Med 1996; 154:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/31\">",
"      Wiest GH, Harsch IA, Fuchs FS, et al. Initiation of CPAP therapy for OSA: does prophylactic humidification during CPAP pressure titration improve initial patient acceptance and comfort? Respiration 2002; 69:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/32\">",
"      Mador MJ, Krauza M, Pervez A, et al. Effect of heated humidification on compliance and quality of life in patients with sleep apnea using nasal continuous positive airway pressure. Chest 2005; 128:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/33\">",
"      Rakotonanahary D, Pelletier-Fleury N, Gagnadoux F, Fleury B. Predictive factors for the need for additional humidification during nasal continuous positive airway pressure therapy. Chest 2001; 119:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/34\">",
"      Pressman MR, Peterson DD, Meyer TJ, et al. Ramp abuse. A novel form of patient noncompliance to administration of nasal continuous positive airway pressure for treatment of obstructive sleep apnea. Am J Respir Crit Care Med 1995; 151:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10296/abstract/35\">",
"      Fromm RE Jr, Varon J, Lechin AE, Hirshkowitz M. CPAP machine performance and altitude. Chest 1995; 108:1577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7677 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10296=[""].join("\n");
var outline_f10_3_10296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MODES OF POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fixed CPAP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Autotitrating CPAP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bilevel positive airway pressure (BPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SELECTING THE MODE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT-DEVICE INTERFACE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DETERMINING THE AMOUNT OF POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Full-night studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Split-night studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      In-home studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACCESSORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pressure relief",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Humidification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pressure ramp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Altitude compensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EARLY PATIENT EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13132679\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_3_10297="Primary spontaneous pneumothorax in adults";
var content_f10_3_10297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary spontaneous pneumothorax in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Richard W Light, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10297/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/3/10297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary spontaneous pneumothorax (PSP) is a pneumothorax that occurs without a precipitating event in a person who does not have known lung disease. In actuality, most individuals with PSP have unrecognized lung disease, with the pneumothorax resulting from rupture of a subpleural bleb [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this topic review, the incidence, pathogenesis, presentation, and management of PSP are discussed. Secondary spontaneous pneumothorax, which occurs as a complication of underlying lung disease, is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of primary spontaneous pneumothorax (PSP) in men varies geographically, from 7.4 per 100,000 population per year in the United States to 37 per 100,000 population per year in the United Kingdom. The incidence is substantially less in women than in men, ranging from 1.2 per 100,000 population per year in the United States to 15.4 per 100,000 population per year in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/6\">",
"     6",
"    </a>",
"    ]. The reason for these differences is unknown.",
"   </p>",
"   <p>",
"    Estimates of the incidence of recurrent PSP range from 25 percent to more than 50 percent, with most recurrences occurring within the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, a study of 153 patients with PSP found a recurrence rate of 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/7\">",
"     7",
"    </a>",
"    ]. Female gender, tall stature in men, low body weight, and failure to stop smoking have been associated with an increased risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have been proposed or shown to predispose patients to primary spontaneous pneumothorax (PSP) include smoking, family history, Marfan syndrome, homocystinuria, and thoracic endometriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is a significant risk factor for primary spontaneous pneumothorax (PSP), probably due to consequences of airway inflammation. As an example, in an analysis of four studies that included 505 patients with PSP, 461 of the patients (91 percent) were smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, the risk of PSP was directly related to the amount of cigarette smoking. Compared to nonsmokers, the relative risk of PSP in men was seven times higher in light smokers (1 to 12 cigarettes per day), 21 times higher in moderate smokers (13 to 22 cigarettes per day), and 102 times higher in heavy smokers (&gt;22 cigarettes per day). For women, the relative risk was 4, 14, and 68 times higher in light, moderate, and heavy smokers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory bronchiolitis, a form of airway inflammation associated with cigarette smoking, may contribute to the development and recurrence of PSP. In a study of 115 patients with PSP who underwent video-assisted thoracoscopic surgery (VATS), pneumothorax recurrence rates were higher in patients with extensive rather than nonextensive respiratory bronchiolitis for both nonoperative and postoperative pneumothorax (p &lt;0.004 and 0.001, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports have been published describing the clustering of PSP in certain families [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. Autosomal dominant, autosomal recessive, polygenic, and X-linked recessive inheritance mechanisms have all been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The autosomal dominant Birt-Hogg-Dube syndrome, which predisposes patients to benign skin tumors and renal cancer, is associated with an increased incidence of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/15,16,18-21\">",
"     15,16,18-21",
"    </a>",
"    ]. In one study of 198 patients with this syndrome, 48 patients (24 percent) had a history of pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of lung cysts was associated with pneumothorax, as well as lung cyst volume, diameter, and number.",
"   </p>",
"   <p>",
"    The gene responsible for this familial cancer syndrome (called FLCN) has been mapped to chromosome 17p11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. FLCN and its associated protein, folliculin, appear to have important tumor suppression function. However, other mutations of FLCN have been associated with spontaneous pneumothorax and bullous lung disease in the absence of the oncologic manifestations of Birt-Hogg-Dube syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. In one Finnish family with an extensive history of PSP, a novel mutation was associated with autosomal dominant inheritance of bullous lung lesions in all carriers (100 percent penetrance) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing is available for the Birt-Hogg-Dube syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/22\">",
"     22",
"    </a>",
"    ]. Periodic screening for renal tumors is recommended in affected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link&amp;anchor=H4#H4\">",
"     \"Hereditary kidney cancer syndromes\", section on 'Birt-Hogg-Dube syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSP also occurs with increased frequency in patients with Marfan syndrome and homocystinuria. In addition, catamenial pneumothorax may result from thoracic endometriosis, and should be considered in women presenting with PSP temporally related to menstruation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link&amp;anchor=H9#H9\">",
"     \"Thoracic endometriosis\", section on 'Catamenial pneumothorax and hemothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several case reports have described the occurrence of spontaneous pneumothorax among patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. It is thought that the pulmonary parenchymal consequences of malnutrition contribute to development of pneumothorax in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H1782633#H1782633\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Pulmonary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary spontaneous pneumothorax (PSP) usually occurs when the patient is at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients are typically in their early 20s, with PSP being rare after age 40. Patients usually complain of the sudden onset of dyspnea and pleuritic chest pain. The severity of the symptoms is primarily related to the volume of air in the pleural space, with dyspnea being more prominent if the pneumothorax is large.",
"   </p>",
"   <p>",
"    Characteristic physical findings when a large pneumothorax is present include decreased chest excursion on the affected side, diminished breath sounds, and hyperresonant percussion. Subcutaneous emphysema may be present. Evidence of labored breathing and hemodynamic compromise (eg, tachycardia, hypotension) suggests a possible tension pneumothorax, which necessitates emergency decompression.",
"   </p>",
"   <p>",
"    Hypoxemia is common because collapsed and poorly ventilated portions of lung continue to receive significant perfusion. In contrast, hypercapnia is unusual because underlying lung function is relatively normal and adequate alveolar ventilation can be maintained by the contralateral lung [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute respiratory alkalosis may exist if pain, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia are substantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pneumothorax is established by demonstrating a white visceral pleural line on the chest radiograph. The visceral pleural line defines the interface of the lung and pleural air; it is either straight or convex towards the chest wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56589 \" href=\"UTD.htm?40/52/41797\">",
"     image 1",
"    </a>",
"    ). In most cases, no pulmonary vessels are visible beyond the visceral pleural edge. Inspiratory and expiratory films have equal sensitivity in detecting pneumothoraces; thus, a standard inspiratory chest radiograph is sufficient in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The underlying lung parenchyma should be examined for the presence of underlying lung disease that would suggest a secondary spontaneous pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tension pneumothorax may develop in approximately 1 to 2 percent of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the sensitivity and specificity of the plain chest radiograph for detection of tension are unclear. Contralateral shift of the trachea and mediastinum is a typical finding in spontaneous pneumothorax and not necessarily suggestive of tension. Conversely, patients may have clinical evidence of tension (eg, tachycardia, hypotension, dyspnea) in the absence of \"typical\" radiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link&amp;anchor=H2#H2\">",
"     \"Imaging of pneumothorax\", section on 'Types of pneumothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT scanning is generally not necessary unless abnormalities are noted on the plain chest radiograph that require further evaluation, or aberrant chest tube placement is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary spontaneous pneumothorax (PSP) is established by detection of a visceral pleural line on the chest radiograph of a patient without underlying lung disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis includes the causes of spontaneous pneumothorax in patients who have underlying lung disease that has not yet been diagnosed (eg, catamenial pneumothorax, chronic obstructive lung disease, interstitial lung disease, lung cancer, lymphangioleiomyomatosis). When managing patients with a persistent air leak or recurrent spontaneous pneumothorax, a CT scan should be considered as well as a lung biopsy at the time of thoracoscopy. The diseases associated with secondary spontaneous pneumothorax are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H2#H2\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management is directed at removing air from the pleural space, with subsequent management directed at preventing recurrence. In the discussion that follows, we expand upon published clinical consensus statements [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These consensus statements were derived using the Delphi method, a process of collecting data from the opinions of published experts using several rounds of questionnaires [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment options for primary spontaneous pneumothorax (PSP) include observation, supplemental oxygen, needle aspiration of intrapleural air, chest tube insertion (ie, tube thoracostomy), and thoracoscopy. The choice of procedure depends on patient characteristics and clinical circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are clinically stable and having their first PSP can be administered supplemental oxygen and observed if their pneumothorax is small (&le;2 to 3 cm between the lung and chest wall on a chest radiograph) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who are clinically stable and having their first PSP should undergo needle aspiration if their pneumothorax is large (&gt;3 cm rim of air on chest radiograph), or if they are symptomatic with chest pain or dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/31,35,36\">",
"       31,35,36",
"      </a>",
"      ]. Patients who fail aspiration should have a chest tube inserted (ie, tube thoracostomy) and thoracoscopy should be considered during the same hospitalization. Chemical pleurodesis through the chest tube should be performed, if the air leak persists and thoracoscopy is not readily available.",
"     </li>",
"     <li>",
"      Patients who are clinically stable with either a recurrent PSP or a concomitant hemothorax (ie, a hemopneumothorax), should undergo thoracoscopy after chest tube insertion. If thoracoscopy is not readily available, chemical pleurodesis through the chest tube may be performed after drainage of the pleural space.",
"     </li>",
"     <li>",
"      Clinically unstable patients should undergo chest tube insertion. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tube thoracostomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If chest tube insertion is delayed and the patient is unstable, decompression of the pleural space can be performed by placing a 14 gauge intravenous catheter into the pleural space. A catheter or needle as long as 7 cm may be needed, depending on the thickness of the chest wall. The insertion site has traditionally been in the second or third intercostal space (ICS) at the midclavicular line, but chest wall thickness at that site may prevent access to the pleural space. Alternatively, an insertion site in the fifth ICS in the anterior axillary line or anterior to the midaxillary line may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H6#H6\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation should last six hours, after which reliable patients with ready access to emergency medical services can be discharged home if a repeat chest radiograph excludes progression of the pneumothorax. While the patient is hospitalized, supplemental oxygen should be administered to facilitate resorption of the pleural air.",
"   </p>",
"   <p>",
"    The importance of supplemental oxygen should not be underestimated. Air in the pleural space is reabsorbed when the communication between the alveoli and the pleural space (ie, the air leak) closes. The rate of resorption can be markedly increased if supplemental oxygen is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/37\">",
"     37",
"    </a>",
"    ]. As an example, a normal rate of resorption is approximately 1.25 percent of the volume of the hemithorax per 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the rate of resorption increases six-fold if humidified 100 percent oxygen is administered in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is most easily accomplished with a commercially available thoracentesis kit. An 18-gauge needle with an 8 to 9 French (Fr) catheter is inserted into the pleural space, the catheter is threaded deeper into the pleural space, and then the needle is withdrawn. Air is manually withdrawn through the indwelling catheter until no more can be aspirated. It is assumed that there is a persistent air leak if there is still no resistance after four liters of air has been aspirated and the lung has not expanded. Thoracoscopy should be performed if this occurs. Alternatively, a chest tube should be inserted if thoracoscopy is not readily available.",
"   </p>",
"   <p>",
"    Two equally acceptable approaches exist once no further air can be aspirated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A closed stopcock can be attached and the indwelling catheter secured to the chest wall. A chest radiograph should be obtained four hours later and, if adequate lung expansion has occurred, the catheter can be removed. Following an additional two hours of observation, another chest radiograph should be performed. The patient can be discharged if the lung remains expanded on this chest radiograph [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The catheter can be left in place and attached to a Heimlich (ie, one-way) valve. The patient can then be discharged with follow up within two days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/32,41\">",
"       32,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H885075#H885075\">",
"       \"Placement and management of thoracostomy tubes\", section on 'Tube selection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the advantages of aspiration over tube thoracostomy is that the patient need not be hospitalized, whether the catheter is removed after the aspiration or left attached to the Heimlich valve.",
"   </p>",
"   <p>",
"    Based on evidence from several studies, we prefer to manage most hemodynamically-stable patients initially with aspiration, rather than tube thoracostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/31,42-47\">",
"     31,42-47",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of three randomized, controlled trials (194 patients) that compared aspiration versus tube thoracostomy, aspiration resulted in shorter hospitalizations and similar clinical outcomes at one week and one year [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial, 137 patients who had a first episode of PSP were assigned to receive manual aspiration or tube thoracostomy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/43\">",
"       43",
"      </a>",
"      ]. The groups had similar rates of immediate (62 versus 68 percent) and one-week success (89 versus 88 percent); however, aspiration was associated with a shorter hospital stay (1.8 versus 4 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tube thoracostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PSP can be managed successfully with a small chest tube (&le;22 Fr) or chest catheter (&le;14 Fr) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. The chest tube can be connected to a water seal device, with or without suction and left in position until the pneumothorax resolves. We suggest that suction be applied to the chest tube if the pneumothorax fails to resolve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the air leak has resolved, the lung has expanded, and the pleural air has been removed, the chest tube can be removed in a sequential fashion. Specifically, we advocate that the chest tube be clamped twelve hours after the last evidence of an air leak and that a chest radiograph be performed 24 hours after the last evidence of an air leak. The chest tube can be removed if the pneumothorax has not reaccumulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315210789\">",
"    <span class=\"h3\">",
"     Thoracoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopy (VATS) is effective in the treatment of spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/5,49-51\">",
"     5,49-51",
"    </a>",
"    ]. With this procedure, pleurodesis is created by pleural abrasion or a partial parietal pleurectomy; when necessary, an endoscopic stapler can be used to resect bullae, as reported in several uncontrolled observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Persistent air leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advocate a more aggressive approach if an air leak persists after three days. For patients whose lung is at least 90 percent expanded but who have a persistent air leak, the usual choices include attaching a Heimlich valve to the chest tube, infusing autologous blood into the pleural space, and performing video-assisted thoracoscopy to oversew the area of leak and perform mechanical pleurodesis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'VATS pleurodesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The simplest approach is to attach a unidirectional flutter valve (ie, a Heimlich valve) to the chest tube, which usually allows rapid discharge of the patient with subsequent outpatient management.",
"   </p>",
"   <p>",
"    An alternative technique for patients with a persistent air leak is to perform an autologous blood patch [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. This involves withdrawal of blood from a peripheral arm vein and aseptic infusion of the blood into the pleural space through the chest tube. The ideal amount of blood to infuse into the pleural space is not known. In one series that included both spontaneous and postoperative pneumothoraces, the mean volume of blood infused was 90 mL and the range was 24 to 200 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/56\">",
"     56",
"    </a>",
"    ]. After infusion of the blood, the tubing from the chest tube is draped over a hook approximately 60 cm above the patient's chest and then down to a water seal device on the floor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/57\">",
"     57",
"    </a>",
"    ]. The chest tube is removed 24 hours after cessation of the air leak. The main side effect is empyema, which occurred in 9 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Failure of lung reexpansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have a persistent air leak and whose lung is less than 90 percent expanded, the preferred procedure is VATS. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'VATS pleurodesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recurrence prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated recurrence rate, after the first pneumothorax is 23 to 50 percent, over a one to five year follow up period, with the highest risk occurring in the first 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/32,59,60\">",
"     32,59,60",
"    </a>",
"    ]. We suggest that all patients with recurrent PSP should undergo an intervention to prevent future recurrences once the acute air leak has resolved, the lung has expanded, and the pleural air has been removed. In addition, we suggest that patients experiencing their first PSP should have a preventive intervention if they require VATS or tube thoracostomy as part of their initial management, or have a vocation in which recurrence of the pneumothorax is dangerous to the patient or others (eg, airplane pilot or deep sea diver). Options for preventing recurrence include pleurodesis via VATS, chemical pleurodesis via tube thoracostomy or pigtail catheter at the time of aspiration, and thoracotomy. The choice between these procedures is best dictated by the expertise of the practitioner at each institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     VATS pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopic surgery (VATS) is not only effective in the treatment of spontaneous pneumothorax as described above, but also in the prevention of recurrent pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/5,49-55,61-64\">",
"     5,49-55,61-64",
"    </a>",
"    ]. The rate of recurrent pneumothorax is less than 5 percent after VATS with",
"    <span class=\"nowrap\">",
"     bleb/bullae",
"    </span>",
"    resection and pleurodesis. Several techniques have been recommended to induce pleural symphysis including parietal pleurectomy, intrapleural instillation of talc or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative, laser abrasion of the parietal pleura, and pleural abrasion with dry gauze. We prefer mechanical pleurodesis using pleural abrasion with dry gauze, since it is both simple and effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chemical pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are unable or unwilling to undergo VATS, intrapleural injection of a chemical irritant, most commonly a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ), or talc is another alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/31\">",
"     31",
"    </a>",
"    ]. We prefer to use the tetracycline derivative, doxycycline, for the reasons that follow, although many experts prefer talc.",
"   </p>",
"   <p>",
"    Chemical pleurodesis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives decreases the recurrence rate of pneumothorax to 20 to 25 percent. Two large trials of 442 patients with PSP, compared pleurodesis with the intrapleural instillation of a tetracycline derivative (tetracycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ) to aspiration and drainage without pleurodesis and showed comparable reduction in the rates of recurrent PSP by 20 to 25 percent, for minocycline and tetracycline respectively, over a one to five year followup period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. One study confirmed efficacy in the first seven days, when the risk of recurrence is highest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/66\">",
"     66",
"    </a>",
"    ]. Respiratory failure due to an apparent allergic reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    intrapleural instillation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/67\">",
"     67",
"    </a>",
"    ]. However, chemical pleurodesis with tetracycline (or talc) is associated with intense chest pain and in some cases chronic pain that may limit the use of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Talc slurry administered via chest tube can also be used to treat PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/62,68,69\">",
"     62,68,69",
"    </a>",
"    ]. Pneumothorax recurrence rates vary between 5 and 8 percent. However, controversy exists whether talc should be used as the sclerosant agent in young, otherwise healthy individuals because of safety reasons and fear for long-term complications. Intrapleural injection of talc for malignant pleural effusions has been associated with the development of the acute respiratory distress syndrome (ARDS) in 1 to 2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/70\">",
"     70",
"    </a>",
"    ]. Additionally, in one patient, extensive pleural thickening with calcifications developed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/71\">",
"     71",
"    </a>",
"    ]. On the other hand, several studies support the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    for prevention of recurrent pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/62,72,73\">",
"     62,72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with recurrent PSP, who have a chest tube in place and are not candidates for VATS pleurodesis, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for pleurodesis because we believe that its effectiveness is comparable to talc and it has not been associated with the development of ARDS. We suggest using doxycycline (500 mg dissolved in a total volume of 50 mL of normal saline) administered via the chest tube. Intrapleural doxycycline can be very painful; as a result, patients should be premedicated with analgesics (eg, opiates) and, possibly, anxiolytics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ). Some experts also use intrapleural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    25 mL (250 mg) of a 1 percent solution; however, intrapleural lidocaine alone is ineffective for pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for open thoracotomy are the same as those for VATS. Thoracoscopy has essentially replaced open thoracotomy in the management of spontaneous pneumothorax in many medical centers for two main reasons: hospitalization is shorter and postoperative pain is less [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Thoracotomy is presently recommended only if thoracoscopy is unavailable or has failed. During thoracotomy, apical pleural blebs are oversewn and the pleura is scarified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strong association between smoking and an initial PSP suggests that smoking cessation may help prevent recurrent pneumothoraces; this benefit has been confirmed by at least one retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10297/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/30/40418?source=see_link\">",
"       \"Patient information: Pneumothorax (collapsed lung) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary spontaneous pneumothorax (PSP) is a pneumothorax that occurs without a precipitating event in a person who does not have known lung disease. In actuality, most individuals with PSP have unrecognized lung disease, with the pneumothorax resulting from rupture of a subpleural bleb. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The incidence is increased in men, smokers, and patients with a family history of PSP. Recurrence is estimated to occur in 25 to 54 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      PSP usually occurs when the patient is at rest and manifests as acute dyspnea and pleuritic chest pain. The peak age is in the early 20s. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Early management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest supplemental oxygen and observation if the patient is clinically stable and the pneumothorax is small (ie, the distance between the lung and the chest wall is &le;3 cm on a chest radiograph), rather than aspiration, chest tube insertion, or video-assisted thoracoscopy (VATS) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Observation should last six hours, after which the patient can be discharged home, if a repeat chest radiograph excludes progression of the pneumothorax and the patient has access to emergency medical services. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Supplemental oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend pleural aspiration as initial therapy if the patient is clinically stable and the pneumothorax is large, rather than supplemental oxygen with observation, chest tube insertion, or VATS (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This recommendation is based on the observation that the success of pleural aspiration is sufficiently high to warrant its trial before progressing to options that, although more likely to succeed, are also more likely to have adverse effects. A chest tube should be inserted if aspiration fails and VATS should be considered during the same hospitalization based upon the high success rate of VATS, both short- and long-term. Chemical pleurodesis should be performed through the chest tube if VATS is not readily available. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who are clinically stable with a recurrent PSP undergo VATS after chest tube insertion (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based upon both the short-term success rate of VATS and our belief that all patients with recurrent PSP should undergo a preventive intervention, which can be accomplished at the same time by VATS. Chemical pleurodesis should be performed through the chest tube if VATS is not readily available. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically unstable patients should undergo chest tube insertion. Decompression performed by advancing a standard 14 gauge intravenous catheter into the pleural space at the junction of the midclavicular line and the second or third intercostal space can be performed as a bridge, if the chest tube insertion is delayed. The chest tube can be connected to a water seal device, with or without suction. We suggest that suction be applied to the chest tube if the pneumothorax fails to resolve (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Tube thoracostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who require mechanical ventilation or who may have a large air leak should be managed with a 24 to 28 French (Fr) chest tube, rather than a smaller chest tube. All other patients who require chest tube insertion can be managed with a 16 to 22 Fr chest tube or a &le;14 Fr chest catheter, instead of a larger chest tube. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tube thoracostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being managed with a chest tube whose lung is at least 90 percent expanded but who have an air leak that persists longer than three days, we suggest that the chest tube be attached to a Heimlich valve and the patient discharged home, rather than ongoing management with a chest tube (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative approach is to perform an autologous blood patch. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Persistent air leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being managed with a chest tube who have a persistent air leak and whose lung is less than 90 percent expanded, we suggest VATS, rather than ongoing management with a chest tube (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Failure of lung reexpansion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Preventing recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a preventive intervention for patients experiencing their first PSP if they are undergoing VATS or tube thoracostomy as part of their initial management, or have a vocation in which recurrence of the pneumothorax is dangerous to the patient or others (eg, airplane pilot or deep sea diver) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Otherwise, we prefer to forego preventive interventions until a patient experiences recurrent PSP. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Recurrence prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that a preventive procedure is required, we recommend VATS with pleurodesis, rather than tube thoracostomy with chemical pleurodesis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This procedure reduces the recurrence rate to less than 5 percent. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'VATS pleurodesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not operative candidates or who refuse VATS, we recommend tube thoracostomy with chemical pleurodesis, rather than tube thoracostomy drainage alone, once it has been determined that a preventive intervention is indicated (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This procedure reduces the recurrence rate to less than 25 percent. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chemical pleurodesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/1\">",
"      Sahn SA, Heffner JE. Spontaneous pneumothorax. N Engl J Med 2000; 342:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/2\">",
"      Gobbel WG Jr, Rhea WG Jr, Nelson IA, Daniel RA Jr. Spontaneous pneumothorax. J Thorac Cardiovasc Surg 1963; 46:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/3\">",
"      Lesur O, Delorme N, Fromaget JM, et al. Computed tomography in the etiologic assessment of idiopathic spontaneous pneumothorax. Chest 1990; 98:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/4\">",
"      Bense L, Lewander R, Eklund G, et al. Nonsmoking, non-alpha 1-antitrypsin deficiency-induced emphysema in nonsmokers with healed spontaneous pneumothorax, identified by computed tomography of the lungs. Chest 1993; 103:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/5\">",
"      Hwong TM, Ng CS, Lee TW, et al. Video-assisted thoracic surgery for primary spontaneous hemopneumothorax. Eur J Cardiothorac Surg 2004; 26:893.",
"     </a>",
"    </li>",
"    <li>",
"     Light RW. Pleural Diseases, 6th ed, Lippincott, Williams and Wilkins, Philadelphia 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/7\">",
"      Sadikot RT, Greene T, Meadows K, Arnold AG. Recurrence of primary spontaneous pneumothorax. Thorax 1997; 52:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/8\">",
"      Guo Y, Xie C, Rodriguez RM, Light RW. Factors related to recurrence of spontaneous pneumothorax. Respirology 2005; 10:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/9\">",
"      Bense L, Eklund G, Wiman LG. Smoking and the increased risk of contracting spontaneous pneumothorax. Chest 1987; 92:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/10\">",
"      Cheng YL, Huang TW, Lin CK, et al. The impact of smoking in primary spontaneous pneumothorax. J Thorac Cardiovasc Surg 2009; 138:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/11\">",
"      Painter JN, Tapanainen H, Somer M, et al. A 4-bp deletion in the Birt-Hogg-Dub&eacute; gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet 2005; 76:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/12\">",
"      Koivisto PA, Mustonen A. Primary spontaneous pneumothorax in two siblings suggests autosomal recessive inheritance. Chest 2001; 119:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/13\">",
"      Abolnik IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of primary spontaneous pneumothorax. Am J Med Genet 1991; 40:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/14\">",
"      Gibson GJ. Familial pneumothoraces and bullae. Thorax 1977; 32:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/15\">",
"      Khoo SK, Giraud S, Kahnoski K, et al. Clinical and genetic studies of Birt-Hogg-Dub&eacute; syndrome. J Med Genet 2002; 39:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/16\">",
"      Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub&eacute; syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/17\">",
"      Graham RB, Nolasco M, Peterlin B, Garcia CK. Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults. Am J Respir Crit Care Med 2005; 172:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/18\">",
"      Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dub&eacute; syndrome. Am J Respir Crit Care Med 2007; 175:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/19\">",
"      Agarwal PP, Gross BH, Holloway BJ, et al. Thoracic CT findings in Birt-Hogg-Dube syndrome. AJR Am J Roentgenol 2011; 196:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/20\">",
"      Hopkins TG, Maher ER, Reid E, Marciniak SJ. Recurrent pneumothorax. Lancet 2011; 377:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/21\">",
"      Felton SJ, Madan V. Facial and upper body papules in a patient with a family history of recurrent pneumothorax. JAMA 2012; 308:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/22\">",
"      Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub&eacute; syndrome. Cancer Cell 2002; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/23\">",
"      Johnson MM. Catamenial pneumothorax and other thoracic manifestations of endometriosis. Clin Chest Med 2004; 25:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/24\">",
"      Joseph J, Sahn SA. Thoracic endometriosis syndrome: new observations from an analysis of 110 cases. Am J Med 1996; 100:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/25\">",
"      Morse JL, Safdar B. Acute tension pneumothorax and tension pneumoperitoneum in a patient with anorexia nervosa. J Emerg Med 2010; 38:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/26\">",
"      Biffl WL, Narayanan V, Gaudiani JL, Mehler PS. The management of pneumothorax in patients with anorexia nervosa: A case report and review of the literature. Patient Saf Surg 2010; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/27\">",
"      Corless JA, Delaney JC, Page RD. Simultaneous bilateral spontaneous pneumothoraces in a young woman with anorexia nervosa. Int J Eat Disord 2001; 30:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/28\">",
"      Bense L, Wiman LG, Hedenstierna G. Onset of symptoms in spontaneous pneumothorax: correlations to physical activity. Eur J Respir Dis 1987; 71:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/29\">",
"      Seow A, Kazerooni EA, Pernicano PG, Neary M. Comparison of upright inspiratory and expiratory chest radiographs for detecting pneumothoraces. AJR Am J Roentgenol 1996; 166:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/30\">",
"      Noppen M, De Keukeleire T. Pneumothorax. Respiration 2008; 76:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/31\">",
"      MacDuff A, Arnold A, Harvey J, BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/32\">",
"      Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/33\">",
"      Dalkey NC, Helmer O. An experimental application of the Delphi method to the use of experts. Publication no. RM-727-PR. Rand Corp 1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/34\">",
"      Kelly AM, Kerr D, Clooney M. Outcomes of emergency department patients treated for primary spontaneous pneumothorax. Chest 2008; 134:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/35\">",
"      Janssen J, Cardillo G. Primary spontaneous pneumothorax: towards outpatient treatment and abandoning chest tube drainage. Respiration 2011; 82:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/36\">",
"      Gaudio M, Hafner JW. Evidence-based emergency medicine/systematic review abstract: Simple aspiration compared to chest tube insertion in the management of primary spontaneous pneumothorax. Ann Emerg Med 2009; 54:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/37\">",
"      Northfield TC. Oxygen therapy for spontaneous pneumothorax. Br Med J 1971; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/38\">",
"      CHERNICK V, AVERY ME. SPONTANEOUS ALVEOLAR RUPTURE AT BIRTH. Pediatrics 1963; 32:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/39\">",
"      Ho KK, Ong ME, Koh MS, et al. A randomized controlled trial comparing minichest tube and needle aspiration in outpatient management of primary spontaneous pneumothorax. Am J Emerg Med 2011; 29:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/40\">",
"      Vallee P, Sullivan M, Richardson H, et al. Sequential treatment of a simple pneumothorax. Ann Emerg Med 1988; 17:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/41\">",
"      Hassani B, Foote J, Borgundvaag B. Outpatient management of primary spontaneous pneumothorax in the emergency department of a community hospital using a small-bore catheter and a Heimlich valve. Acad Emerg Med 2009; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/42\">",
"      Devanand A, Koh MS, Ong TH, et al. Simple aspiration versus chest-tube insertion in the management of primary spontaneous pneumothorax: a systematic review. Respir Med 2004; 98:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/43\">",
"      Ayed AK, Chandrasekaran C, Sukumar M. Aspiration versus tube drainage in primary spontaneous pneumothorax: a randomised study. Eur Respir J 2006; 27:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/44\">",
"      Wakai A, O'Sullivan RG, McCabe G. Simple aspiration versus intercostal tube drainage for primary spontaneous pneumothorax in adults. Cochrane Database Syst Rev 2007; :CD004479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/45\">",
"      Noppen M, Alexander P, Driesen P, et al. Manual aspiration versus chest tube drainage in first episodes of primary spontaneous pneumothorax: a multicenter, prospective, randomized pilot study. Am J Respir Crit Care Med 2002; 165:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/46\">",
"      Benton IJ, Benfield GF. Comparison of a large and small-calibre tube drain for managing spontaneous pneumothoraces. Respir Med 2009; 103:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/47\">",
"      Parlak M, Uil SM, van den Berg JW. A prospective, randomised trial of pneumothorax therapy: manual aspiration versus conventional chest tube drainage. Respir Med 2012; 106:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/48\">",
"      Minami H, Saka H, Senda K, et al. Small caliber catheter drainage for spontaneous pneumothorax. Am J Med Sci 1992; 304:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/49\">",
"      Sawada S, Watanabe Y, Moriyama S. Video-assisted thoracoscopic surgery for primary spontaneous pneumothorax: evaluation of indications and long-term outcome compared with conservative treatment and open thoracotomy. Chest 2005; 127:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/50\">",
"      Ayed AK, Al-Din HJ. The results of thoracoscopic surgery for primary spontaneous pneumothorax. Chest 2000; 118:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/51\">",
"      Freixinet JL, Canal&iacute;s E, Juli&aacute; G, et al. Axillary thoracotomy versus videothoracoscopy for the treatment of primary spontaneous pneumothorax. Ann Thorac Surg 2004; 78:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/52\">",
"      Inderbitzi RG, Leiser A, Furrer M, Althaus U. Three years' experience in video-assisted thoracic surgery (VATS) for spontaneous pneumothorax. J Thorac Cardiovasc Surg 1994; 107:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/53\">",
"      Cardillo G, Facciolo F, Giunti R, et al. Videothoracoscopic treatment of primary spontaneous pneumothorax: a 6-year experience. Ann Thorac Surg 2000; 69:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/54\">",
"      Hatz RA, Kaps MF, Meimarakis G, et al. Long-term results after video-assisted thoracoscopic surgery for first-time and recurrent spontaneous pneumothorax. Ann Thorac Surg 2000; 70:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/55\">",
"      Lang-Lazdunski L, de Kerangal X, Pons F, Jancovici R. Primary spontaneous pneumothorax: one-stage treatment by bilateral videothoracoscopy. Ann Thorac Surg 2000; 70:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/56\">",
"      Oliveira FH, Cataneo DC, Ruiz RL Jr, Cataneo AJ. Persistent pleuropulmonary air leak treated with autologous blood: results from a university hospital and review of literature. Respiration 2010; 79:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/57\">",
"      Ozpolat B. Autologous blood patch pleurodesis in the management of prolonged air leak. Thorac Cardiovasc Surg 2010; 58:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/58\">",
"      Cagirici U, Sahin B, Cakan A, et al. Autologous blood patch pleurodesis in spontaneous pneumothorax with persistent air leak. Scand Cardiovasc J 1998; 32:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/59\">",
"      Light RW. Management of spontaneous pneumothorax. Am Rev Respir Dis 1993; 148:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/60\">",
"      Henry M, Arnold T, Harvey J, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of spontaneous pneumothorax. Thorax 2003; 58 Suppl 2:ii39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/61\">",
"      Janssen JP, van Mourik J, Cuesta Valentin M, et al. Treatment of patients with spontaneous pneumothorax during videothoracoscopy. Eur Respir J 1994; 7:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/62\">",
"      Gy&ouml;rik S, Erni S, Studler U, et al. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/63\">",
"      Nathan DP, Taylor NE, Low DW, et al. Thoracoscopic total parietal pleurectomy for primary spontaneous pneumothorax. Ann Thorac Surg 2008; 85:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/64\">",
"      Rena O, Massera F, Papalia E, et al. Surgical pleurodesis for Vanderschueren's stage III primary spontaneous pneumothorax. Eur Respir J 2008; 31:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/65\">",
"      Light RW, O'Hara VS, Moritz TE, et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. Results of a Department of Veterans Affairs cooperative study. JAMA 1990; 264:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/66\">",
"      Chen JS, Tsai KT, Hsu HH, et al. Intrapleural minocycline following simple aspiration for initial treatment of primary spontaneous pneumothorax. Respir Med 2008; 102:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/67\">",
"      DiBardino DJ, Vanatta JM, Fagan SP, Awad SS. Acute respiratory failure after pleurodesis with doxycycline. Ann Thorac Surg 2002; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/68\">",
"      Almind M, Lange P, Viskum K. Spontaneous pneumothorax: comparison of simple drainage, talc pleurodesis, and tetracycline pleurodesis. Thorax 1989; 44:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/69\">",
"      Tschopp JM, Boutin C, Astoul P, et al. Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study. Eur Respir J 2002; 20:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/70\">",
"      Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/71\">",
"      Lange P, Mortensen J, Groth S. Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage. Thorax 1988; 43:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/72\">",
"      Cardillo G, Carleo F, Carbone L, et al. Long-term lung function following videothoracoscopic talc poudrage for primary spontaneous recurrent pneumothorax. Eur J Cardiothorac Surg 2007; 31:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/73\">",
"      Hunt I, Barber B, Southon R, Treasure T. Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax? Interact Cardiovasc Thorac Surg 2007; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/74\">",
"      Hazelrigg SR, Landreneau RJ, Mack M, et al. Thoracoscopic stapled resection for spontaneous pneumothorax. J Thorac Cardiovasc Surg 1993; 105:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10297/abstract/75\">",
"      Urschel JD. Thoracoscopic treatment of spontaneous pneumothorax. A review. J Cardiovasc Surg (Torino) 1993; 34:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6706 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10297=[""].join("\n");
var outline_f10_3_10297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tube thoracostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H315210789\">",
"      - Thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Persistent air leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Failure of lung reexpansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recurrence prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - VATS pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Early management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Preventing recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6706|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/52/41797\" title=\"diagnostic image 1\">",
"      Chest Xray of pneumothorax after stab wound",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/30/40418?source=related_link\">",
"      Patient information: Pneumothorax (collapsed lung) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=related_link\">",
"      Talc pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_3_10298="Management of warfarin-associated intracerebral hemorrhage";
var content_f10_3_10298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of warfarin-associated intracerebral hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     W David Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Maria I Aguilar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Jeffrey Weitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/3/10298/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/3/10298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of chronic oral anticoagulation with a vitamin K antagonist can be complicated by anticoagulation-associated intracerebral hemorrhage (AAICH), especially in elderly patients. AAICH is the most devastating complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, accounting for 90 percent of warfarin-related deaths and most of the remaining permanent disability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In terms of absolute risk, the rate of spontaneous intracerebral hemorrhage (ICH) among 70 year-old subjects averages 0.15",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    In those anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to an INR of 2.0 to 3.0, the rate of ICH is increased to 0.3 to 0.8",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    - and other vitamin K antagonist-associated ICH (AAICH, as defined above), a medical emergency, will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General overviews of the complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy and of the evaluation of stroke are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=see_link&amp;anchor=H10#H10\">",
"     \"Anticoagulation in older adults\", section on 'Risk of bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey of consecutive patients admitted with supratentorial ICH to the Massachusetts General Hospital between 1994 and 2001 found that 26 percent were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; on average, one patient per month with AAICH was admitted to this tertiary care hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/4\">",
"     4",
"    </a>",
"    ]. Other studies of ICH reported that about 12 percent (range 6 to 18 percent) of patients with primary ICH were receiving oral anticoagulants at the time of admission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of AAICH has been increasing ever since the publication of important clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use for preventing ischemic stroke in elderly patients with atrial fibrillation. As an example, a study from the five-county Greater",
"    <span class=\"nowrap\">",
"     Cincinnati/Northern",
"    </span>",
"    Kentucky area estimated the incidence of AAICH during three periods: 1988,",
"    <span class=\"nowrap\">",
"     1993/1994,",
"    </span>",
"    and 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/10\">",
"     10",
"    </a>",
"    ]. Results of this study included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual incidence of AAICH in 1999 was more than five times that noted in 1988 (4.4 versus 0.8",
"      <span class=\"nowrap\">",
"       cases/100,000",
"      </span>",
"      persons per year), while the annual incidence of all ICH increased by only 50 percent between these two time periods (24.6 versus 16.5). This increase in AAICH paralleled a fourfold higher delivery of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to pharmacies during this same interval.",
"     </li>",
"     <li>",
"      For data obtained in 1999, the annual rates of AAICH increased strongly with age, being 0.3, 5.5, 24.3, and 45.9",
"      <span class=\"nowrap\">",
"       cases/100,000",
"      </span>",
"      per year for those &lt;50, 50 to 69, 70 to 79, and &ge;80 years of age, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant bleeding in general is strongly associated with excessive anticoagulation (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"UTD.htm?42/18/43296\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78252 \" href=\"UTD.htm?41/27/42430\">",
"     figure 2",
"    </a>",
"    ). However, most episodes of AAICH occur during anticoagulation intensities that are within the therapeutic ranges for most medical condition (ie, INRs between 2.0 and 3.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/4,5,11-14\">",
"     4,5,11-14",
"    </a>",
"    ]. The estimated absolute rate in such patients is 0.3 to 0.8",
"    <span class=\"nowrap\">",
"     percent/year,",
"    </span>",
"    depending on patient age, concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use, and blood pressure control.",
"   </p>",
"   <p>",
"    The degree of INR prolongation at the time of AAICH correlates with initial hematoma size, progressive hematoma enlargement after admission, functional outcome, and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/4,9,15,16\">",
"     4,9,15,16",
"    </a>",
"    ]. Over one-half of patients with AAICH die within 30 days of the onset of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/4,5,11,12,17-19\">",
"     4,5,11,12,17-19",
"    </a>",
"    ]. In one study, for example, AAICH was fatal in two-thirds of patients with INRs &gt;3.0 on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'ICH risk with antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality rate associated with AAICH varies according to the neurologic status of the patient at the time of admission. A Swedish multicenter study found the following 30-day mortality rates of AAICH for the following clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unconscious on admission &mdash; 96 percent",
"     </li>",
"     <li>",
"      Unconscious before start of active treatment &mdash; 80 percent",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      antagonists while still conscious &mdash; 28 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of focal neurologic signs (eg, hemiparesis, aphasia, ataxia) in an anticoagulated patient, especially if associated with headache, nausea and vomiting, confusion, or obtundation, warrants emergent evaluation for the presence of ICH. The onset of symptoms is usually sudden (ie \"stroke-like\"). In about one-half of patients, the hematoma continues to enlarge during the initial 12 to 24 hours, with attendant management implications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11,16-18,20,21\">",
"     11,16-18,20,21",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef61491 \" href=\"UTD.htm?6/23/6526\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mean age of patients with AAICH is in the 70s, reflecting the age distribution of anticoagulated patients, combined with a special propensity for AAICH among the elderly. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slow rate of hematoma enlargement in AAICH contrasts with a more rapid course of bleeding typical of ICH in patients who are not anticoagulated. In one study that employed serial CT scanning, 7 of 13 patients (54 percent) with AAICH were noted to have ICH expansion at a median time of 21.4 hours (range: 4.6 to 61 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, expansion was noted in 9 of 57 (16 percent) of those hemorrhages not associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use, although at a shorter median time of 8.4 hours (range 2.4 to 31 hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Intracerebral hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the hematoma grows, progressive stupor and hemiplegia evolve into coma as transtentorial herniation supervenes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73390 \" href=\"UTD.htm?17/8/17540\">",
"     image 1",
"    </a>",
"    ). Especially frequent involvement of the cerebellum in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated ICH has been reported in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/9,11,12,17,22-24\">",
"     9,11,12,17,22-24",
"    </a>",
"    ]. The relative distribution of lobar versus deep white",
"    <span class=\"nowrap\">",
"     matter/basal",
"    </span>",
"    ganglia locations appears to be similar in spontaneous versus AAICH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICH is visible immediately as hyperdense \"white\" areas on computed tomography (CT); a dark rim of uncongealed blood may also be present in actively bleeding patients with excessively prolonged INRs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Routine MRI sequences may not detect bleeding within the first few hours, but special gradient echo (\"susceptibility-weighted\") techniques are very sensitive for acute bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link&amp;anchor=H43#H43\">",
"     \"Overview of the evaluation of stroke\", section on 'Evaluation of patients with intracerebral hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H17#H17\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large volume (&gt;30 mL), intraventricular extension, and shift of midline structures are all radiologic predictors of a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11,12,15,22,23,27\">",
"     11,12,15,22,23,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REVERSING THE COAGULATION DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     AAICH is a medical emergency requiring urgent reversal of anticoagulation",
"    </strong>",
"    . Even small hematomas in anticoagulated patients can continue to enlarge, particularly if the INR is &gt;3.0 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73390 \" href=\"UTD.htm?17/8/17540\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/16,28\">",
"     16,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to clinically significant bleeding in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -treated patients is discussed in detail elsewhere, but will be reviewed here in the context of AAICH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. The single randomized trial concerning the treatment of AAICH included only five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/30\">",
"     30",
"    </a>",
"    ]. Accordingly, treatment recommendations discussed here are based upon evidence from retrospective analysis of case series, rather than prospective, randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intravenous vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses (ie, 10 to 20 mg) of intravenous vitamin K can fully reverse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced anticoagulation. However, this effect takes approximately 12 to 24 hours, during which time the ICH may continue to enlarge. Since the goal of treatment of AAICH is to return the INR to normal",
"    <strong>",
"     as soon as possible",
"    </strong>",
"    , treatment with vitamin K alone will not achieve this end, although vitamin K must be given in every case in order to achieve sustained reversal of an elevated INR. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Initial treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, in a retrospective study of AAICH, six patients with an initial INR on admission of 4.2 &plusmn; 2.0 were treated with vitamin K alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/31\">",
"     31",
"    </a>",
"    ]. At approximately 12 hours after initiation of treatment their INR was still elevated at 3.0 &plusmn; 1.7.",
"   </p>",
"   <p>",
"    High doses of vitamin K also result in a variable period of refractoriness to re-institution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , a factor that needs to be kept in mind if resumption of anticoagulation is contemplated (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Resumption of anticoagulation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eight units of fresh frozen plasma (FFP) are often required to immediately reverse the coagulation defect in a patient treated with a vitamin K antagonist. However, the associated volume load (approximately 2 liters) can be prohibitive, especially in patients with underlying cardiac disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidance on the dose of FFP to be used is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other drawbacks of FFP in this setting include the time required to check for blood compatibility (ie, ABO), thaw, and infuse this product, during which time the size of the hematoma may expand. In one report, for example, the median time interval between admission to a neuro-intensive care unit and INR normalization (ie, INR &le;1.2) was 30 hours (range: 14 to 50 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost for a course of treatment with FFP in a patient with AAICH and an INR of 3.0 has been variably estimated to be $200 to $400 US dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Unactivated prothrombin-complex concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unactivated prothrombin-complex concentrates (PCC, also called factor IX complex), which consist of the vitamin K-dependent coagulation factors (ie, factors II, VII, IX, and X), normalize the INR more rapidly than infusion of FFP or vitamin K alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14,33-37\">",
"     14,33-37",
"    </a>",
"    ]. As an example, in a prospective multinational clinical trial, infusion of unactivated PCC resulted in an INR &le;1.4 within 30 minutes of infusion in all 43 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While PCC products are easily administered and do not constitute as much of a volume load as does FFP, they are not always available at some institutions and may not be stocked in emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCC products available in Canada and Europe (eg, Beriplex, Octaplex, Cofact, Proplex) contain all four coagulation factors (ie, four-factor PCC) (see",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/20/25924?source=see_link\">",
"       \"Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information\"",
"      </a>",
"      ),",
"     </li>",
"     <li>",
"      PCC products available in the United States (Profilnine, Bebulin) contain little or no factor VII (ie, three-factor PCC) (see",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=see_link\">",
"       \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/3,39-41\">",
"       3,39-41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three-factor PCCs thus may be insufficient, by themselves, to immediately reverse the deficit in factor VII, and, we believe, should be given along with either FFP or low doses of recombinant human factor VII in order to supply the \"missing\" factor VII.",
"   </p>",
"   <p>",
"    Thrombotic events have complicated infusion of PCC, but this risk is difficult to quantify due to varying preparations, doses, and differing patient populations in available reports [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/34,42,43\">",
"     34,42,43",
"    </a>",
"    ]. Most PCC preparations contain low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to prevent clotting factor activation. They also contain variable amounts of protein C and protein S, vitamin K-dependent anticoagulants that co-purify with the clotting proteins. It is unknown whether these components attenuate the thrombotic risk of PCC preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If vitamin K is not also given at the time of presentation, the use of PCC alone may result in a delayed secondary rise in the INR as the coagulation factors are metabolized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14\">",
"     14",
"    </a>",
"    ]. This is especially true of factor VII, which has an in vivo half-life of only four to six hours. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Heparin prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H14#H14\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost for a course of treatment with PCC in a patient with ICH and an INR of 3.0 has been variably estimated to be $1000 to $2000 US dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant factor VIIa has been used to treat major intracerebral bleeding, both spontaneous as well as following treatment with a number of different anticoagulant agents, including vitamin K antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/44-51\">",
"     44-51",
"    </a>",
"    ], including traumatic intracerebral bleeding in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    immediately prior to the trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H13#H13\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two concerns are that use of recombinant factor VIIa corrects only the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced reduction in factor VII activity, while four-factor PCC, FFP, and vitamin K correct the deficiency in",
"    <strong>",
"     all four",
"    </strong>",
"    of the vitamin K-dependent coagulation factors (eg, factors II, VII, IX, and X). In addition, administration of recombinant factor VIIa alone may correct the INR, since the prothrombin time is most sensitive to reductions in factor VII, giving a false sense of security that the bleeding diathesis has been corrected. There are only limited data in patients with AAICH that deal with this concern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial report of a small number of patients with variable characteristics suggested that use of recombinant factor VIIa alone (initial dose: 10 to 50",
"      <span class=\"nowrap\">",
"       microg/kg)",
"      </span>",
"      was an effective approach to reversing AAICH [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of seven consecutive patients with AAICH and a mean pre-treatment INR of 2.7 (range: 1.6 to 5.6), use of recombinant factor VIIa (mean initial dose 62",
"      <span class=\"nowrap\">",
"       microg/kg)",
"      </span>",
"      was associated with an immediate reduction in the INR ranging from 0.6 to 3.5, with a mean post-treatment INR of 1.08 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/53\">",
"       53",
"      </a>",
"      ]. However, full and lasting reversal of the INR was achieved only with the combined use of vitamin K, FFP, and recombinant factor VIIa. This is partially because the half-life of factor VII is short (4 to 6 hours); the half-life of activated factor VII (ie, factor VIIa) is even shorter, approximately 2.3 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this latter study, the mean time from AAICH onset to treatment with factor VIIa was 6.2 hours (range: 1.3 to 18 hours). Two of the seven patients died within the first week of neurologic injury; the five surviving patients were left with severe neurologic impairment.",
"   </p>",
"   <p>",
"    Infusion of high-dose factor VIIa (80",
"    <span class=\"nowrap\">",
"     microg/kg)",
"    </span>",
"    in patients with spontaneous ICH (ie, not AAICH) was significantly associated with increased arterial thrombosis (eg, myocardial and cerebral infarctions) in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/50\">",
"     50",
"    </a>",
"    ]. No increase was apparent with infusion of a lower dose (20",
"    <span class=\"nowrap\">",
"     microg/kg).",
"    </span>",
"    In a case series of 101 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated intracranial hemorrhage (54 percent intracerebral, 30 percent subdural hematomas) who received factor VIIa (mean dose 52",
"    <span class=\"nowrap\">",
"     mcg/kg),",
"    </span>",
"    eight patients (8 percent) developed thromboembolic complications within two weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost for a course of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    in a patient with ICH and an INR of 3.0 is variably estimated to be $5000 to $15,000 US dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies comparing various treatments to help determine whether use of PCC results in improved clinical outcomes compared with vitamin K",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    FFP in patients with AAICH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11,31,34,36\">",
"     11,31,34,36",
"    </a>",
"    ]. Additionally, there are no studies directly comparing recombinant factor VIIa infusion to PCC or FFP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The single available randomized trial included only two patients with AAICH treated with FFP alone and three treated with FFP plus PCC, along with eight additional patients with anticoagulation-associated subdural hematomas or subarachnoid hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/30\">",
"       30",
"      </a>",
"      ]. Although there were no significant differences in neurologic outcome between the two treatment groups, the addition of PCC was associated with a faster rate of correction of the INR.",
"     </li>",
"     <li>",
"      A similar INR benefit with PCC was noted in a retrospective study in which the mean INR fell from 2.8 to 1.2 within 4.8 hours after PCC compared with a fall in INR from 3.0 to 1.7 within 7.3 hours after FFP [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/34\">",
"       34",
"      </a>",
"      ]. PCC therapy was also associated with significantly less progression of neurologic symptoms.",
"     </li>",
"     <li>",
"      A later retrospective study found that the 31 patients with AAICH who received PCCs alone or in combination with FFP or vitamin K had a significantly lower incidence of hematoma expansion compared with the 24 patients who did not receive PCCs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/31\">",
"       31",
"      </a>",
"      ]. As with earlier studies, most of the benefit in the PCC-treated group (ie, reduced incidence and extent of hematoma growth) appeared to be related to earlier correction of the INR. However, neither treatment was associated with an improvement in outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few relevant guidelines for the reversal of anticoagulation in patients with AAICH, and expert opinion on this subject differs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2,3,55-57\">",
"     2,3,55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCC, recombinant factor VIIa, or fresh frozen plasma given with intravenous vitamin K were advocated in the 2008 American College of Chest Physicians (ACCP) Guidelines for patients with life-threatening bleeding such as intracranial hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/58\">",
"       58",
"      </a>",
"      ]. However, the 2012 ACCP Guidelines suggest the use of 4-factor PCC (not available in the United States), rather than plasma (Grade 2C) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      American Heart Association",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      American Stroke Association guidelines recommend replacement of the vitamin K-dependent factors to correct the INR and the administration of intravenous vitamin K. PCCs were considered a reasonable alternative to FFP. Recombinant factor VIIa was not routinely recommended as a sole agent for reversal [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other guidelines have suggested using various combinations of vitamin K, FFP, PCC, and recombinant factor VIIa [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/29,57,60,61\">",
"       29,57,60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PCC preparations are not readily available in emergency departments at most United States hospitals; their use is often restricted to hematology specialists, reducing their immediate availability. As a result, acute treatment with infusion of FFP along with vitamin K has been the most frequently used therapy for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -associated ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the preparations used, it is extremely important to minimize delays in their administration, in hopes of reducing the high mortality and morbidity of AAICH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/29,62\">",
"     29,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with AAICH we recommend emergent initial",
"    <strong>",
"     fourfold",
"    </strong>",
"    treatment in an attempt to reverse the anticoagulation as rapidly as possible and minimize or prevent enlargement of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/63\">",
"     63",
"    </a>",
"    ]. The following recommendations are in general agreement with the 2011 British Committee for Standards in Hematology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/64\">",
"     64",
"    </a>",
"    ], the 2012 ACCP Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/59\">",
"     59",
"    </a>",
"    ] and the 2007 American Heart",
"    <span class=\"nowrap\">",
"     Association/",
"    </span>",
"    American Stroke Association Stroke Council Guidelines (",
"    <a class=\"graphic graphic_table graphicRef79151 \" href=\"UTD.htm?40/48/41739\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate cessation of all anticoagulant and antiplatelet therapy",
"     </li>",
"     <li>",
"      Vitamin K 10 mg by",
"      <strong>",
"       slow intravenous",
"      </strong>",
"      infusion (eg, no faster than 1",
"      <span class=\"nowrap\">",
"       mg/min",
"      </span>",
"      to minimize",
"      <span class=\"nowrap\">",
"       anaphylactic/anaphylactoid",
"      </span>",
"      risk) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14,34\">",
"       14,34",
"      </a>",
"      ]. Vitamin K can be repeated every 12 hours for persistent INR elevation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infusion of four-factor PCC alone or three-factor PCC in combination with FFP or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"     </li>",
"     <li>",
"      If PCC is not rapidly available, the use of FFP, with or without recombinant factor VIIa, is indicated, with the caveats as noted above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fresh frozen plasma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calculation of the dose of PCC (in International Units) or FFP (in mL) required to reverse the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be estimated based upon the patient's initial INR and body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/65\">",
"     65",
"    </a>",
"    ]. Guidance on the suggested dose of PCC to be employed is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of PCC is based on the factor IX content of the preparation; after initial infusion of 500 to 1000 international units at a rate of 100 international",
"    <span class=\"nowrap\">",
"     units/min,",
"    </span>",
"    subsequent infusion of PCC should be at a rate of &le;25 international",
"    <span class=\"nowrap\">",
"     units/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment goals and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy should be an INR in the normal range (ie, &lt;1.4 in most laboratories) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14,42\">",
"     14,42",
"    </a>",
"    ]. The INR should be checked 30 minutes following the initial infusion to be certain that it has returned to normal; if not, infusion of additional PCC or factor VIIa should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Serial INR determinations should be performed over the next 24 hours (eg, INR checked every 4 to 6 hours for the first 24 hours), and then checked daily for a few days to assure that the initial INR correction is maintained. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Unactivated prothrombin-complex concentrates'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are limited data on the efficacy of PCC in patients with AAICH. Successful treatment of nine such patients using relatively low doses of PCC has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients were given 500 or 1000 international units depending upon prolongation of the INR to &lt;4.5 or &gt;4.5, respectively, with additional administration of 500 international units based upon a repeat INR obtained after the initial infusion. The INR was corrected within 10 minutes of completion of the infusion at a median dosage of 12.5 international",
"    <span class=\"nowrap\">",
"     units/kg.",
"    </span>",
"    Hematoma enlargement occurred in only two of the nine patients; there were no thromboembolic episodes in this group, which included four patients with prosthetic heart valves.",
"   </p>",
"   <p>",
"    In this and two other series of patients treated with PCC, there was only one of 10 patients who suffered subsequent ICH enlargement when the INR was corrected to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/14,16,66\">",
"     14,16,66",
"    </a>",
"    ]. Worsening occurred 12 to 72 hours later in four patients with an incompletely corrected INR (eg, INRs of 1.5, 1.9, 2.7, and 3.2), combined with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in 3. Based upon this anecdotal evidence, it seems prudent to monitor the patient carefully in order to keep the INR in the normal range (ie, INR &lt;1.2) for the first 72 hours after ICH.",
"   </p>",
"   <p>",
"    Available data suggest that the use of PCC in AAICH is relatively safe (",
"    <a class=\"graphic graphic_table graphicRef54930 \" href=\"UTD.htm?7/60/8141\">",
"     table 2",
"    </a>",
"    ). However, in one study, large ischemic strokes occurred on days 2, 4, and 5 in three of seven patients treated with PCC (including two of seven with prosthetic heart valves) despite concomitant treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in low doses that did not prolong the activated partial thromboplastin time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/66\">",
"     66",
"    </a>",
"    ]. The dosages and content of the PCC preparation were not reported.",
"   </p>",
"   <p>",
"    Patients presenting with large hematomas who are comatose along with signs of transtentorial herniation have a negligible chance of recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. No therapy has been proven beneficial in this setting and the expense of PCC or factor VIIa may not be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heparin prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, thrombosis has been reported following the use of PCC, and the risk may vary with the specific preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/34,42,43,66\">",
"     34,42,43,66",
"    </a>",
"    ]. Because of this concern, it has been recommended that low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMW heparin be given following infusion of PCC to minimize this risk. However, there are no strongly supportive data for this course of action.",
"   </p>",
"   <p>",
"    If the INR is corrected to normal using PCC, it may be reasonable to begin low-dose subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low-dose LMW heparin 48 hours after ICH onset in patients with prosthetic heart valves and to restart",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    at five to seven days. The timing of heparin prophylaxis and reinitiation of warfarin therapy in these and other patients are discussed in detail below (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Resumption of anticoagulation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical evacuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgical evacuation in cerebellar and lobar ICH during anticoagulation has not been well defined, and most neurosurgeons are reluctant to operate in the setting of impaired hemostasis. However, given the high mortality accompanying AAICH, surgical treatment after reversing anticoagulation can be considered in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/23,53,66,67\">",
"     23,53,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Favorable outcomes have been reported in some patients with significant shifts of midline structures, uncal herniation, large hemorrhage volume,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    preoperative coma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H21#H21\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic blood pressure is often markedly elevated following AAICH, but hypertension has not been shown to be an independent predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/11\">",
"     11",
"    </a>",
"    ]. Although there are no good data regarding optimal management, keeping the systolic blood pressure &lt;180 mmHg during the acute phase appears reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2,14,16\">",
"     2,14,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Resumption of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for chronic oral anticoagulation should be carefully reassessed in the wake of an episode of AAICH. Available data do not allow accurate estimation of the long-term risk of recurrent ICH for survivors of AAICH who are subsequently restarted on oral anticoagulation (",
"    <a class=\"graphic graphic_table graphicRef72853 \" href=\"UTD.htm?5/32/5644\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/19,69\">",
"     19,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The few available case series suffer from potential selection and publication biases. Survivors selected for resumption of anticoagulation tend to be younger patients with prosthetic heart valves; their absolute risk of recurrent ICH following resumption of anticoagulation is likely to be much lower than that for elderly patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/5,70,71\">",
"     5,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI gradient-echo techniques to detect clinically silent microbleeds may stratify the risk of recurrent ICH. However, the sensitivity and specificity of these techniques have not been adequately defined to apply to individual patients at the present time.",
"   </p>",
"   <p>",
"    For",
"    <strong>",
"     primary prevention",
"    </strong>",
"    of ischemic stroke in most elderly patients with atrial fibrillation (AF), the long-term high risk of recurrent AAICH usually does not warrant reinitiation of anticoagulation. For patients with prosthetic heart valves or for",
"    <strong>",
"     secondary prevention",
"    </strong>",
"    of ischemic stroke in patients with AF, the risks of thromboembolism in the absence of anticoagulation are much higher, and the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    assessment appears to favor use of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/19,72\">",
"     19,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Optimal timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data are inadequate to determine the optimal timing for restarting anticoagulation following an episode of AAICH (",
"    <a class=\"graphic graphic_table graphicRef79024 \" href=\"UTD.htm?16/32/16908\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2\">",
"     2",
"    </a>",
"    ]. The acute treatment used to reverse anticoagulation may be a factor in this decision, since, as noted above, high doses of vitamin K may make the patient refractory to reinstitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a variable period of time.",
"   </p>",
"   <p>",
"    The conflicting messages from available case series are illustrated by the following reports and a literature review:",
"   </p>",
"   <p>",
"    In one series, 141 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated intracranial hemorrhage (including 87 with ICH and 43 with subdural hemorrhage) and a high thromboembolic risk had anticoagulation interrupted for a mean of 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/73\">",
"     73",
"    </a>",
"    ]. Only 3 patients (2 percent) experienced thromboembolic events (including one of 57 with prosthetic heart valves). The authors concluded that the risk of thromboembolism is low if warfarin is discontinued for only one to two weeks. In this report, no information was given about reversal of anticoagulation and whether INRs were corrected to normal in most patients. However, a previous report describing part of this patient cohort mentioned routine use of FFP and vitamin K [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thrombotic risk may be greater in patients treated with PCC. As noted above, large ischemic strokes were reported in three of seven patients with AAICH and prosthetic cardiac valves treated with PCC, despite concomitant treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in low doses insufficient to increase the activated partial thromboplastin time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/66\">",
"     66",
"    </a>",
"    ]. As a result, the authors advocated the use of full-dose intravenous heparin on the day following treatment with PCC.",
"   </p>",
"   <p>",
"    A literature review of 20 hemorrhagic and 28 thromboembolic (TE) events that occurred subsequent to an anticoagulant-related ICH made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhagic complications were more common within the first 24 to 72 hours following presentation. Risk factors for hemorrhage included younger age, traumatic cause for the index ICH, subdural hematomas, and failure to reverse anticoagulation (",
"      <a class=\"graphic graphic_table graphicRef56046 \" href=\"UTD.htm?21/45/22236\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      TE complications mostly took place after 72 hours following presentation and were more common in younger patients and those with spinal hemorrhage, multiple hemorrhages, and non-traumatic cause for the index ICH. Reinitiation of anticoagulation at a lower intensity significantly increased the risk of TE complications (",
"      <a class=\"graphic graphic_table graphicRef56046 \" href=\"UTD.htm?21/45/22236\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although even less data were available concerning the timing of reinitiation of anticoagulation and subsequent hemorrhagic or TE events, when anticoagulation was reinitiated within 24 hours, six of the seven complications were hemorrhagic. When anticoagulation was reinitiated more than 72 hours after the index ICH, 10 of the 12 complications were TE (",
"      <a class=\"graphic graphic_table graphicRef56046 \" href=\"UTD.htm?21/45/22236\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In short, available data are sparse, mostly retrospective, and are generally inadequate to assess the risks and benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for VTE prevention in patients with acute ICH. However, most of the hemorrhagic events that have been reported occurred when anticoagulation was started within the first 24 hours, and most of the TE events when anticoagulation was started more than 72 hours following the index event.",
"   </p>",
"   <p>",
"    There are alternative ways to interpret these anecdotal data. The range of recommendations include withholding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation for four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/76\">",
"     76",
"    </a>",
"    ], withholding warfarin for one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/5,28,73,74\">",
"     5,28,73,74",
"    </a>",
"    ], and the administration of full-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    immediately after the INR has been corrected to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/66,77\">",
"     66,77",
"    </a>",
"    ]. One hypothesis to explain the dramatic difference in observed rates of thromboembolism following reversal of anticoagulation is a prothrombotic state caused by infusion of high-dose PCC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of consensus on this issue, if the INR is corrected to normal using PCC, it seems reasonable to begin low-dose subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMW heparin 48 hours after ICH onset for routine VTE prophylaxis. For patients who will resume anticoagulation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be restarted at 7 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/2,55,78\">",
"     2,55,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link&amp;anchor=H5#H5\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumatic compression stockings and early ambulation should be considered if leg paresis is present and control of hypertension, if present, is strongly recommended. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Management of hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Use of antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiplatelet agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) is known to increase the risk of bleeding at any site in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -treated patients, and is therefore likely to increase the risk of recurrent ICH. As an example, in a meta-analysis of six trials, the relative risk for ICH was 2.4 with warfarin plus aspirin compared to warfarin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic use of warfarin\", section on 'Use of NSAIDs and antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, antiplatelet agents, including low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , should be avoided if possible in patients restarted on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    after an episode of AAICH. When aspirin must be used, the lowest effective INR (eg, 1.8 to 2.5 for patients with AF) should be achieved before aspirin is started, coupled with especially vigilant INR monitoring to avoid excessive anticoagulation. Control of blood pressure is also critical for minimizing the risk of recurrent ICH. Lowering the systolic blood pressure by 10 mmHg is likely to reduce this risk by one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?10/3/10298/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of focal neurologic signs (eg, hemiparesis, aphasia, ataxia) in a patient receiving anticoagulation with a vitamin K antagonist, especially if associated with headache, nausea and vomiting, confusion, or obtundation, warrants emergent evaluation for the presence of intracerebral hemorrhage (ICH).",
"   </p>",
"   <p>",
"    ICH is visible immediately as hyperdense \"white\" areas on computed tomography (CT); a dark rim of uncongealed blood may also be present in actively bleeding patients with an excessively prolonged INR. Special gradient echo (\"susceptibility-weighted\") MRI techniques are also very sensitive for acute bleeding. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnostic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The possibility of",
"    <strong>",
"     delayed",
"    </strong>",
"    intracranial bleeding after",
"    <span class=\"nowrap\">",
"     falls/trauma",
"    </span>",
"    should also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant-associated ICH (AAICH) is a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    with an extremely high morbidity and mortality. Even small hemorrhagic areas in anticoagulated patients can continue to enlarge, particularly if the INR is &gt;3.0. Accordingly, treatment must be provided to",
"    <strong>",
"     reverse the effects of anticoagulation in as timely a manner as possible and to maintain such correction for a minimum of 72 hours",
"    </strong>",
"    . (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Initial treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to attain the above-noted goals, we recommend that the following plan be initiated (",
"    <a class=\"graphic graphic_table graphicRef79151 \" href=\"UTD.htm?40/48/41739\">",
"     table 1",
"    </a>",
"    )&nbsp;(",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate cessation of all anticoagulant and antiplatelet therapy",
"     </li>",
"     <li>",
"      For immediate and short-term reversal of anticoagulation (eg, minutes to hours) we recommend infusion of an agent (ie, prothrombin complex concentrates (PCC),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      , fresh frozen plasma (FFP)) to reverse the anticoagulant effect as rapidly as possible. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Choice of agent'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For longer-term reversal of anticoagulation (ie, hours to days) we recommend administration of vitamin K by slow intravenous infusion, rather than by the oral or subcutaneous route. The usual dose is 10 mg, which can be repeated every 12 hours for persistent INR elevation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials which have determined the relative efficacy and safety of PCC, FFP, and factor VIIa in AAICH. The choice of agent primarily depends upon its timely availability in an urgent care setting (",
"    <a class=\"graphic graphic_table graphicRef79151 \" href=\"UTD.htm?40/48/41739\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Therapeutic options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In institutions where four-factor PCC is available (eg, Canada and Europe), we suggest PCC over factor VIIa or FFP because it rapidly provides all of the vitamin-K dependent coagulation factors in a small infused volume (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The distinction between 3-factor and 4-factor PCC preparations can be found above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Unactivated prothrombin-complex concentrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In institutions where four-factor PCC is not available (eg, PCC with adequate amounts of factor VII), we suggest the use of three-factor PCC along with small volumes of FFP (eg, 2 units) to supply the missing factor VII (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If volume overload from FFP is a concern, three-factor PCC plus low-dose recombinant factor VIIa (eg, 20",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      is a reasonable option. Fresh frozen plasma is indicated when neither PCC nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      is available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Additional management issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few controlled trials available for guidance, the following additional management issues need to be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keeping the systolic blood pressure &lt;180 mmHg during the acute phase is advisable. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high mortality accompanying AAICH, surgical evacuation of the hematoma after reversing anticoagulation can be considered in selected patients. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgical evacuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the INR has been corrected to normal using PCCs, it is reasonable to begin low-dose prophylactic subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or LMW heparin 48 hours after ICH onset, unless there remains a neurosurgical reason to withhold. For patients who will resume anticoagulation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      can be restarted at 7 to 14 days. Pneumatic compression stockings and early ambulation should be considered if leg paresis is present.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/1\">",
"      Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/2\">",
"      Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/3\">",
"      Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117:6091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/4\">",
"      Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/5\">",
"      Punthakee X, Doobay J, Anand SS. Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res 2002; 108:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/6\">",
"      Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002; 33:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/7\">",
"      Berwaerts J, Robb OJ, Jeffers TA, Webster J. Intracerebral haemorrhages and oral anticoagulation in the north of Scotland. Scott Med J 2000; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/8\">",
"      Nilsson OG, Lindgren A, St&aring;hl N, et al. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000; 69:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/9\">",
"      Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/10\">",
"      Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/11\">",
"      Sj&ouml;blom L, H&aring;rdemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/12\">",
"      Neau JP, Couderq C, Ingrand P, et al. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001; 11:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/13\">",
"      Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/14\">",
"      Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/15\">",
"      Berwaerts J, Dijkhuizen RS, Robb OJ, Webster J. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke 2000; 31:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/16\">",
"      Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/17\">",
"      Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/18\">",
"      Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/19\">",
"      Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol 2008; 65:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/20\">",
"      Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/21\">",
"      Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/22\">",
"      Kase CS, Robinson RK, Stein RW, et al. Anticoagulant-related intracerebral hemorrhage. Neurology 1985; 35:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/23\">",
"      R&aring;dberg JA, Olsson JE, R&aring;dberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991; 22:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/24\">",
"      Toyoda K, Okada Y, Ibayashi S, et al. Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovasc Dis 2007; 23:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/25\">",
"      Ichikawa K, Yanagihara C. Sedimentation level in acute intracerebral hematoma in a patient receiving anticoagulation therapy: an autopsy study. Neuroradiology 1998; 40:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/26\">",
"      Linfante I, Llinas RH, Caplan LR, Warach S. MRI features of intracerebral hemorrhage within 2 hours from symptom onset. Stroke 1999; 30:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/27\">",
"      Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/28\">",
"      Estol CJ, Kase CS. Need for Continued Use of Anticoagulants After Intracerebral Hemorrhage. Curr Treat Options Cardiovasc Med 2003; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/29\">",
"      Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006; 37:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/30\">",
"      Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/31\">",
"      Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/32\">",
"      Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/33\">",
"      Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/34\">",
"      Fredriksson K, Norrving B, Str&ouml;mblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/35\">",
"      Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/36\">",
"      Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008; 8:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/37\">",
"      Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care 2010; 12:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/38\">",
"      Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/39\">",
"      Evans SJ, Biss TT, Wells RH, Hanley JP. Emergency warfarin reversal with prothrombin complex concentrates: UK wide study. Br J Haematol 2008; 141:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/40\">",
"      Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/41\">",
"      Rizos T, Jenetzky E, Herweh C, et al. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol 2010; 67:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/42\">",
"      Hellstern P, Halbmayer WM, K&ouml;hler M, et al. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 1999; 95:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/43\">",
"      Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999; 95:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/44\">",
"      Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004; 41:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/45\">",
"      Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/46\">",
"      Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002; 8:CS98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/47\">",
"      Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis 1998; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/48\">",
"      S&oslash;rensen B, Johansen P, Nielsen GL, et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/49\">",
"      Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/50\">",
"      Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/51\">",
"      Ilyas C, Beyer GM, Dutton RP, et al. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth 2008; 20:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/52\">",
"      Nishijima DK, Dager WE, Schrot RJ, Holmes JF. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med 2010; 17:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/53\">",
"      Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/54\">",
"      Robinson MT, Rabinstein AA, Meschia JF, Freeman WD. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke 2010; 41:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/55\">",
"      Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/56\">",
"      Goldstein JN, Rosand J, Schwamm LH. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2008; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/57\">",
"      Aiyagari V, Testai FD. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/58\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/59\">",
"      Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/60\">",
"      Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/61\">",
"      Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/62\">",
"      Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/63\">",
"      Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 2003; 34:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/64\">",
"      Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/65\">",
"      Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/66\">",
"      Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 2000; 247:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/67\">",
"      Kawamata T, Takeshita M, Kubo O, et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 1995; 44:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/68\">",
"      Rabinstein AA, Wijdicks EF. Determinants of outcome in anticoagulation-associated cerebral hematoma requiring emergency evacuation. Arch Neurol 2007; 64:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/69\">",
"      De Vleeschouwer S, Van Calenbergh F, van Loon J, et al. Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation. Acta Chir Belg 2005; 105:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/70\">",
"      Butler AC, Tait RC. Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up. Br J Haematol 1998; 103:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/71\">",
"      Lau CP, Chang CM, Lau GK, et al. Cerebral haemorrhage in anticoagulated patients with non-septic mechanical valvular prosthesis. Int J Cardiol 1991; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/72\">",
"      Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/73\">",
"      Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000; 57:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/74\">",
"      Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 1998; 42:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/75\">",
"      Hawryluk GW, Austin JW, Furlan JC, et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 2010; 8:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/76\">",
"      Crawley F, Bevan D, Wren D. Management of intracranial bleeding associated with anticoagulation: balancing the risk of further bleeding against thromboembolism from prosthetic heart valves. J Neurol Neurosurg Psychiatry 2000; 69:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/77\">",
"      Leker RR, Abramsky O. Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology 1998; 50:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/78\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/3/10298/abstract/79\">",
"      Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1325 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10298=[""].join("\n");
var outline_f10_3_10298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REVERSING THE COAGULATION DEFECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intravenous vitamin K",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Unactivated prothrombin-complex concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment goals and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heparin prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical evacuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Resumption of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Optimal timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Use of antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Initial treatment plan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Additional management issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1325|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/8/17540\" title=\"diagnostic image 1\">",
"      Intracerebral hemorrh warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1325|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/18/43296\" title=\"figure 1\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/27/42430\" title=\"figure 2\">",
"      Optimal INR oral anticoag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6526\" title=\"figure 3\">",
"      Time course cerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/48/41739\" title=\"table 1\">",
"      Rx warfarin associated ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/60/8141\" title=\"table 2\">",
"      Prothrombin complex concentrates in ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/32/5644\" title=\"table 3\">",
"      Long term anticoagulation after ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/32/16908\" title=\"table 4\">",
"      Resumption anticoag after ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/45/22236\" title=\"table 5\">",
"      Hemorrhagic and thrombotic complications after ICH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/20/25924?source=related_link\">",
"      Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_3_10299="Modes transmission hepatitis A";
var content_f10_3_10299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transmission of hepatitis A virus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Person to person contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homosexual contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Contact with contaminated food or water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raw or undercooked shellfish (oysters, clams, mussels)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Foods contaminated by infected food handlers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persons in daycare centers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persons in institutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Military personnel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transmission through blood transfusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transmission via intravenous drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No identifiable risk factor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10299=[""].join("\n");
var outline_f10_3_10299=null;
var title_f10_3_10300="ESC primary prevention SCD HCM";
var content_f10_3_10300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology recommendations for prevention of sudden cardiac death: Hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Primary prevention: recommendations",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Secondary prevention: recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ICD",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        Class IIb",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers",
"       </td>",
"       <td>",
"        Class III",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil",
"       </td>",
"       <td>",
"        Class III",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICD: implantable cardioverter defibrillator.",
"    </div>",
"    <div class=\"reference\">",
"     Priori, SG, Aliot, E, Blomstrom-Lundqvist, C, et al, Eur Heart J 2001; 22:1374.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10300=[""].join("\n");
var outline_f10_3_10300=null;
var title_f10_3_10301="Monitoring STI and OI in adolescent HIV";
var content_f10_3_10301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring for sexually transmitted and opportunistic infections in adolescents with HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended frequency/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis serologies",
"       </td>",
"       <td>",
"        At initial diagnosis; also may be indicated in patients with initial negative serology if CD4 drops below 100 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RPR or VDRL*",
"       </td>",
"       <td>",
"        At least yearly; in areas highly endemic for syphilis or high risk populations (ie, MSM) every 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonorrhea/chlamydia screening*",
"       </td>",
"       <td>",
"        Every 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAP smear (females)",
"        <sup>",
"         &bull;",
"        </sup>",
"        /anal cytology (males)",
"       </td>",
"       <td>",
"        Every 6 months initially, if negative x 2, annually",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis screening",
"       </td>",
"       <td>",
"        Annually: TST or IGRA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis serologies",
"       </td>",
"       <td>",
"        <p>",
"         Annually: anti-HCV to screen for new infection.",
"        </p>",
"        <p>",
"         At initial diagnosis: anti-HAV; if negative, HAV vaccine series should be administered.",
"        </p>",
"        <p>",
"         At initial diagnosis: anti-HBs, HBsAg, anti-HBc; if all are negative, hepatitis B vaccine series should be administered",
"         <sup>",
"          &Delta;",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph",
"       </td>",
"       <td>",
"        As needed (eg, for symptoms and signs suggesting pulmonary disease or newly detected latent tuberculosis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; RPR: rapid plasma reagin; VDRL: venereal disease research laboratory; MSM: men who have sex with men; PAP: Papanicolaou smear; TST: tuberculin skin test; IGRA: interferon-gamma release assay; anti-HCV: hepatitis C antibody; anti-HAV: hepatitis A virus antibody; anti-HBs: hepatitis B surface antibody; HBsAg: hepatitis B surface antigen; anti-HBc: hepatitis B core antibody.",
"     <br>",
"      * Testing should be performed among HIV positive adolescents who are sexually active; it is not necessary among HIV positive adolescents with vertical transmission until they become sexually active.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       In contrast to the recommendations for healthy adolescents, sexually active HIV-infected female adolescents should undergo cervical cancer screening after the onset of sexual activity and not wait until 21 years of age.",
"       <br>",
"        &Delta; If anti-HBs negative after the first vaccination series, the series may be repeated once. Patients with negative anti-HBs who are not hepatitis B infected (anti-HBc negative and HBsAg negative) should be monitored annually or if symptomatic for new infection.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1. Available at:",
"        <a href=\"file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf\" target=\"_blank\">",
"         file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"       <li>",
"        Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at:",
"        <a href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\" target=\"_blank\">",
"         file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"       <li>",
"        ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010; 116:1492.",
"       </li>",
"       <li>",
"        ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010; 116:469.",
"       </li>",
"       <li>",
"        New York State Department of Health Guidelines. Available at:",
"        <a href=\"file://www.natap.org/2010/HIV/032510_01.htm\" target=\"_blank\">",
"         file://www.natap.org/2010/HIV/032510_01.htm",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10301=[""].join("\n");
var outline_f10_3_10301=null;
var title_f10_3_10302="Energy requirements children";
var content_f10_3_10302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80428%7EPEDS%2F68420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80428%7EPEDS%2F68420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caloric intake by age, gender, and activity level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Age (y)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Activity level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Males",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Sedentary",
"       </td>",
"       <td class=\"subtitle3\">",
"        Active",
"       </td>",
"       <td class=\"subtitle3\">",
"        Sedentary",
"       </td>",
"       <td class=\"subtitle3\">",
"        Active",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2200",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2200",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        2600",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        2800",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2200",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"       <td>",
"        3200",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"       <td>",
"        3200",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"       <td>",
"        3200",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sedentary: less than 30 minutes daily of additional moderate physical activity; Active: 60 minutes or more daily of additional moderate physical activity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended daily amount from each food group, by calorie level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"15%\">",
"     </colgroup>",
"     <colgroup span=\"7\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Calorie level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1200",
"       </td>",
"       <td class=\"subtitle2\">",
"        1400",
"       </td>",
"       <td class=\"subtitle2\">",
"        1600",
"       </td>",
"       <td class=\"subtitle2\">",
"        1800",
"       </td>",
"       <td class=\"subtitle2\">",
"        2000",
"       </td>",
"       <td class=\"subtitle2\">",
"        2200",
"       </td>",
"       <td class=\"subtitle2\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grains*",
"       </td>",
"       <td>",
"        4 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        7 ounces",
"       </td>",
"       <td>",
"        10 ounces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        4 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruits",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dairy",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein foods",
"       </td>",
"       <td>",
"        3 ounces",
"       </td>",
"       <td>",
"        4 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5.5 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        7 ounces",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In general, 1 slice of bread, 1 cup of ready-to-eat cereal, or &frac12; cup of cooked rice, cooked pasta, or cooked cereal can be considered as 1 ounce equivalent from the Grains Group. At least half of these servings should be whole grains.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     1 cup vegetables is approximately equal to 12 baby carrots, or one large tomato. Because of high water content, a serving of lettuce must be twice as large (1 cup of lettuce = 1/2 cup of other vegetables).",
"     <br/>",
"     &Delta; 1 cup of fruit is approximately equal to one apple or banana, 2 plums, 1/8th melon, or eight strawberries.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Milk should be fat-free or low-fat after two years of age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: the United States Department of Agriculture \"Choose My Plate\" website, available at:",
"     <a href=\"file://www.choosemyplate.gov\" target=\"_blank\">",
"      www.choosemyplate.gov",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10302=[""].join("\n");
var outline_f10_3_10302=null;
var title_f10_3_10303="Steroids in childhood ITP I";
var content_f10_3_10303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69938%7EPEDS%2F81932%7EPEDS%2F58690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=19\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69938%7EPEDS%2F81932%7EPEDS%2F58690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=19\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical trial evidence: effectiveness of glucocorticoids, IVIg, and anti-D in initial treatment of ITP in children-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Authors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pop. age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Randomized treatment arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeding symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        McWilliams and",
"Mauner",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        27",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        6 yr mean",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        NR",
"       </td>",
"       <td>",
"        Prednisone (2 mg/kg/d x 21 d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Median time to platelet count of 150K",
"       </td>",
"       <td>",
"        21 d",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No treatment",
"       </td>",
"       <td>",
"        (p &le;.03)",
"60 d",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Sartorius",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        93",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        60 mo-16 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &gt;6 mo",
"       </td>",
"       <td>",
"        Prednisone (60 mg/m2/d x 21 d, then tapered)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Proportion with platelet count &gt;30K and",
"&gt;100K, and with (p &lt;.01) negative Rumpel-Leede test",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Prednisone &gt; Placebo (p &lt;.01)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Prednisone &lt; placebo (by Rumpel-Leede test",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placebo",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Buchanan and",
"Holtkamp",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        27",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &lt;11 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        28 d",
"       </td>",
"       <td>",
"        Prednisone (2 mg/kg/d x 14 d, then taper to d 21)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Platelet count, Bleeding time, clinical bleeding score",
"at d 0-28&nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Prednisone &gt; placebo (p &lt;.05) only at d 7",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Prednisone &lt; placebo (p &lt; .05) only at d",
"7 (bleeding time and clinical score)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Increased appetite, weight gain",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placebo",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Imbach et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        94",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &lt;16 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1 yr",
"       </td>",
"       <td>",
"        Prednisone (60 mg/m2/d x 21 d, follow-up protocol for",
"poor",
"response/ remissions)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Proportion with platelet count &gt;100K",
"       </td>",
"       <td>",
"        77 percent",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        77 percent weight gain or acne",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (0.4 g/kg/d x 5 d, follow-up protocol for",
"poor response/ remissions",
"       </td>",
"       <td>",
"        83 percent (no difference)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        22 percent with headache, fever, vomiting, vertigo",
"       </td>",
"       <td>",
"        1 died on day 6, excluded from analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Mazzucconi et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        61",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2-12 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &gt;6 mo",
"       </td>",
"       <td>",
"        Prednisone (0.5 mg/kg/d x 1 mo or until platelet",
"normalization)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Proportion with platelet count &gt;150K",
"       </td>",
"       <td>",
"        62 percent",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone (1.5 mg/kg/d x 1 mo or until platelet",
"normalization)",
"       </td>",
"       <td>",
"        81 percent (p &lt;.05)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George, JN, Woolf, SH, Raskob, GE, et al. Blood 1996; 88:3. Copyright &copy; 1996 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical trial evidence: effectiveness of glucocorticoids, IVIg, and anti-D in initial treatment of ITP in children-II (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Authors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pop. age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Randomized treatment arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeding symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Belluci et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        160",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &lt;15 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &gt;12 mo",
"       </td>",
"       <td>",
"        Prednisone (0.25 mg/kg/d x 3 wk)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Proportion with platelet count &gt;100K for",
"&gt;3 mo",
"       </td>",
"       <td>",
"        71 percent",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone (1 mg/kg/d x 3 wk)",
"       </td>",
"       <td>",
"        77 percent (no&nbsp;difference)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Khalifa et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        30",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        2 mo-15 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &gt;6 mo",
"       </td>",
"       <td>",
"        M'prednisolone (IV, 10 mg/kg/d x 5 d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mean platelet count on days 1-14",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone (2 mg/kg/d x 4 wk)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (0.4 g/kg/d x 5 d)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Ozsoyle et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        20",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2 mo-11 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &gt;6 mo",
"       </td>",
"       <td>",
"        M'prednisolone (po, 30 mg/kg/d x 3 d, then 20 mg/kg/d x",
"4 d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Proportion with platelet count &gt;150K in 3 d, 6 mo",
"       </td>",
"       <td>",
"        60 percent, 90 percent (no difference)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (0.4 g/kg/d x 5 d)",
"       </td>",
"       <td>",
"        60 percent, 75 percent",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Blanchette et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        53",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        7 mo-14&nbsp;yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        180 d",
"       </td>",
"       <td>",
"        Prednisone (4 mg/kg/d x 7 d, then tapered to d 21) IVIg",
"(1 g/kg/d x 2 d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Median time to platelet count &gt;20K, &gt;50K",
"       </td>",
"       <td>",
"        2 d, 4d",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Weight gain, behavioral change 75 percent with nausea,",
"vomiting, headache, fever",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No therapy",
"       </td>",
"       <td>",
"        1 d, 2 d (p&lt; .01 vs prednisone) 4 d, 16 d (p",
"&lt;0.1 vs either treatment)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Blanchette",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        146",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        6 mo-18yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        6-32 mo",
"       </td>",
"       <td>",
"        Prednisone (4 mg/kg/d x 7 d, then tapered to d 21)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Median time to platelet count &gt;20K, &gt;50K",
"       </td>",
"       <td>",
"        2 d, 3 d",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (1 g/kg/d x 2 d)",
"       </td>",
"       <td>",
"        2 d, 2 d",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        16-18 percent with fever, nausea, vomiting, headache",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        IVIg (0.8 g/kg once)",
"       </td>",
"       <td>",
"        1 d, 2 d (p &lt;.05 vs. prednisone)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Anti-D (25 &micro;g/kg/d",
"x 2 d)",
"       </td>",
"       <td>",
"        2 d, 2.5 d (p &lt; .05 vs. both IVIg regimens)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        24 percent with hemoglobin &lt;10 g/dL",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George, JN, Woolf, SH, Raskob, GE, et al. Blood 1996; 88:3. Copyright &copy; 1996 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical trial evidence: effectiveness of glucocorticoids, IVIg, and anti-D in initial treatment of ITP in children-III (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Authors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pop. age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Randomized treatment arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeding symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Albayrak et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        57",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        2 mo- 17 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        6 mo",
"       </td>",
"       <td>",
"        M'prednisolone (po, 30 mg/kg/d x 7d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mean platelet count on days 0-30",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mean &gt;100K by d 4. No difference among groups",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Increased appetite and Cushingoid",
"appearance",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M'prednisolone (po, 50 mg/kg/d x 7 d)",
"       </td>",
"       <td>",
"        1 ICH",
"       </td>",
"       <td>",
"        Increased appetite and Cushingoid appearance",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (0.5 g/kg/d x 5 d)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        1 pt with aseptic meningitis; 2 with headache, vomiting",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; ICH: intracerebral hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George, JN, Woolf, SH, Raskob, GE, et al. Blood 1996; 88:3. Copyright &copy; 1996 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_3_10303=[""].join("\n");
var outline_f10_3_10303=null;
